[{"drug": "Adefovir", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Lamivudine (LAM) and adefovir dipivoxil (ADV) are widely used in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), but few studies have directly compared their therapeutic efficacy and treatment cost. "}, {"drug": "Adefovir", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "adefovir group: 8%, P=0.047).The entecavir group and the adefovir group showed no significant differences upon per-protocol analysis and intention-to-treat analysis, nor in the rates of hepatocellular carcinoma development (entecavir group: 8.1% vs. "}, {"drug": "Sofosbuvir", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "These patients who did not achieve normalization of ALT after sofosbuvir plus RBV treatment need more careful observation for emergence of hepatocellular carcinoma even after achievement of SVR. "}, {"drug": "Sofosbuvir", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here, we evaluated 54 patients with chronic HCV genotype 1b infection, free of decompensated cirrhosis, and hepatocellular carcinoma, for sustained virological response after 12 weeks (SVR12) of once-daily treatment with 90\u2009mg ledipasvir and 400\u2009mg sofosbuvir. "}, {"drug": "Sofosbuvir", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "One hundred seventy-five patients with chronic HCV genotype 1 infection, without decompensated liver cirrhosis and hepatocellular carcinoma, were evaluated SVR12 by ledipasvir 90\u2009mg plus sofosbuvir 400\u2009mg once-daily for 12 weeks. "}, {"drug": "Sofosbuvir", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "RESULTS: For genotype 1 treatment-naive HCV patients, for OMB/PTV/r\u2009+\u2009DSV\u2009\u00b1\u2009RBV, PegIFN\u2009+\u2009ribavirin (PegIFN/RBV), sofosbuvir\u2009+\u2009PegIFN/RBV, telaprevir\u2009+\u2009PegIFN/RBV, boceprevir\u2009+\u2009PegIFN/RBV, lifetime risk of decompensated liver disease was 5.6%, 18.9%, 7.4%, 11.7%, and 14.9%; hepatocellular carcinoma was 5.4%, 9.2%, 5.7%, 7.0%, and 7.4%; and death from liver disease was 8.7%, 22.2%, 10.4%, 14.8%, and 17.6%, respectively. "}, {"drug": "Sofosbuvir", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sofosbuvir produced the largest absolute reductions in decompensated cirrhosis (16%) and hepatocellular carcinoma (9%), resulting in 2.1 additional QALYs at an added cost exceeding $54,000 compared with no treatment. "}, {"drug": "Sofosbuvir", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: In a phase 2, open-label study, 61 patients with HCV of any genotype and cirrhosis (Child-Turcotte-Pugh score, \u22647) who were on waitlists for liver transplantation for hepatocellular carcinoma, received up to 48 weeks of sofosbuvir (400 mg) and ribavirin before liver transplantation. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The present study was designed to investigate the synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 (Aspp2-ad) and oxaliplatin via p53-independent pathway in\u00a0vitro and in\u00a0vivo. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background: The Oxaliplatin plus 5-Fluorouracil /Leucovorin (FOLFOX4) regimen have been approved by Chinese Food and Drug Administration (CFDA), and covered by health insurance for patients with advanced hepatocellular carcinoma (HCC) in China. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "By knocking down the interleukin-17 receptor and lysosome-associated membrane protein 2A (a key protein in chaperone-mediated autophagy) in hepatocellular carcinoma cells, we found that interleukin-17 stimulated chaperone-mediated autophagy, which further suppressed apoptosis upon oxaliplatin treatment. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Thus M2 macrophages in the hepatocellular carcinoma microenvironment generate large amounts of interleukin-17, which suppress oxaliplatin-induced tumor cell apoptosis by activating chaperone-mediated autophagy and in turn reducing cyclin D1 expression. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In the present study, we found low endogenous expressions of GAS7C mRNA and protein in hepatocellular carcinoma (HCC) cell lines compared with normal liver cells, and that there was a distinct increase of GAS7C expression in HCC cells treated with oxaliplatin. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Oxaliplatin-based chemotherapy is an alternative systemic treatment for patients with metastatic hepatocellular carcinoma (HCC) who were refractory or intolerant to sorafenib. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The present study demonstrated that oxaliplatin was able to increase the levels of IL-17/IL-17R in hepatocellular carcinoma (HCC) patients and cells lines, and that it had important roles in reducing the susceptibility of the cells to oxaliplatin-induced apoptosis. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Many clinical studies have demonstrated the survival benefits of oxaliplatin-based chemotherapy for advanced hepatocellular carcinoma patients. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Therefore, we aim to evaluate the efficacy and safety of oxaliplatin-based chemotherapy in patients with advanced hepatocellular carcinoma by conducting a meta-analysis of prospective studies. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Only prospective studies evaluating oxaliplatin-based chemotherapy in patients with advanced hepatocellular carcinoma were selected. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Oxaliplatin-based chemotherapy appears to be effective and safe for the treatment of advanced hepatocellular carcinoma. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The presented study aimed to investigate the antitumor efficacy of combination of oxaliplatin with rapamycin, an mTOR inhibitor, in hepatocellular carcinoma (HCC). "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this report, we aim to assess the efficacy and safety of raltitrexed plus oxaliplatin (OXA)-based transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (uHCC). "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "These findings suggested that Lentinan may be an ideal agent for the combination therapy of oxaliplatin against hepatocellular carcinoma. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report a case of a 31-year-old man with metastatic fibrolamellar hepatocellular carcinoma (FLHCC) treated with gemcitabine and oxaliplatin complicated by hyperammonemic encephalopathy biochemically consistent with acquired ornithine transcarbamylase deficiency. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this study, we found that \u03b2-elemene, which alone had little effect on hepatocellular carcinoma (HCC) cell proliferation, exerted a synergistic anti-proliferative effect in HCC cells when dosed in combination with oxaliplatin, which increased the amounts of platinum accumulation and platinum-DNA adduct significantly and augmented the oxaliplatin-induced apoptosis. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Hepatocellular carcinoma (HCC) is generally believed to have low sensitivity to chemotherapeutic agents including oxaliplatin (OXA). "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the efficacy and safety of chemoembolization alone or chemoembolization combined with hepatic arterial infusion chemotherapy (HAIC), including oxaliplatin (OXA), 5-fluorouracil (5-FU) and folinic acid (CF), in inoperable hepatocellular carcinoma (HCC) without distant metastasis. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Furthermore, upregulated HOXC8 expression was associated with oxaliplatin resistance in hepatocellular carcinoma. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC). "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The purpose of this study was to assess the efficacy and safety of gemcitabine and oxaliplatin (GEMOX) combined with sorafenib, as first-line therapy, followed by sorafenib as maintenance therapy for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) compared with doxorubicin alone in terms of overall survival (OS), progression-free survival (PFS), and safety in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Hepatocellular carcinoma cells (MHCC97H cells) were subcutaneously injected into mice to form tumors, and the mice were intravenously treated with either oxaliplatin or glucose. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma cells is associated with increased autocrine of IGF1. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate the effect of Oxaliplatin (L-OHP) on cell cycle in hepatocellular carcinoma cell line HepG2 and the involved mechanism. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC). "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "These data clearly demonstrate that SYY renders hepatocellular carcinoma sensitive to oxaliplatin through the inhibition of stemness. "}, {"drug": "Oxaliplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "However, the role of sCLU in the resistance of hepatocellular carcinoma (HCC) to oxaliplatin (OXA), a recently used third-generation platinum agent, remains unclear. "}, {"drug": "Foretinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Purpose: This phase I/II single-arm study evaluated the safety, pharmacokinetics, pharmacodynamics, and activity of foretinib, an oral multikinase inhibitor of MET, ROS, RON, AXL, TIE-2, and VEGFR2, in the first-line setting in advanced hepatocellular carcinoma patients.Experimental Design: In the phase I part, advanced hepatocellular carcinoma patients were dose escalated on foretinib (30-60 mg) every day using the standard 3+3 design. "}, {"drug": "Foretinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Multivariate analyses identified IL6 and IL8 as independent predictors of OS.Conclusions: Foretinib demonstrated promising antitumor activity and good tolerability in the first-line setting in Asian advanced hepatocellular carcinoma patients. "}, {"drug": "Foretinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Hepatocellular carcinoma (HCC) pathogenesis is associated with overexpression of MET, and physiologic changes in the livers of HCC patients may decrease CYP3A isozyme-mediated metabolism of foretinib. "}, {"drug": "Temsirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This work investigates on putative cytotoxic effects in four different hepatocellular carcinoma (HCC) cell lines after irradiation with photons or carbon ions in combination with new targeted molecular therapy using either Temsirolimus (TEM) or Gemcitabine (GEM). "}, {"drug": "Temsirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety, activity, pharmacokinetics (PK), and biomarkers of the mammalian target of rapamycin inhibitor, temsirolimus, combined with sorafenib in hepatocellular carcinoma (HCC). "}, {"drug": "Temsirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K (BKM-120) or both (BEZ-235 and GDC-0980) in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) cells characterized for acquired resistance to sorafenib or sunitinib. "}, {"drug": "ThermoDox", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "HEAT trial) evaluating the combination of ThermoDox\u00ae and radiofrequency ablation (RFA) in comparison to RFA alone for treatment of inoperable hepatocellular carcinoma (HCC) failed to reach its primary endpoint in progression-free survival (PFS). "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: The purpose of this study was to determine whether biomarkers from baseline plasma and archival tissue specimens collected from patients enrolled in the EVOLVE-1 trial - a randomized phase 3 study of everolimus in hepatocellular carcinoma (HCC) - were associated with prognosis, etiology or ethnicity. "}, {"drug": "Everolimus", "disease": "hepatic carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The mTORC1-inhibitor everolimus shows limited efficacy in treating patients with gastro-entero-pancreatic or pulmonary neuroendocrine tumors (NETs), and poor outcome in patients with malignant pheochromocytoma or hepatic carcinoma. "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Therefore, we tested the effect of lovastatin--known to inhibit both ERK and AKT signaling--and everolimus, separately and in combination, on cell viability and signaling pathways in human midgut (GOT), pancreatic (BON1), and pulmonary (H727) NET, hepatocellular carcinoma (HepG2, Huh7), and mouse pheochromocytoma (MPC, MTT) cell lines. "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Promising results in the prevention of hepatocellular carcinoma (HCC) recurrence have been reported with the use of mTOR inhibitors including everolimus and sirolimus and the ongoing open-label prospective randomized controlled SILVER. "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib-everolimus combination therapy may be more effective than sorafenib monotherapy for hepatocellular carcinoma (HCC). "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Indications for conversion to everolimus were renal dysfunction (32.6% of cases), hepatocellular carcinoma (HCC; 30.2%; prophylactic treatment for 68.9%), and de novo malignancy (29.7%). "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This review provides an overview of the efficacy and safety of everolimus-based regimens in liver transplantation in the de novo and maintenance settings, as well as in special populations such as patients with hepatocellular carcinoma recurrence, hepatitis C virus-positive patients, and pediatric transplant recipients. "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "OBJECTIVE: To assess the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed. "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS AND RELEVANCE: Everolimus did not improve overall survival in patients with advanced hepatocellular carcinoma whose disease progressed during or after receiving sorafenib or who were intolerant of sorafenib. "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Everolimus, a mammalian target of rapamycin inhibitor, has been shown to reduce growth factor-mediated cell proliferation, but data regarding its effectiveness and impact on renal function and recurrence of hepatocellular carcinoma (HCC) in liver transplant (LT) recipients are limited. "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K (BKM-120) or both (BEZ-235 and GDC-0980) in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) cells characterized for acquired resistance to sorafenib or sunitinib. "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved as an immunosuppressant and for second-line therapy of hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: The recommended everolimus dosing schedule for future hepatocellular carcinoma studies is 7.5 mg daily. "}, {"drug": "Everolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: The aim of this study was to assess the safety and efficacy of sorafenib, with or without everolimus, in the treatment of recurrent hepatocellular carcinoma (HCC) after an orthotopic liver transplantation (OLT). "}, {"drug": "Dasabuvir", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC). "}, {"drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma", "polarity": 1, "orig_sen": "The tumor was diagnosed as an unresectable intrahepatic cholangiocarcinoma, and chemotherapy (a combination of gemcitabine and S-1) was initiated. "}, {"drug": "sunitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Viability of human colorectal cancer (CRC, HCT116 and HT29) and hepatocellular carcinoma (HCC, HepG2) cells upon exposure to sunitinib DEB was measured using a bioluminescent assay. "}, {"drug": "sunitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To evaluate the safety/efficacy and explore biomarkers for a rationally designed combination of sunitinib and transarterial chemoembolization (TACE) in a prospective phase 2 study of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sunitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Patients age 20 years or older with relapsed or metastatic renal cell carcinoma, unresectable hepatocellular carcinoma, or gastrointestinal stromal tumor resistant to imatinib and sunitinib were included. "}, {"drug": "sunitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We investigated the expression of the main ABC proteins and the role of cytoplasmic vacuoles in the MDR of six hepatocellular carcinoma (HCC) cell lines, and confirmed the accumulation of the yellow anti-cancer drug sunitinib in giant (four lines) and small cytoplasmic vacuoles of lysosomal origin (two lines). "}, {"drug": "sunitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of this study was to compare the efficacy of sunitinib combined with transarterial chemoembolization (TACE) versus TACE alone for treating patients with advanced-stage hepatocellular carcinoma (HCC). "}, {"drug": "sunitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "AIMS: To assess the heterogeneity of tumor using fractal analysis of contrast-enhanced computed tomography (CE-CT) images for predicting survival of hepatocellular carcinoma (HCC) patients treated with sunitinib. "}, {"drug": "sunitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K (BKM-120) or both (BEZ-235 and GDC-0980) in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) cells characterized for acquired resistance to sorafenib or sunitinib. "}, {"drug": "sunitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We performed in vitro experiments to study whether Sunitinib, a platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) RTKs' inhibitor, could block both activated HSC functions and angiogenesis and thus prevent the progression of cirrhotic liver to hepatocellular carcinoma. "}, {"drug": "sunitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In conclusion, the present study demonstrates that the RTK inhibitor Sunitinib blocks the activation of HSC and angiogenesis suggesting its potential as a drug candidate in pathological conditions like liver fibrosis and hepatocellular carcinoma. "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This work investigates on putative cytotoxic effects in four different hepatocellular carcinoma (HCC) cell lines after irradiation with photons or carbon ions in combination with new targeted molecular therapy using either Temsirolimus (TEM) or Gemcitabine (GEM). "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the effect of a sirolimus-based immunosuppressive protocol on tumor recurrence and survival after liver transplantation (LT) in hepatocellular carcinoma (HCC) patients. "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Multivariate analysis indicated that HCV, alcoholic liver disease, autoimmune liver disease, nonalcoholic steatohepatitis, re-transplantation, combined transplantation, hepatocellular carcinoma, immunosuppression regime of cellcept, cyclosporine, sirolimus, steroids and tacrolimus were independent predictors for the development of solid malignancies after liver transplantation. "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC). "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Promising results in the prevention of hepatocellular carcinoma (HCC) recurrence have been reported with the use of mTOR inhibitors including everolimus and sirolimus and the ongoing open-label prospective randomized controlled SILVER. "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "There is some evidence that sirolimus retards hepatic fibrosis, is renal sparing and may be of benefit in preventing hepatocellular carcinoma (HCC) recurrence. "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "A 47-year-old male liver transplant recipient in 2009, who had hepatitis C and incidental hepatocellular carcinoma, underwent immunosuppressive therapy (cyclosporine and sirolimus). "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the influence of sirolimus on the long-term survival of patients after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC). "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety, activity, pharmacokinetics (PK), and biomarkers of the mammalian target of rapamycin inhibitor, temsirolimus, combined with sorafenib in hepatocellular carcinoma (HCC). "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K (BKM-120) or both (BEZ-235 and GDC-0980) in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) cells characterized for acquired resistance to sorafenib or sunitinib. "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The use of sirolimus (SRL)-based immunosuppression protocols have been reported to reduce recurrence rates following liver transplantation (LT) for hepatocellular carcinoma (HCC), although this is still a matter for debate. "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: The review showed lower recurrence rate, longer recurrence-free survival and overall survival and lower recurrence-related mortality in sirolimus-treated patients in comparison with the calcineurin inhibitor-treated patients following liver transplantation for hepatocellular carcinoma. "}, {"drug": "Sirolimus", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The reasons for the introduction of sirolimus were acute rejection (n = 8; 53.3%), chronic rejection (n = 2; 13.3%), development of malignancy (n = 3; 20%) or prior hepatocellular carcinoma (n = 2; 13.3%). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background: The Oxaliplatin plus 5-Fluorouracil /Leucovorin (FOLFOX4) regimen have been approved by Chinese Food and Drug Administration (CFDA), and covered by health insurance for patients with advanced hepatocellular carcinoma (HCC) in China. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We assessed the efficacy and safety of S-1, a chemotherapeutic agent based on fluorouracil, in patients with sorafenib-refractory advanced hepatocellular carcinoma. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background: The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Hepatocellular carcinoma (HCC), one of the most common types of liver cancer, could be treated with 5-fluorouracil (5-FU). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In\u00a0vitro antiproliferative activity of prepared compounds evaluated on five human cancer cell lines revealed that N,N-1,3-bis-(1,2,3-triazole)-5-bromouracil (5-7) and 5,6-disubstituted furo[2,3-d]pyrimidine-2-one-1,2,3-triazole 34a hybrids exhibited the most pronounced cytostatic acitivities against hepatocellular carcinoma (HepG2) and cervical carcinoma (HeLa) cells with higher potencies than the reference drug 5-fluorouracil. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In the present study, we show that miR-122 confers resistance to 5-fluorouracil induced hepatocellular carcinoma cell apoptosis in vitro and reduces the potency of 5-fluorouracil in the inhibition of tumor growth in a mouse xenograft model in vivo. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Knockdown of PCDH20 expression increases Akt phosphorylation, which leads to elevated mTOR activity and enhanced 5-fluorouracil resistance; whereas rescue of PCDH20 expression in miR-122-expressing cells decreases Akt and mTOR phosphorylation, re-sensitizing hepatocellular carcinoma cell to 5-fluorouracil induced apoptosis. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "A major implication of our study is that inhibition of miR-122 or restoration of PCDH20 expression may have significant therapeutic potential to overcome drug resistance in hepatocellular carcinoma and that the combined use of an Akt inhibitor with 5-fluorouracil may increase efficacy in liver cancer treatment. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Notably, besides the anti-HBV DNA replication activity, compound 4j also exhibited more potent in\u00a0vitro cytotoxic activity than 5-fluorouracil in two hepatocellular carcinoma cell (HCC) lines (QGY-7701 and SMMC-7721), indicating that 4j may be a promising lead for the exploration of drugs with dual therapeutic effects on HBV infection and HBV-induced HCC. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here we report an investigation on the effect of a combined treatment on human hepatocellular carcinoma BEL-7402 cells using low-intensity ultrasound (US) and 5-fluorouracil (5-FU). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Three human hepatocellular carcinoma cell lines--HepG2, Hep3B and HuH-7--were pre- and post-treated with doxorubicin, 5-fluorouracil (5-FU) and cisplatin. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We conducted a phase I/II study in patients with advanced hepatocellular carcinoma (HCC) to determine the recommended dose, as well as the safety and efficacy, of combination therapy of sorafenib with hepatic arterial infusion chemotherapy (HAIC) using low dose cisplatin (CDDP) and 5-fluorouracil (5FU). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here, we investigated the synergistic effect of OMT with 5-fluorouracil (5-Fu) on the tumor growth inhibition of hepatocellular carcinoma cells (HCC; Hep-G2 and SMMC-7721) and explored the underlying mechanism. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study aimed to investigate the combination of luteolin and 5-fluorouracil on proliferations of hepatocellular carcinoma cells and the potential mechanisms. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here, we report the effect of an APN inhibitor 4cc in enhancing sensitivity of hepatocellular carcinoma (HCC) cell lines and xenograft model in response to 5-fluorouracil (5-FU) in vivo and in vitro. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "liver hepatocellular carcinoma (HepG2), colon carcinoma (Caco-2) and a non-cancer cell line Human Embryonic Kidney (HEK293), using the MTT cell viability assay and compared against a standard anticancer drug, 5-fluorouracil. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the efficacy and safety of chemoembolization alone or chemoembolization combined with hepatic arterial infusion chemotherapy (HAIC), including oxaliplatin (OXA), 5-fluorouracil (5-FU) and folinic acid (CF), in inoperable hepatocellular carcinoma (HCC) without distant metastasis. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The preliminary assays indicated that some of the newly obtained compounds exhibited good antitumor activities against human hepatocellular liver carcinoma (HepG2), heptoma (Huh-7), melanoma (A875) and 5-fluorouracil-resistant human hepatocellular carcinoma (BEL-7402/5-FU) cell lines compared with 5-fluorouracil (5-FU), which might be considered as promising lead scaffold for further design and synthesis of highly potential anticancer agents. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The present study is designed to explore the influence of CGA on the effects of 5-fluorouracil (5-FU) on human hepatocellular carcinoma cells (HepG2 and Hep3B). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Herein, we report that NPs conjugated with antibody against GRP78 (mAb GRP78-NPs) inhibit the adhesion, invasion, and metastasis of hepatocellular carcinoma (HCC) and promote drug delivery of 5-fluorouracil into GRP78 high-expressed human hepatocellular carcinoma cells. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The present study investigated the ability of metformin to reverse multidrug resistance (MDR) in human hepatocellular carcinoma Bel\u20117402/5\u2011fluorouracil (5\u2011Fu; Bel/Fu) cells. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report a case of long-term survival of a patient who received low-dose 5-fluorouracil and cisplatin (FP) systemic chemotherapy and underwent partial resection of the lung for a tumor thrombus in the inferior caval vein (IVC) and multiple lung metastases from recurrent hepatocellular carcinoma (HCC). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) compared with doxorubicin alone in terms of overall survival (OS), progression-free survival (PFS), and safety in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In the current study, we examined clonogenic survival, DNA damage, and cell cycle distribution in hepatocellular carcinoma (HCC) cell lines treated with LDR in combination with varying doses and schedules of 5-fluorouracil (5-FU), gemcitabine, and sorafenib. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " 5-fluorouracil (5-FU)-based chemotherapy is widely used in the treatment of human hepatocellular carcinoma. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: The present pilot study aimed to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with interferon-beta (IFN-\u03b2) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "OBJECTIVE: In present work, lactobionic acid conjugated PLGA nanoparticles (LDNPs) bearing 5-Fluorouracil (5-FU) were developed for targeted delivery to hepatocellular carcinoma. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: The human hepatocellular carcinoma cell line HepG2 MCSs were used as in vitro models to investigate the effects of celecoxib combined with 5-fluorouracil or sorafenib or gefitinib treatment on cell growth, apoptosis, and signaling pathway. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and cisplatin for intractable advanced hepatocellular carcinoma (HCC) may have survival benefits. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "shRNA-mediated PDE3B depletion in CDDP-resistant cells derived from SCC cells and Hela cells and induced CDDP sensitivity and inhibited tumor growth with elevated cyclic GMP induction resulting in upregulation of the multidrug-resistant molecule, but this did not occur in the 5-fluorouracil-resistant hepatocellular carcinoma cell lines. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Our study found that the expression of miR-27a was down-regulated in the multidrug-resistant hepatocellular carcinoma cell line BEL-7402/5-fluorouracil (BEL/5-FU) compared with its parental BEL-7402 cell line, while the MDR1/P-glycoprotein expression was elevated. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " 5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used for the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Previously, a pilot genome-wide association study has identified candidate single nucleotide polymorphism predictors for the therapeutic response of 5-fluorouracil, mitoxantrone and cisplatin (FMP) combination chemotherapy in advanced hepatocellular carcinoma (HCC). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Multidrug resistant H22 (H22/FAP) hepatocellular carcinoma cells were produced in vitro by continuous exposure to increasing doses of doxorubicin, cisplatin and 5-fluorouracil (FAP regimen). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine whether 5-fluorouracil (5-FU) sensitivity is associated with the mRNA expressions of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and thymidine phosphorylase (TP) in patients with hepatocellular carcinoma (HCC) treated with 5-FU-based transarterial chemoembolization (TACE). "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Modified cisplatin/interferon \u03b1-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon \u03b1-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepatocellular carcinoma. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Acquired resistance to 5-fluorouracil (5-FU) is a serious therapeutic obstacle in advanced hepatocellular carcinoma (HCC) patients. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The efficacy of combination therapy with subcutaneous interferon (IFN)-\u03b1 and intra-arterial 5-fluorouracil (5-FU) as a postoperative adjuvant for resectable advanced hepatocellular carcinoma (HCC) invading the major branches of the portal vein (PVTT) was examined. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " 5-fluorouracil (5-FU) is one of the standard chemoradiotherapy regimens for hepatocellular carcinoma (HCC) treatment. "}, {"drug": "Fluorouracil", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODOLOGY: We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma. "}, {"drug": "celecoxib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Interferon-\u03b1 and the COX-2 inhibitor celecoxib synergistically increased TRAIL-induced apoptosis in hepatocellular carcinoma. "}, {"drug": "celecoxib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The data demonstrated that celecoxib induced apoptosis in mouse liver cancer cells via the mitochondria-dependent pathway rather than the PPAR\u03b3/NF-\u03baB signaling pathway, which indicates that celecoxib may be an effective agent in the clinical management of hepatocellular carcinoma. "}, {"drug": "celecoxib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Celecoxib, a COX-2 inhibitor and non-steroidal anti-inflammatory drug, can prevent several types of cancer, including hepatocellular carcinoma (HCC). "}, {"drug": "celecoxib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: The human hepatocellular carcinoma cell line HepG2 MCSs were used as in vitro models to investigate the effects of celecoxib combined with 5-fluorouracil or sorafenib or gefitinib treatment on cell growth, apoptosis, and signaling pathway. "}, {"drug": "celecoxib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Our results provided molecular evidence to support celecoxib combination-treatment strategies for patients with human hepatocellular carcinoma. "}, {"drug": "celecoxib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate the effect of celecoxib on regulatory T cells (Treg) in mouse hepatocellular carcinoma (HCC). "}, {"drug": "celecoxib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: These results suggest that celecoxib may play a role in modifying the natural history of hepatocellular carcinoma development. "}, {"drug": "celecoxib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To validate the efficacy of an innovative multimodality therapy with transcatheter arterial embolization (TAE) plus octreotide and celecoxib in reducing neoangiogenesis and prolonging the survival of rabbits with hepatocellular carcinoma. "}, {"drug": "Cetuximab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The specific targeting ability of cetuximab-NDs-cisplatin system on human liver hepatocellular carcinoma (HepG2) cells is evaluated through epidermal growth factor receptor (EGFR) blocking experiments, since EGFR is over-expressed on HepG2 cell membrane. "}, {"drug": "Cetuximab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study aimed to investigate the function of let-7a in regulating the sensitivity of hepatocellular carcinoma (HCC) cell lines to cetuximab. "}, {"drug": "Cetuximab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We have demonstrated that non-invasive RF-induced hyperthermia when combined with targeted delivery of gemcitabine is more effective and safe at dosages ~275-fold lower than the current clinically-delivered systemic dose of gemcitabine.FROM THE CLINICAL EDITOR: In a model of hepatocellular carcinoma, the authors demonstrate that non-invasive RF-induced hyperthermia applied with cetuximab targeted delivery of Au NP-gemcitabine conjugate is more effective and safe at dosages ~ 275-fold lower than the current clinically-used systemic dose of gemcitabine. "}, {"drug": "belinostat", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We studied the pharmacokinetics of belinostat in hepatocellular carcinoma patients to determine the main pathway of metabolism of belinostat. "}, {"drug": "belinostat", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. "}, {"drug": "HBIG", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The effects of HBcrAg, hepatocellular carcinoma (HCC) recurrence, and HBs gene mutation on HBV reinfection and withdrawal from hepatitis B immune globulin (HBIG) were analyzed. "}, {"drug": "HBIG", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the impact of high-dose hepatitis B immunoglobulin (HBIG) on hepatocellular carcinoma (HCC) and hepatitis B virus (HBV) recurrence and overall survival after living donor liver transplantation (LDLT). "}, {"drug": "HBIG", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Three of the seven patients (42.9%) developed recurrence after cessation of HBIG, and three (42.9%) were cases with hepatocellular carcinoma (HCC) recurrence after LDLT. "}, {"drug": "HBIG", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Pretransplant hepatocellular carcinoma, high viral load and posttransplant prophylactic protocol (lamivudine and HBIG vs entecavir and HBIG) were associated with HBV recurrence. "}, {"drug": "HBIG", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "A preoperative HBV DNA load of more than 10(5) IU/mL, HBIG monotherapy, and hepatocellular carcinoma in the explant liver were independent risk factors for HBV recurrence following LT in multivariate analysis. "}, {"drug": "HBIG", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "DOI: 10.1556/OH.2013.29625 PMID: 23853347 [Indexed for MEDLINE]  Reinfection with hepatitis B virus (HBV) after liver transplantation (LT) may favor the recurrence of hepatocellular carcinoma (HCC), and combination therapy with hepatitis B immunoglobulin (HBIG) and nucleoside/nucleotide analogues may reduce HBV recurrence after LT. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To investigate whether bevacizumab compromises early response assessment after Transarterial Chemoembolization (TACE) in patients with hepatocellular carcinoma by 3D quantitative European Association for the Study of the Liver (qEASL) criteria in comparison to other imaging-based criteria. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: AGS (gastric cancer), Caco-2 (colorectal cancer) and HepG2/C3A (hepatocellular carcinoma), were treated with telomerase inhibitors BIBR-1232 (10\u03bcM) and costunolide (10\u03bcM), with bevacizumab (Avastin\u00ae at 5 ng/ml or 100\u03bcg/ml) or with a combination of both types of inhibitors. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This prospective study was to investigate the value of [(11)C]-acetate PET and [(18)F]-FDG PET in the evaluation of hepatocellular carcinoma (HCC) before and after treatment with transarterial chemoembolization (TACE) and vascular endothelial growth factor (VEGF) antibody (bevacizumab). "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: The four Phase I studies were a multiple-ascending dose study in 23 patients with solid tumors (Study 1), an open-label study in seven patients with colorectal/ovarian cancer (Study 2), a sorafenib combination study in nine patients with hepatocellular carcinoma (Study 3), and a bevacizumab combination study in 22 patients with recurrent glioblastoma (Study 4). "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "BACKGROUND: Early clinical studies of bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) have a tolerable toxicity and a promising clinical outcome. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To investigate the efficacy and safety of conventional transarterial chemoembolization (TACE) (cTACE) in combination with bevacizumab or a placebo in patients with hepatocellular carcinoma (HCC) in a randomized controlled double-blind phase II trial. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of the present study was to explore the effects of curcumin in combination with bevacizumab on the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)/K-ras pathway in hepatocellular carcinoma. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Ongoing clinical trials are testing TRC105 in combination with bevacizumab in glioblastoma and with VEGFR TKIs in renal cell carcinoma, hepatocellular carcinoma, and soft tissue sarcoma. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Radioembolization as part of first-line therapy in metastatic colorectal tumors is being tested in large international trials combined with FOLFOX6 and bevacizumab, as well as in hepatocellular carcinoma with sorafenib. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: The bevacizumab/erlotinib combination was reported with high clinical activity for advanced hepatocellular carcinoma (HCC) by a phase II study conducted in the USA. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "There are no other reports about erlotinib-induced leukocytoclastic vasculitis (LV) in the erlotinib-bevacizumab regimen for bone metastasis, from a relapsed hepatocellular carcinoma (HCC) in liver-transplanted patients. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: PubMed, the Cochrane Library, and Google Scholar were searched using the terms \"bevacizumab AND hepatocellular carcinoma AND (advanced OR unresectable)\". "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Preclinical studies have demonstrated the additive effect of rapamycin with bevacizumab for hepatocellular carcinoma treatment. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Adult participants with advanced hepatocellular carcinoma received intravenous bevacizumab (5mg/kg every 14 days) and oral rapamycin (1-6 mg/day; 3+3 dose escalation design). "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this study, we reported that bevacizumab treatment reduced the development of new blood vessels and inhibited cell growth in xenografts of hepatocellular carcinoma (HCC) tumors. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS AND METHODS: Athymic nude mice bearing human hepatocellular carcinoma xenografts were treated with bevacizumab and imaged daily with power Doppler ultrasound to quantify tumour blood flow. "}, {"drug": "Bevacizumab", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the combination of erlotinib and bevacizumab in subjects with hepatocellular carcinoma (HCC) who are not candidates for local therapy. "}, {"drug": "Licartin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study evaluated the safety and objective response of combining 131I-labeled-metuximab (Licartin) with transarterial chemoembolization (TACE) in the treatment of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "Licartin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of the present study was to examine the safety and efficacy of a peripheral intravenous bolus of Licartin for the treatment of advanced hepatocellular carcinoma (HCC), and to explore the clinical value of this treatment. "}, {"drug": "Licartin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Metuximab is the generic name of Licartin, a new drug for radioimmunotherapy of hepatocellular carcinoma. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Mechanistic target of rapamycin (mTOR) signaling is typically increased in hepatocellular carcinoma (HCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The Akt/mammalian target of rapamycin (mTOR) and the extracellular signal-regulated kinase 1/2 (ERK1/2) pathways are both involved in nutrient-induced autophagic phenomenon and exhibit vital relevance to oncogenesis in various cancer cell types, including hepatocellular carcinoma (HCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Dysregulation of mammalian target of rapamycin (mTOR) in hepatocellular carcinoma (HCC) represents a valuable treatment target. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We have shown previously that rapamycin, the canonical inhibitor of the mechanistic target of rapamycin (mTOR) complex 1, markedly inhibits the growth of focal lesions in the resistant hepatocyte (Solt-Farber) model of hepatocellular carcinoma (HCC) in the rat. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: We investigated the mutational landscape of mammalian target of rapamycin (mTOR) signalling cascade in hepatocellular carcinomas (HCCs) with chronic HBV background, aiming to evaluate and delineate mutation-dependent mechanism of mTOR hyperactivation in hepatocarcinogenesis. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Rapamycin, a specific inhibitor of mTOR used extensively as an immunosuppressant, has been expanded recently to cancer therapy, because the mTOR signal is known to be up-regulated in various cancer cells including hepatocellular carcinoma (HCC) cells. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The presented study aimed to investigate the antitumor efficacy of combination of oxaliplatin with rapamycin, an mTOR inhibitor, in hepatocellular carcinoma (HCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Metformin inhibits the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, which is frequently upregulated in hepatocellular carcinoma (HCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: We aimed to investigate the associations between components of the phosphatase and tensin homolog deleted on chromosome 10/protein kinase B/mammalian target of rapamycin (PTEN/AKT/mTOR) pathway and liver cancer stem cell (LCSC) markers, including CD133, CD90, CD44, and epithelial cell adhesion molecule (EpCAM), and to further evaluate the predictive values of these biomarkers for recurrence and survival in hepatocellular carcinoma (HCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Aberrant activation of mammalian target of rapamycin (mTOR) plays pivotal roles in promoting hepatocellular carcinoma (HCC) tumorigenesis and chemoresistance. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Recent studies have indicated that mammalian target of rapamycin (mTOR) signaling has a critical role in the pathogenesis of hepatocellular carcinoma (HCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Mammalian target of rapamycin (mTOR) is frequently upregulated in hepatocellular carcinoma (HCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of the present study was to investigate the combined effects of inhibiting the Ras homolog gene family, member C (RhoC)/Rho kinase and phosphoinositide 3 kinase/Akt/mammalian target of rapamycin (mTOR) pathways on hepatocellular carcinoma cell growth. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The PubMed and Ovid MEDLINE databases were searched from 2000 to March 2015, using a combination of relevant text words and MeSH terms: metformin and mammalian target of rapamycin, hepatitis B virus (HBV), hepatitis B virus (HCV), non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma (HCC) or cholangiocarcinoma. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Hepatitis B virus (HBV) pre-S2 mutant can induce hepatocellular carcinoma (HCC) via the induction of endoplasmic reticulum stress to activate mammalian target of rapamycin (MTOR) signaling. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "There is evidence that AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) become dysregulated during the development of hepatocellular carcinoma (HCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Adiponectin blocks hepatocellular carcinoma (HCC) progression by inducing cell apoptosis through the modulation of C-Jun N-terminal kinase and mammalian target of rapamycin. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Aberrant signaling mediated by the mammalian target of rapamycin (mTOR) occurs at high frequency in hepatocellular carcinoma (HCC), indicating that mTOR is a candidate for targeted therapy. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The present study aimed to investigate the in vitro synergistic anticancer effect of combined treatment of rapamycin at various concentrations (0, 10, 50, 100 and 200 nM) and berberine (62.5 \u00b5M) in SMMC7721 and HepG2 hepatocellular carcinoma (HCC) cell lines, and the potential underlying molecular mechanism. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Inhibition of mTOR phosphorylation by rapamycin enhanced the radiosensitivity of BKM120-treated hepatocellular carcinoma cells. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Obesity-induced insulin resistance depends, in part, on chronic activation of mammalian target of rapamycin complex 1 (mTORC1), which also occurs in human and mouse hepatocellular carcinoma (HCC), a frequently fatal liver cancer. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "There is now evidence to suggest that microtubule-binding agents may be effective in the treatment of hepatocellular carcinoma, especially when used in combination with mammalian target of rapamycin inhibitors. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Everolimus, a mammalian target of rapamycin inhibitor, has been shown to reduce growth factor-mediated cell proliferation, but data regarding its effectiveness and impact on renal function and recurrence of hepatocellular carcinoma (HCC) in liver transplant (LT) recipients are limited. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Dysregulation of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling has been found in several types of human cancer, including hepatocellular carcinoma (HCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety, activity, pharmacokinetics (PK), and biomarkers of the mammalian target of rapamycin inhibitor, temsirolimus, combined with sorafenib in hepatocellular carcinoma (HCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Mammalian target of rapamycin (mTOR) and the microtubules are shown to be potential targets for treating hepatocellular carcinoma (HCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K (BKM-120) or both (BEZ-235 and GDC-0980) in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) cells characterized for acquired resistance to sorafenib or sunitinib. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved as an immunosuppressant and for second-line therapy of hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Preclinical studies have demonstrated the additive effect of rapamycin with bevacizumab for hepatocellular carcinoma treatment. "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Adult participants with advanced hepatocellular carcinoma received intravenous bevacizumab (5mg/kg every 14 days) and oral rapamycin (1-6 mg/day; 3+3 dose escalation design). "}, {"drug": "Rapamycin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Deregulation of mammalian target of rapamycin (mTOR) signalling is common in human hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is currently the only US Food and Drug Administration (FDA)-approved molecular inhibitor for the systemic therapy of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The management of recurrent hepatocellular carcinoma untreatable with surgical options is based on systemic therapy with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background-aims: The clinical benefit of sorafenib in patients with hepatocellular carcinoma (HCC) has been undervalued due to the absence of complete responses even though patients who develop early dermatologic reactions have shown very positive outcome. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Purpose Sorafenib is currently the only Food and Drug Administration-approved first-line therapy for patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Patients and Methods We retrospectively evaluated 4,903 patients from 128 Veterans Health Administration hospitals who were prescribed sorafenib for hepatocellular carcinoma between January 2006 and April 2015. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Furthermore, compound 10m, was found to be about 2-folds more potent than the anticancer drug Sorafenib in hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Comprehensive treatments together with sorafenib provide a survival benefit for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib remains the only standard first-line drug for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib remains the only approved drug for treating patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multitargeted kinase inhibitor currently used in the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The effect of skeletal muscle mass (SMM) on the outcomes of sorafenib treatment for hepatocellular carcinoma (HCC) has not been established. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background: Some researchers have suggested that vitamin K enhances the antitumor effect of sorafenib for hepatocellular carcinoma (HCC) in vitro and in vivo. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is a standard treatment for patients (pts) with advanced hepatocellular carcinoma (aHCC), although the clinical benefit is heterogeneous between different pts groups. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Peritoneal metastasis of hepatocellular carcinoma is rare and the benefit of systemic chemotherapy is poor and from Sorafenib is not well described. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Sorafenib, a multikinase inhibitor, is the standard therapy for patients with advanced-stage hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The present study aimed to examine the impact of sarcopenia, defined as low muscle mass on computed tomography (CT), prior to sorafenib therapy on the clinical outcomes of patients with hepatocellular carcinoma (HCC) receiving sorafenib therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In the previous research literature, only one case of sorafenib-induced RPLS, in a patient with hepatocellular carcinoma, has been reported. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Patients with hepatocellular carcinoma (HCC) who respond to sorafenib have been reported to exhibit an increase in the level of des-\u03b3-carboxyprothrombin (DCP) in the blood, subsequent to the initiation of sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is recommended for the treatment of advanced-stage hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This could change with the imminent announcement of results from the phase 3 Sorafenib vs Radioembolization in Advanced Hepatocellular carcinoma (SARAH) trial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "There is also a review of key prospective and retrospective studies evaluating the use of Y-90 SIRT, specifically Y-90 resin microspheres in unresectable HCC, which led to the development of the SARAH trial.METHODS: To identify relevant publications, the PubMed database was queried using one or more of the following search terms alone or in combination with Boolean operators: epidemiology, hepatocellular, hepatocellular cancer, hepatocellular carcinoma, unresectable, radioembolisation, selective internal radiation therapy, SIR-Spheres, yttrium 90, TACE, and sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) but is challenging after treatment failure. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the standard treatment of advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "RESULTS: Since 2005, 129 patients were treated with sorafenib for hepatocellular carcinoma: 31 in the EP (24%), 22 in a clinical trial (17%), and 76 with UC (59%). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Hence, somatostatin receptor-directed strategies, sorafenib, and imatinib have revolutioned the management of neuroendocrine tumours (NET), hepatocellular carcinoma (HCC), and gastrointestinal stromal tumours (GIST), respectively, and are now used as first-line treatment in many patients affected by these tumours. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is a first-line treatment option for advanced hepatocellular carcinoma (HCC) patients; however, survival predictors upon progression have not been well characterized. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Use of sorafenib remains debated in elderly patients treated for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Despite clinical studies with different mechanisms of action, no new systemic therapies were approved for hepatocellular carcinoma (HCC) between sorafenib in 2007 and regorafenib in 2017. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Purpose: Sorafenib is the only currently approved systemic therapy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multikinase inhibitor and is effective in treating hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " LESSONS LEARNED: There continues to be a lack of systemic options for advanced hepatocellular carcinoma (HCC); sorafenib and, very recently, regorafenib are the only approved options. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "BACKGROUND: Sorafenib is the currently approved first-line treatment for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "placebo in patients with unresectable hepatocellular carcinoma (HCC) in two phase III studies, SHARP (Sorafenib HCC Assessment Randomized Protocol) and Asia Pacific (AP). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Regorafenib, a multikinase inhibitor, has demonstrated prolonged survival by 2.8 months as a second-line agent in patients with hepatocellular carcinoma (HCC) who progress on sorafenib therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Sorafenib is the recommended standard of care for advanced hepatocellular carcinoma (HCC) patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background/Aims: Limited information is available regarding patient survival after sorafenib discontinuation in patients with hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "INTERPRETATION: The addition of sorafenib to DEB-TACE does not improve progression-free survival in European patients with hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib has been used as a standard therapy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced stage Hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 patients have achieved a complete response (CR) in advanced HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Molecule-targeted therapy, such as sorafenib, is one of the effectively therapeutic options for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The Barcelona Clinic Liver Cancer staging system recommends a tyrosine kinase inhibitor (sorafenib) as standard therapy in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIM: Sorafenib is the standard of care for patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI), with limited survival. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) and sorafenib (SOR) are well-established treatments for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The small molecule multi-kinase inhibitor sorafenib has become the standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " LESSONS LEARNED: Trebananib leveraging anti-angiogenic mechanism that is distinct from the classic sorafenib anti-vascular endothelial growth factor inhibition did not demonstrate improved progression-free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC).In support of previously reported high Ang-2 levels' association with poor outcome in HCC for patients, trebananib treatment with lower baseline Ang-2 at study entry was associated with improved overall survival to 22 months and may suggest future studies to be performed within the context of low baseline Ang-2. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To report patient-focused outcomes as measured by quality of life (QoL) and performance status (PS) in REACH, a phase III placebo-controlled randomised study, assessing ramucirumab in advanced hepatocellular carcinoma (HCC) patients who received prior sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The tyrosine kinase inhibitor sorafenib is the only therapeutic agent approved for the treatment of advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib is high. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Therefore, targeting compensatory metabolic reprogramming of glutamine metabolism in sorafenib-resistant HCC by inhibiting PPAR\u03b4 constitutes a potential therapeutic strategy for overcoming sorafenib-resistance in HCC.Implications: This study provides novel insight into the mechanism underlying sorafenib resistance and a potential therapeutic strategy targeting PPAR\u03b4 in advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To investigate the feasibility of perfusion-CT (p-CT) measurements in quantitative assessment of hemodynamic changes related to sorafenib in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC) and well preserved liver function. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Objective: The objective of this study was to determine the effects of sorafenib on TH levels in patients with hepatocellular carcinoma (HCC) and to evaluate possible mechanisms. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: Sorafenib is the first molecular targeted drug approved for the treatment of advanced hepatocellular carcinoma (HCC) and is a potent small molecule inhibitor of multiple kinases. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is currently used to treat advanced and/or unresectable hepatocellular carcinoma (HCC), but the increase of the median survival was only 3\u00a0months. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a multi-kinase inhibitor, inhibits tumor angiogenesis and is the first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the only standard treatment for unresectable hepatocellular carcinoma (HCC), but it provides modest survival benefits over placebo, necessitating predictive biomarkers of the response to sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To explore the relationship between regorafenib exposure and efficacy in patients with hepatocellular carcinoma (HCC) who had disease progression during sorafenib treatment (RESORCE). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib, a multikinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet derived growth factor receptor-\u03b2, B-Raf proto-oncogene, serine/threonine kinase and C-Raf proto-oncogene, serine/threonine kinase, is a novel reference standard for the treatment of advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The FDA recently expanded label indications for regorafenib to include treating patients with advanced hepatocellular carcinoma whose disease has progressed on the standard of care, sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Objective To investigate the roles of tumor-associated macrophages (TAMs) and epithelial growth factor receptor (EGFR)/\u03b2-catenin signaling pathway in sorafenib resistance of hepatocellular carcinoma cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The protein expressions of \u03b2-catenin and EGFR in sorafenib-resistant cells and hepatocellular carcinoma tissues were higher than those in the controls. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Conclusion TAMs and EGFR/\u03b2-catenin signaling pathway promote the proliferation, invasion and migration of sorafenib resistance of hepatocellular carcinoma cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We assessed the efficacy and safety of S-1, a chemotherapeutic agent based on fluorouracil, in patients with sorafenib-refractory advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Patients with advanced hepatocellular carcinoma who were ineligible for surgical or local-regional therapy and judged refractory to sorafenib (ie, had progressed on sorafenib or had discontinued sorafenib because of adverse events) were randomly assigned (2:1) to receive oral S-1 (weight-banded 80 mg/m(2) [80-120 mg per day]), or placebo, twice per day for 28 days consecutively, followed by a minimum 14 day drug-free period. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "INTERPRETATION: S-1 did not prolong overall survival in patients with sorafenib-refractory advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib and cisplatin plus gemcitabine currently represent first-line treatment standards in advanced hepatocellular carcinoma and biliary cancer, respectively. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the current standard treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is not recommended for advanced hepatocellular carcinoma (HCC) patients with Vp4 (portal invasion at the main trunk) by the Japan Society of Hepatology (JSH) due to a risk of hepatic failure. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Resistance to sorafenib in hepatocellular carcinoma (HCC) cells exhibiting stemness was evaluated using a sphere formation assay. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aims of this study were to assess the heterogeneity of BCLC-C hepatocellular carcinoma (HCC) cases, propose a novel subclassification for these cases, and suggest optimal treatment strategies other than sorafenib.We retrospectively analyzed 196 consecutive BCLC-C HCC patients who were diagnosed and treated between January 2008 and December 2015.All 196 patients were classified according to the modified Union for International Cancer Control (Stage I, 0.0%; Stage II, 8.2%; Stage III, 64.3%; Stage IVA, 21.9%; and Stage IVB, 5.6%) and American Joint Committee on Cancer TNM staging systems (Stage I, 0.0%; Stage II, 16.3%; Stage IIIA, 27.6%; Stage IIIB, 49.5%; Stage IIIC, 1.5%; Stage IVA, 1.0%; and Stage IVB, 4.1%). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the only approved targeted drug for hepatocellular carcinoma (HCC), but its effect on patients' survival gain is limited and varies over a wide range depending on pathogenetic conditions. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Western and some Asian guidelines stratify hepatocellular carcinoma with portal vein tumor thrombus together with metastatic hepatocellular carcinoma and therefore recommend only palliative treatment with sorafenib or other systemic agents. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Drug resistance to sorafenib is common in patients with hepatocellular carcinoma(HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of the present study was to compare the effectiveness of transarterial chemoembolization (TACE), TACE combined with Jie-du granules (JD), and TACE combined with sorafenib (SOR) for treating patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Oxaliplatin-based chemotherapy is an alternative systemic treatment for patients with metastatic hepatocellular carcinoma (HCC) who were refractory or intolerant to sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Use of the tyrosine kinase inhibitor sorafenib in patients with advanced hepatocellular carcinoma (HCC) is often hindered by the development of resistance, which has been recently shown to be associated with the emergence of a cancer stem cell (CSC) subpopulation. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Sorafenib, a multikinase inhibitor, is effective in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC); however, its therapeutic value in patients with HCC following resection remains controversial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "2-Deoxy-d-glucose (2DG) is an analogue of glucose, and sorafenib is a kinase inhibitor and molecular agent used to treat hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The purpose of this study was to examine the safety and efficacy of sorafenib in Chinese patients with unresectable hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Data of 338 Chinese patients from the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib study database were included. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We thus conclude that earlier administration of sorafenib may result in improved outcomes in patients with unresectable hepatocellular carcinoma and portal vein tumor thrombosis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Among these analogues, 3y exhibited a better cytotoxic effect on human hepatocellular carcinoma (HCC) Hep 3B cells and displayed less cytotoxicity on normal human umbilical vein endothelial cells, compared with Sorafenib, a targeted therapy for advanced HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Food and Drug Administration for hepatocellular carcinoma and other cancers, and showed only modest activity.Sorafenib's metabolism occurs via the CYP3A4 pathway, which is inhibited by ritonavir, a commonly used antiretroviral agent used by most patients in this study. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We found out that Vidatox increases HCC proliferation and invasion whereas it does not seem to interact with sorafenib, the orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: The four Phase I studies were a multiple-ascending dose study in 23 patients with solid tumors (Study 1), an open-label study in seven patients with colorectal/ovarian cancer (Study 2), a sorafenib combination study in nine patients with hepatocellular carcinoma (Study 3), and a bevacizumab combination study in 22 patients with recurrent glioblastoma (Study 4). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib (Nexavar(\u00ae)) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To perform a cost-effectiveness analysis comparing the use of transarterial radioembolization (TARE) with that of sorafenib in the treatment of patients with intermediate or advanced hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer staging system. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: We studied the relation between the polymorphism of P-glycoprotein (P-gp) and of breast cancer resistance protein (BCRP), encoded by ABCB1 and ABCG2 genes, respectively, and the pharmacokinetic variability and clinical response during the treatment with sorafenib of hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "AUTHORS' CONCLUSIONS: Currently, there is no evidence from randomised clinical trials that people with intermediate-stage hepatocellular carcinoma would benefit from systemic chemotherapy with sorafenib either alone or when transarterial chemoembolisation was used as a cointervention (very low quality evidence). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is a multi-targeting tyrosine kinase inhibitor that improves patient survival on hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a RAF inhibitor approved for several cancers, including hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib has been globally approved as the standard treatment for patients with advanced Hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: We conducted a phase I study of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for unresectable hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Current treatment options for unresectable hepatocellular carcinoma include various ablative and transarterial therapies in addition to the drug sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Purpose To identify early biomarkers for the prediction of the therapeutic response in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) and sorafenib (referred to as TACE plus sorafenib) and establish an effective prognostic nomogram. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: To investigate variables before sorafenib therapy on the clinical outcomes in hepatocellular carcinoma (HCC) patients receiving sorafenib and to further assess and compare the predictive performance of continuous parameters using time-dependent receiver operating characteristics (ROC) analysis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Neutral PPE nanoparticles were able to encapsulate two hydrophobic drugs, namely, sorafenib and paclitaxel, which are commonly used for the treatment of hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Although sorafenib is the only available drug with proven efficacy for patients with advanced hepatocellular carcinoma (HCC), the clinical efficacy of sorafenib is variable and unpredictable. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " At advanced stages of hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only effective treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Ectopic overexpression of T\u03b24 in hepatocellular carcinoma cells could significantly enhance sphere-forming capacities and infiltrating phenotypes in vitro, and promote growth of tumors refractory to the VEGFR multikinase inhibitor sorafenib in vivo Clinically, sorafenib failed to improve the progression-free survival in patients with T\u03b24-high hepatocellular carcinoma, indicating that T\u03b24 expression could be available as a surrogate marker of susceptibility to this drug. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the impact of hepatitis C virus (HCV) eradication on the clinical outcome of patients with HCV-related advanced hepatocellular carcinoma (HCC) treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib was the only small-molecule drug approved by FDA for treatment of the advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: The presence of dermatologic reaction as an adverse event to sorafenib treatment in patients with unresectable hepatocellular carcinoma has been indicated as a prognostic factor for survival in a recent prospective analysis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: This retrospective analysis showed the use of sorafenib in patients selected according to BCLC staging, and it is the first external validation of early dermatologic adverse events as a predictor of overall survival in patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Transarterial chemoembolization (TACE) or sorafenib is recommended for hepatocellular carcinoma BCLC stages B and C respectively. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: Response to sorafenib is highly variable in hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The SorAfenib versus Radioembolisation in Advanced Hepatocellular carcinoma (SARAH; 459 patients) trial is being performed in Europe and the SIRt VErsus SorafeNIB (SIRveNIB; 360 patients) trial in the Asia Pacific region. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic treatment that has been shown to increase overall survival. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the drug of choice in the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Melatonin has been shown to exert anticancer activity on hepatocellular carcinoma (HCC) through its antiproliferative and pro-apoptotic effect in both experimental and clinical studies, and sorafenib is the only approved drug for the systemic treatment of HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The benefits of transarterial chemoembolization plus sorafenib (TACE-S) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remain controversial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib, the medical treatment of reference against advanced stages of hepatocellular carcinoma (HCC), inhibits the RAF-MEK-ERK cascade in HCC cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In the advanced and metastatic setting, only two targeted drugs have been approved by the Food &amp; Drug Administration (FDA), which are sorafenib for hepatocellular carcinoma and erlotinib for PDA. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Since Sorafenib, a multikinase inhibitor has shown modest efficacy in advanced hepatocellular carcinoma additional treatments are highly needed. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is an FDA-approved multitarget tyrosine and serine/threonine kinase inhibitor currently used to treat hepatocellular carcinoma, advanced renal carcinoma and radioactive iodine-resistant thyroid carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is thus far the only systemic treatment for hepatocellular carcinoma (HCC) based on the results of two randomized controlled trials performed in Western and in Eastern countries, despite a poor response rate (from 2% to 3.3%) following conventional evaluation criteria. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The prognostic role of aberrant serum miRNA expression for predicting response to sorafenib treatment in advanced hepatocellular carcinoma (HCC) patients has not been well characterized. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Purpose Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, sorafenib has become the standard of care for patients with advanced unresectable hepatocellular carcinoma, but the relation between survival advantage and disease etiology remains unclear. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Theysohn, Alexander Dech\u00eane, Stefan M\u00fcller: Speaker honoraria and advisory board meetings BTG Intl.; Jan Best: Travel grant Bayer; Alexander Dech\u00eane: Speaker honoraria and advisory board meetings Bayer  PURPOSE: To assess the efficacy and safety of S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: PubMed, the Cochrane Library, EMBASE, and ClinicalTrials.gov were searched using the terms \"Hepatocellular Carcinoma\" or \"HCC\" or \"Hepatoma\" or \"Liver cancer\" and \"S-1\" and \"Sorafenib\" or \"Nexavar\". "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a chemotherapeutic agent approved for the treatment of hepatocellular carcinoma (HCC) in China. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is an antitumor drug for treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background: Sorafenib (Nexavar(\u00ae)) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: Sorafenib is the current standard treatment for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The multi\u2011kinase inhibitor sorafenib is the only drug for which randomized control trials have shown improved patient survival in advanced hepatocellular carcinoma\u00a0(HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The treatment responses of sorafenib in hepatocellular carcinoma are modest which may be due to different characteristics of cancer cells or insufficient therapeutic concentrations. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The anti-proliferative effects and differential expressions of 8 genes related to sorafenib anti-cancer mechanisms (tyrosine kinase receptor genes: KDR, PDGFRB; RAF cascade: RAF1, BRAF, MAP2K1, MAP2K2, MAPK1, MAPK3) were investigated in primary cultured hepatocellular carcinoma cells collected from 8 patients using clinically applied sorafenib concentrations (5, 10\u03bcg/mL). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) and sorafenib combination treatment for unselected hepatocellular carcinoma (HCC) is controversial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib significantly improves survival in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We recently published a paper entitled \"Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma\" in the Journal of the National Cancer Institute, providing a potential explanation for this limited benefit. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To provide support for combined usage of phosphoinositide 3-kinase (PI3K) inhibitors or mitogen-activated protein kinase pathway inhibitors together with sorafenib in treatment of sorafenib-resistant hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Our studies have showed that both inhibitors of PI3K/mTOR and RAS/ERK signaling are potentially effective antihepatocellular carcinoma drugs especially in treating sorafenib-resistant hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " \u200bIntroduction: Clinical markers to predict the benefit from sorafenib in patients diagnosed with hepatocellular carcinoma (HCC) are lacking. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "There is a lack of evidence about the prognostic value of serum LDH level in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment from hepatitis B virus endemic areas. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We found that long non-coding RNA TUC338 is involved in the development of hepatocellular carcinoma (HCC) and sorafenib resistance. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is an oral anti-angiogenic multi-kinase inhibitor used for systemic therapy in patients with advanced hepatocellular carcinoma (HCC) who are not suitable candidates for surgery or liver transplantation. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Regorafenib inhibits multiple kinases involved in tumor proliferation and neoangiogenesis, which has produced a survival benefit in hepatocellular carcinoma (HCC) after sorafenib failure. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS) with Sonazoid in evaluating early response to sorafenib for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This study aimed to identify the health-related quality of life (HRQOL) domains associated with prognosis by assessing longitudinal alterations in HRQOL in patients with advanced hepatocellular carcinoma receiving sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: We prospectively assessed HRQOL by administering the SF-36 questionnaire 3-monthly to consecutive patients with advanced hepatocellular carcinoma receiving sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Thus, HRQOL could be a valuable marker to predict the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib as an effective multikinase inhibitor has been approved for the clinical treatment against advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: In this pilot study, we assessed the safety and tolerability of combining sorafenib with (90)Y radioembolization for the treatment of unresectable hepatocellular carcinoma (hcc). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare in a randomized controlled trial (RCT) 3-year survival of cirrhotic patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT) treated with sorafenib plus percutaneous radiofrequency ablation (RFA) of both intraparenchymal HCC and PVTT (combination Group) or sorafenib alone (sorafenib-alone Group). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib is an oral multiple tyrosine kinase inhibitor and is currently the only evidence-based treatment recommended for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We report a case of osteonecrosis of the jaw that occurred during sorafenib therapy in a patient with advanced hepatocellular carcinoma not treated with bisphosphonates or other antiangiogenic drugs. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "RESULTS: A 74-year-old man diagnosed with hepatocellular carcinoma ensuing in hepatitis C virus infection, who was treated with sorafenib at a daily dose of 400 mg, developed osteonecrosis of the right mandibular body. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib was discontinued because of the radiological and laboratory features of hepatocellular carcinoma progression and the high risk of jaw fracture. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " In patients with hepatocellular carcinoma (HCC) receiving sorafenib, drug resistance is common. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To investigate the value of multiparametric magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) for monitoring the ultra-early (within 24 hours) treatment effect of sorafenib in human hepatocellular carcinoma (HCC) xenografts. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: This study aimed to build a prediction score of prognosis for patients with advanced hepatocellular carcinoma (HCC) after sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The most widely used is sorafenib, a potent multikinase inhibitor approved for hepatocellular carcinoma and renal cell carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the only chemotherapeutic approved for treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Macrophage infiltration was reduced in patients with hepatocellular carcinoma who were treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In vitro, sorafenib abolished polarized macrophage-induced epithelial mesenchymal transition (EMT) and migration of hepatocellular carcinoma cells but not normal hepatocytes. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Moreover, sorafenib attenuated HGF secretion in polarized macrophages, and decreased plasma HGF in patients with hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Additionally, sorafenib abolished the polarized macrophage-induced activation of the HGF receptor Met in hepatocellular carcinoma cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Our findings suggest that sorafenib inhibits polarized macrophage-induced EMT in hepatocellular carcinoma cells via the HGF-Met signaling pathway. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "These results contribute to our understanding of the immunological mechanisms that underlie the protective effects of sorafenib in hepatocellular carcinoma therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "However, little is known about the effects of ANGPTL1 on sorafenib resistance and cancer stem cell properties in hepatocellular carcinoma (HCC) and the mechanism underlying these effects. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To report the real-life results of sorafenib use in a cohort of HIV-infected patients with hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: Sorafenib, which has been used extensively for the treatment of renal cell cancer and advanced hepatocellular carcinoma (HCC), has also been shown to have antifibrotic effects in liver fibrosis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "However, their effects on sorafenib resistance in hepatocellular carcinoma (HCC) are not completely understood. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is still the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib resistance remains a major obstacle for the effective treatment of hepatocellular carcinoma (HCC), and a number of miRNAs contribute to this resistance. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This phase I study investigated the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics (PK) and biomarker correlates of selumetinib combined with sorafenib in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The mRECIST and dermatologic adverse events (AEs) can be used to assess the patient response to transarterial chemoembolization (TACE) and/or sorafenib for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is currently used as a standard treatment to suppress the progression of hepatocellular carcinoma (HCC), especially in advanced stages. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Overexpression of NRBP2 reduced the IC50 of sorafenib in hepatocellular carcinoma cells, and NRBP2 expression was negatively correlated with hepatocellular carcinoma cell resistance to the chemotherapy agents, including cisplatin and the Akt signaling inhibitor perifosine. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Thirty patients with unresectable hepatocellular carcinoma were enrolled to groups, depending on whether liver impairment was mild (group I, aspartate aminotransferase and alanine aminotransferase \u22642\u00d7 upper limit of normal and Child-Pugh score 5 [n = 14] or 6 [n = 2]) or moderate (group II, Child-Pugh score 5-6 and aspartate aminotransferase or alanine aminotransferase >2\u00d7 to \u22645\u00d7 upper limit of normal [n = 7] or Child-Pugh score 7 [n = 7]); 22 patients had prior sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC), but data on its use in the elderly are inconclusive. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: The aim of this study was to investigate the relationship between fever within 2 weeks after the start of sorafenib therapy and treatment efficacy in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We evalueted a systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the only chemotherapeutic agent currently approved for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib and regorafenib are small-molecule kinase inhibitors approved for the treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma, renal cell carcinoma, and hepatocellular carcinoma (sorafenib) and of colorectal cancer (regorafenib). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Previously, we proved that sorafenib with anti-EMT potency prevents TGF-\u03b21-induced EMT/invasion by directly activating SH2-domain-containing phosphatase 1 (SHP-1)-dependent p-STAT3Tyr705 suppression in hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The safety and efficacy of the combined use of sorafenib and yttrium-90 resin microspheres (Y90 RMS) to treat advanced hepatocellular carcinoma (HCC) is not well established. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Although the current standard treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is sorafenib, many previous studies have established the need for a reliable local modality for PVTT control, which is a major cause of liver function deterioration and metastasis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We explored the hypothesis that sorafenib may improve the effect of transarterial chemoembolization (TACE) in patients with recurrent hepatocellular carcinoma (HCC) and that longer sorafenib duration was associated with additional survival benefits. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Sorafenib improves survival and is superior to the BSC in cases of untreatable posttransplant hepatocellular carcinoma recurrence. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is an oral antiangiogenic agent administered in advanced-stage hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Treatment outcomes of sorafenib therapy may greatly vary depending not only on tumor spread but also on past clinical processes prior to sorafenib therapy and timing of sorafenib administration in the past clinical course of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Although sorafenib is considered standard therapy for advanced hepatocellular carcinoma (HCC), actual treatments vary. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Since the approval of sorafenib there have been numerous failures of new agents in Phase III studies for treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular carcinoma in China. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: FOLFOX4 chemotherapy is likely to be a cost-effective option compared with sorafenib in the treatment of advanced hepatocellular carcinoma in China. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Effects of sorafenib in hepatocellular carcinoma (HCC) are frequently transient due to tumor-acquired resistance, a phenotype that could be targeted by other molecules to reduce this adaptive response. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To elucidate the clinical significance of muscle wasting in regard to survival of hepatocellular carcinoma (HCC) patients undergoing sorafenib treatment, we evaluated prognostic factors including muscle wasting at the start of sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multikinase inhibitor used as a first-line treatment for advanced hepatocellular carcinoma (HCC), but it has shown modest to low response rates. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To compare the treatment outcomes of sorafenib plus transarterial chemoembolization (TACE) vs TACE alone in patients with hepatocellular carcinoma (HCC) and hepatic vein tumor thrombus (HVTT). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib (SOR) is the first-line treatment for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "LAY SUMMARY: The GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study is a large prospective registry of patients with liver cancer who were treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "After the unsuccessful results with chemotherapy, sorafenib, by interfering with angiogenic pathways, has become pivotal in the treatment of hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "All novel drugs and strategies for treatment of advanced hepatocellular carcinoma must be compared with the results obtained with sorafenib, but no new drug or drug combination has yet achieved better results. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the standard first-line therapy for hepatocellular carcinoma (HCC) and probably ectopic hepatocellular carcinoma (EHCC) as well. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC patients with progressive disease (PD) derive from sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a multi-kinase inhibitor, has shown its promising antitumor effect in a series of clinical trials, and has been approved as the current standard treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the standard therapeutic strategy for recurrent hepatocellular carcinoma (HCC) following hepatectomy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We examined plasma biomarkers as predictive factors for advanced hepatocellular carcinoma(ad-HCC)patients treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a multikinase inhibitor, is currently the only approved drug for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To assess safety, feasibility and effectiveness of transarterial chemoembolization with degradable-starch-microspheres (DSM-TACE) in the treatment of patients with advanced hepatocellular carcinoma (HCC) dismissing or ineligible for multikinase-inhibitor chemotherapy administration (Sorafenib) due to unbearable side effects or clinical contraindications. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC), yet treatment safety may be challenged by portal hypertension. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the only drug that demonstrates a survival benefit for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is a multi-targeted kinase inhibitor with a demonstrated activity in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and it is currently used for the treatment of these pathologies. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a multi-kinase inhibitor, is the only standard clinical drug for patients with advanced hepatocellular carcinoma (HCC); however, development of sorafenib resistance in HCC often prevents its long-term efficacy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The multi-kinase inhibitor sorafenib is clinically approved for the treatment of patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib chemotherapy is the first-line therapy for patients with hepatocellular carcinoma (HCC) in an advanced stage. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "DOI: 10.1016/j.jpge.2016.04.006 PMCID: PMC5580019 PMID: 28868469  The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepatocellular carcinoma (HCC), one of the most lethal types of cancer worldwide. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The prognosis of hepatocellular carcinoma (HCC) remains poor, with only one third of patients eligible for curative treatments and very limited survival benefits with the use of sorafenib, the current standard of care for advanced disease. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To compare the therapeutic effect of portal vein stenting and endovascular implantation of iodine-125 seeds strand followed by transcatheter arterial chemoembolization combined with or without sorafenib in patients for hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIM: Sorafenib and chemoembolization of the liver (TACE) have both produced increased survival in hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The present study aimed to determine the usefulness of contrast-enhanced ultrasonography (CEUS) with Sonazoid in evaluating the therapeutic response to sorafenib for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the efficacy and safety of adjuvant sorafenib after curative resection for patients with Barcelona Clinic Liver Cancer (BCLC)-stage C hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: The efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib for patients with hepatocellular carcinoma (HCC) have been explored by many studies, but the results were controversial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, an oral multikinase inhibitor, is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Recently, we reported that liver Label Retaining Cancer Cells (LRCC) can initiate tumors with only 10 cells and are relatively resistant to the targeted drug Sorafenib, a standard of practice in advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This study investigates whether changes in arterial enhancement of hepatocellular carcinoma (HCC) on contrast-enhanced CT in patients treated with Sorafenib predicts overall survival. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is currently the only targeted therapy available for advanced stage hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "While surgical resection and transplantation are the cornerstone of therapy in early-stage hepatocellular carcinoma, locoregional therapy and sorafenib are beneficial in those with more advanced disease or those who are not surgical candidates. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This case represents one of the few examples of complete response to anti-angiogenic drugs and, to our knowledge, the only case of sustained response, even after the discontinuation of Sorafenib, described so far in the literature.KEY WORDS: hepatocellular carcinoma - HCC - BCLC - sorafenib - complete response. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The mechanism underlying poor prognosis and sorafenib resistance in patients with hepatocellular carcinoma (HCC) is unknown and, to date, no useful predictive biomarkers of sorafenib resistance have been identified. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To investigate the effectiveness of intravoxel incoherent motion (IVIM) in the assessment of the therapeutic efficacy of sorafenib in an orthotopic hepatocellular carcinoma (HCC) xenograft model. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We encountered two patients with hepatocellular carcinoma (HCC) who showed rapid progression of liver failure during sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Some of the latest modalities for the management of hepatocellular carcinoma (HCC) are radiofrequency ablation, trans-arterial chemoembolization, radioembolization and systemic targeted agents like sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare the regulation of serum angiogenic factors in patients with unresectable early hepatocellular carcinoma (HCC) treated with yttrium-90 ((90)Y) radioembolization alone vs with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Although sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC) recurrence, there are limitations to its use because of adverse effects, including effects on liver function. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " LESSONS LEARNED: Combination therapies in patients with hepatocellular carcinoma can be associated with overlapping toxicity and are therefore poorly tolerated.Using sorafenib at the maximum tolerated dose can lead to a higher incidence of toxicities. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "BACKGROUND: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC), and to date, no combination therapy has demonstrated superior survival compared with sorafenib alone. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: We investigated the contribution of subsequent therapy for advanced hepatocellular carcinoma refractory or intolerant to sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: We reviewed the medical records of patients with advanced hepatocellular carcinoma treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Targeting intrahepatic lesions may be useful for treating patients with advanced hepatocellular carcinoma patients after sorafenib treatment is discontinued. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multi-targeted tyrosine kinase inhibitor, with antiangiogenic and antiproliferative properties, approved for the treatment of advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Sorafenib is the current standard therapy for advanced hepatocellular carcinoma, but validated biomarkers predicting clinical outcomes are lacking. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study aimed to identify biomarkers predicting prognosis and/or response to sorafenib, with or without erlotinib, in hepatocellular carcinoma patients from the phase III SEARCH trial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Baseline plasma HGF, VEGFA, KIT, and VEGFC correlated with clinical outcomes in hepatocellular carcinoma patients treated with sorafenib with or without erlotinib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: Neoadjuvant therapies before liver transplantation are a common practice in the management of hepatocellular carcinoma, either in the setting of down staging or as a bridge strategy but sorafenib has been little evaluated. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: These few case reports suggest the potential interest and feasibility of controlled studies to assess the efficacy and safety of sorafenib in neoadjuvant setting for hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study aimed to assess the cost-effectiveness of SBRT compared to sorafenib which is the only drug for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: A Markov decision-analytic model was performed to compare the cost-effectiveness of SBRT and sorafenib for unresectable advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We evaluated radiotherapy using helical tomotherapy (HT) combined with sorafenib for treatment of pulmonary metastases from hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Tumour explants prepared from surgical hepatocellular carcinoma (HCC) samples and serum samples obtained from HCC patients receiving sorafenib were also used. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Despite significant progress, advanced hepatocellular carcinoma (HCC) remains an incurable disease, and the overall efficacy of targeted therapy by Sorafenib remains moderate. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Sorafenib is an oral multikinase inhibitor that improves survival in advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: It is unknown whether the addition of locoregional therapies (LRTx) to sorafenib improves prognosis over sorafenib alone in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "ADRB2 signaling negatively regulated autophagy, leading to hypoxia-inducible factor-1\u03b1 stabilization, reprogramming of hepatocellular carcinoma cells glucose metabolism, and the acquisition of resistance to sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multikinase inhibitor approved as the first line treatment for late stage hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) and sorafenib are the therapeutic standard for intermediate and advanced stage hepatocellular carcinoma (HCC) patients respectively. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: GIDEON was a prospective, global, non-interventional study evaluating the safety of sorafenib in patients with unresectable hepatocellular carcinoma in real-world practice. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Multi-kinase inhibitor sorafenib represents a major breakthrough in the therapy of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Galectin-1 (Gal-1) is involved in several pathological activities associated with tumor progression and chemoresistance, however, the role and molecular mechanism of Gal-1 activity in hepatocellular carcinoma (HCC) epithelial-mesenchymal transition (EMT) and sorafenib resistance remain enigmatic. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate whether sorafenib use after resection impacts tumor relapse and survival in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Although sorafenib was approved as antiangiogenic agent in case of hepatocellular carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully examined in vivo. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Hepatic arterial infusion chemotherapy (HAIC) has been employed as an alternative therapy to sorafenib for the patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Angiogenesis inhibition by the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor sorafenib provides survival benefit in hepatocellular carcinoma (HCC); however, angiogenic escape from sorafenib may occur due to angiogenesis-associated fibroblast growth factor receptor (FGFR) pathway activation. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To the best of our knowledge, none of the prognostic staging systems for hepatocellular carcinoma (HCC) patients who underwent sorafenib therapy is universally adopted or preferred. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We aimed to determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS)with Sonazoid in the evaluation of early response to sorafenib for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In the Italian multicenter ePHAS (eNOS polymorphisms in HCC and sorafenib) study, we analyzed the role of eNOS polymorphisms in relation to clinical outcome in patients with hepatocellular carcinoma (HCC) receiving sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the efficacy of transcatheter arterial chemoembolisation (TACE) compared with surgical intervention and sorafenib for treatment of hepatocellular carcinoma (HCC) in patients with tumor thrombus extending to the main portal vein. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Additionally, we present the case of a patient with hepatocellular carcinoma (HCC) who had prolonged regression of a rib metastasis upon combination treatment with ascorbate and sorafenib, indicating that these studies have direct clinical relevance. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma (HCC) recommends transarterial chemoembolization (TACE) as the first line therapy for stage B patients and sorafenib treatment for stage C patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Following the approval of sorafenib, a large number of molecular targeted agents have been tested clinically for advanced hepatocellular carcinoma (HCC), but all have failed to demonstrate significant efficacy in clinical trials. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Treatment with Sorafenib (GIDEON) is a worldwide, prospective, non-interventional study to evaluate the safety of sorafenib in a variety of patient subsets. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Eligible patients had unresectable hepatocellular carcinoma for whom the decision had been made to treat with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVES: To compare the impact of concurrent TACE\u2009+\u2009sorafenib versus TACE alone on overall survival (OS) and time to progression (TTP) in patients with unresectable hepatocellular carcinoma (uHCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib has improved the median overall survival of unresectable or otherwise untreatable hepatocellular carcinoma (HCC) of \u223c3 months, compared to supportive cares. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this study, we present the 2 hepatocellular carcinoma (HCC) patients suffered from epigastric distress caused by esophageal candidiasis who received sorafenib plus RT. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib has been approved to increase the survival in patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We herein present the case of a 56-year-old man with hepatocellular carcinoma treated with sorafenib at 200 mg once daily. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The combination of doxorubicin (DOX) with sorafenib (SOR) has proven an effective strategy to enhance anti-hepatocellular carcinoma (HCC) efficacy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "LAY SUMMARY: No established therapy for patients with advanced hepatocellular carcinoma and progression under first-line systemic treatment with sorafenib currently exists. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is an oral multikinase inhibitor with anti-proliferative and anti-angiogenic effects and is used worldwide for the treatment of advanced or metastatic hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib was approved for treatment of unresectable hepatocellular carcinoma (HCC) in Japan in 2009. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the standard treatment for patients with hepatocellular carcinoma (HCC) with advanced stage disease. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib, an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma, significantly improves progression-free and overall survival. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "However, only a few studies have evaluated the efficacy of sorafenib in patients with recurrent hepatocellular carcinoma following liver transplantation. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here, we report a case of a patient with recurrent advanced hepatocellular carcinoma after living donor liver transplantation who achieved complete remission in response to sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Sorafenib (SOR) is the standard of care for patients with hepatocellular carcinoma (HCC) and portal vein invasion (PVI), based on the results of phase 3 trials. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In English literature, there are 2 adult patients with metastatic cholangiocarcinoma or hepatocellular carcinoma who developed PRES under sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Current treatment options for unresectable hepatocellular carcinoma include various ablative and trans-arterial therapies in addition to the drug sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "One of the included trials compared radioembolisation versus chemoembolization for intermediate stage hepatocellular carcinoma as classified by the Barcelona Clinic Liver Cancer (BCLC) staging system, while the other included trial was an interim analysis of a randomised trial assessing radioembolisation combined with sorafenib versus sorafenib monotherapy in participants with BCLC-advanced stage hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Radioembolisation followed by sorafenib appeared to be as well tolerated as sorafenib alone for advanced stage hepatocellular carcinoma, but data were too sparse to exclude even major differences. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "However, subsequent phase III trials of antiangiogenic agents in hepatocellular carcinoma have failed to improve survival compared with standard treatment protocols using sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We investigated the phenomenon in 61 patients with advanced hepatocellular carcinoma (HCC) receiving sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib (S), a multitargeted tyrosine kinase inhibitor, is the standard of care for first-line systemic treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is one of the first-line drug which has been extensively used in metastatic and inoperable hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of this retrospective study was the definition of the role of intratumoral OCT1 mRNA expression in hepatocellular carcinoma (HCC) as a biomarker in systemic treatment with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Combination therapy of sorafenib and transarterial chemoembolization (TACE) has shown benefits in treating advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Currently, the only FDA-approved systemic therapy for hepatocellular carcinoma (HCC) is the multi-receptor tyrosine kinase inhibitor, sorafenib, which provides only modest clinical benefit. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib, the first and only targeted drug approved for hepatocellular carcinoma, directly decreased PTP1B activity and promoted the expression of PITX1 and p120RasGAP by PITX1 hyperphosphorylation. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In sorafenib-treated tumor samples, we further found inhibition of PTP1B activity and up-regulation of the PITX1-p120RasGAP axis, suggesting that PTP1B inhibitor may be effective for the treatment of hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Furthermore, high expression of PTP1B was significantly associated with poor tumor differentiation (P = 0.031).CONCLUSION: PTP1B dephosphorylates PITX1 to weaken its protein stability and the transcriptional activity for p120RasGAP gene expression and acts as a determinant of the sorafenib-mediated drug effect; targeting the PITX1-p120RasGAP axis with a PTP1B inhibitor may provide a new therapy for patients with hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This retrospective cohort study aimed to evaluate the prognostic value of the alpha-fetoprotein (AFP) response in advanced-stage hepatocellular carcinoma (HCC) patients treated with sorafenib combined with transarterial chemoembolization. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This meta-analysis aimed to analyze the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Evasive mechanisms triggered by the tyrosine kinase inhibitor sorafenib reduce its efficacy in hepatocellular carcinoma (HCC) treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib has been a standard therapy for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report a case of locally advanced huge hepatocellular carcinoma (HCC) invading the diaphragm and the right lung, which was controlled by sorafenib, thereby allowing curative resection. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "For this patient diagnosed with Barcelona clinic liver cancer (BCLC) classification stage C hepatocellular carcinoma, we initiated 800 mg/body sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib can be provided on an outpatient basis and it may facilitate long-term survival for patients with advanced recurrent hepatocellular carcinoma with IVC tumor thrombus. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the first molecularly targeted drug recommended as a treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This randomized, double-blind, placebo-controlled, phase II study evaluated the efficacy and safety of mapatumumab (a human agonistic monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 1) in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Treatment of advanced hepatocellular carcinoma (HCC) has reached a plateau after the approval of sorafenib in 2007. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The mechanism of resistance of hepatocellular carcinoma (HCC) to sorafenib is unknown and no useful predictive biomarker for sorafenib treatment has been reported. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Since the approval of sorafenib, no other agent has been proven to show survival benefits in clinical trials involving patients with advanced hepatocellular carcinoma (HCC) resistant to sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Whether radiologically detected progressive disease (PD) is an accurate metric for discontinuing sorafenib treatment in patients with hepatocellular carcinoma (HCC) is unclear. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate transarterial chemoembolization (TACE) use prior to and concomitantly with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) across different global regions. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "DOI: 10.11817/j.issn.1672-7347.2015.12.003 PMID: 26739070 [Indexed for MEDLINE]  We report data from the final analysis of the Chinese subset of the GIDEON (the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study, which evaluated the safety and efficacy of sorafenib in Child-Pugh A, B and C patients with unresectable hepatocellular carcinoma (uHCC) in real-life clinical practice. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We conducted a phase I/II study in patients with advanced hepatocellular carcinoma (HCC) to determine the recommended dose, as well as the safety and efficacy, of combination therapy of sorafenib with hepatic arterial infusion chemotherapy (HAIC) using low dose cisplatin (CDDP) and 5-fluorouracil (5FU). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: Patients with intermediate-stage hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE) are considered to be candidates for sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The first aim was to compare Response Evaluation Criteria in Solid Tumor (RECIST) 1.1, modified Response Evaluation Criteria in Solid Tumor (mRECIST), Choi and European Association for the Study of the Liver (EASL) evaluations to assess the response to sorafenib for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Purpose To assess diagnostic values of intra-voxel incoherent motion (IVIM) imaging in evaluating therapeutic effects of sorafenib on hepatocellular carcinoma (HCC) using mouse xenograft model. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: SN-38 and sorafenib have synergistic anticancer activity on hepatocellular carcinoma cells in vitro with the augmentation of apoptosis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multikinase inhibitor for the treatment of hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: A total of 73/140 patients with advanced hepatocellular carcinoma receiving sorafenib developed relevant adverse events (grade \u22652) and were managed with a tolerable-adverse-event-protocol consisting of a drug stepwise dose reduction adjusted on patient's tolerability. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced hepatocellular carcinoma, sorafenib dose adjustments based on inducing tolerability of relevant adverse events prolong drug exposure and maximize survival. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To explore the efficacy of sorafenib in treating hepatocellular carcinoma (HCC) and its relationship with the computed tomography (CT) and magnetic resonance imaging (MRI) features of HCC, analyze the prognostic factors of HCC patients treated with sorafenib, and investigate the relationship between imaging findings and outcomes. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Preoperative serum lactate dehydrogenase (LDH) has been used as a prognostic indicator for patients with hepatocellular carcinoma (HCC) treated with sorafenib or undergoing transcatheter arterial chemoembolization, but its significance in predicting survival of HCC patients who received curative resection remains undefined. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: The therapeutic efficacy of branched-chain amino acid (BCAA) when added to sorafenib has not been fully assessed in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the first and currently the only standard treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib shows efficacy in the management of non-resectable hepatocellular carcinoma (HCC), which is refractory to other chemotherapeutic drugs. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib, an oral multikinase inhibitor, has recentlybeen shown to improve overall survival in patients with advanced hepatocellular carcinoma (HCC) but only a handful of reports of complete remission on sorafenib have been issued. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a type of multikinase inhibitor that exhibits antiangiogenic and antiproliferative effects; in addition, sorafenib is a unique first-line drug recommended for the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is considered to be the first-line therapy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To clarify the effects of cyclin E1 suppression on antitumor efficacy of sorafenib in hepatocellular carcinoma cells and to explore the potential of combining sorafenib with cyclin-dependent kinase (CDK) inhibition in therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: The effects of cyclin E1 suppression on sorafenib-induced apoptosis were tested in both sorafenib-sensitive (Huh-7 and HepG2, IC50 5-6 \u03bcmol/L) and sorafenib-resistant (Huh-7R and HepG2R, IC50 14-15 \u03bcmol/L) hepatocellular carcinoma cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "RESULTS: Cyclin E1 mRNA and protein expressions were suppressed after sorafenib treatment in sorafenib-sensitive but not in sorafenib-resistant hepatocellular carcinoma cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The knockdown of cyclin E1 expression reversed the resistance of hepatocellular carcinoma cells to sorafenib in terms of cell growth and apoptosis induction, whereas the overexpression of cyclin E1 increased the resistance to sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: The cyclin E1 suppression in hepatocellular carcinoma cells may serve as a pharmacodynamic biomarker for predicting sorafenib efficacy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The combination of sorafenib and CDK inhibitors may improve the efficacy of sorafenib in hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib therapy improves survival in unresectable hepatocellular carcinoma (HCC) patients without an objective response. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the only and standard systematic chemotherapy drug for treatment of advanced hepatocellular carcinoma (HCC) at the current stage. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis and the current treatment is limited to sorafenib, an agent with modest benefit. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib (Sor), an effective chemiotherapeutic drug utilized against hepatocellular carcinoma (HCC), robustly interacts with nonionic amphiphilic cyclodextrin (aCD, SC6OH), forming, in aqueous solution, supramolecular complexes that behave as building blocks of highly water-dispersible colloidal nanoassemblies. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "A significant number of derivatives have been found active in both the receptors and also displayed multikinase inhibitory activity similar to Sorafenib, against hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The angiogenesis inhibitor, sorafenib, remains the only available therapy of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The multikinase inhibitor sorafenib has been used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a kinase inhibitor used as anticancer drug against various human tumors, including advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the first-line treatment of choice for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: Sorafenib has become a standard therapy for advanced hepatocellular carcinoma following the demonstration of significant increase in progression-free survival as well as overall survival (OS) in the 2-phase III trials. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here we provide models of human hepatocellular carcinoma (HCC), the most common form of primary liver cancer, in\u00a0vitro and in\u00a0vivo to evaluate the efficacy of NFC alone and in combination with sorafenib, a kinase inhibitor approved for treatment of HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, an oral multi-kinase inhibitor, is the final therapy prior to palliative care for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, an oral multikinase inhibitor, is approved for advanced hepatocellular carcinoma (HCC) treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "However, there is lack of data in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a systemic chemotherapeutic agent for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine the antitumor efficacy and tolerability of combination temozolomide (TMZ) and veliparib (ABT-888) in patients with advanced, sorafenib-refractory hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The survival benefit of combining sorafenib and transarterial chemoembolization (TACE) therapy compared with sorafenib monotherapy for patients with advanced hepatocellular carcinoma (HCC) and main portal vein tumor thrombosis (MPVTT) is unclear. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Although sorafenib is a standard drug for advanced hepatocellular carcinoma (HCC), little is known about a patient's clinical course after treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: We evaluated the relationship between the early clinical response after 2 weeks of sorafenib therapy and the outcomes and anti-tumor response in patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Changes in intra-tumor blood flow on CE-CT, AFP levels, and remnant liver function after 2 weeks of sorafenib therapy may be useful for predicting the outcomes and anti-tumor response to sorafenib in patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the current standard treatment for advanced hepatocellular carcinoma (HCC), but its efficacy is modest with low response rates and short response duration. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Currently, sorafenib is the only available chemotherapeutic agent for advanced hepatocellular carcinoma (HCC), but it cannot be used in patients with liver cirrhosis (LC) or thrombocytopenia. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the standard first-line therapeutic treatment for patients with advanced hepatocellular carcinoma (HCC), but its use is hampered by the development of drug resistance. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Many years after therapeutic wilderness, sorafenib finally showed a clinical benefit in patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This trial was designed to assess the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcinoma after surgical resection or local ablation. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "INTERPRETATION: Our data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is an effective treatment for unresectable hepatocellular carcinoma (HCC) characterized by disease stabilization. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Hepatotoxicity induced by sorafenib and antiviral therapy is a limitation for its continuation treatment for patients with advanced hepatitis B virus-related hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We compared the benefits of sorafenib with that of hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (ad-HCC) refractory to transcatheter arterial chemoembolization (TACE). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib resistance remains a major obstacle for the effective treatments of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Hepatocellular carcinoma (HCC) is associated with high mortality and the current therapy for advanced HCC, Sorafenib, offers limited survival benefits. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The success of sorafenib in prolonging survival of patients with hepatocellular carcinoma (HCC) makes therapeutic inhibition of angiogenesis a component of treatment for HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a specific adenosine triphosphate-competitive RAF inhibitor used as a first-line treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib (SOR) is a promising treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report the first case of initially unresectable advanced hepatocellular carcinoma (HCC) with portal vein and hepatic venous tumor thrombosis and multiple lung metastases that allowed for curative hepatectomy after multidisciplinary treatment including sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this study, we investigated the ability of iRGD to improve the delivery of sorafenib and doxorubicin therapy in hepatocellular carcinoma (HCC) using established mouse models of the disease. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is a small molecule that blocks the activation of C-RAF, B-RAF, c-KIT, FLT-3, RET, VEGFR-2, VEGFR-3 and PDGFR approved for advanced renal cell and hepatocellular carcinoma (b, c). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is the unique recommended molecular-targeted drug for the treatment of patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a multikinase inhibitor, has been used as an anti-angiogenic agent against highly vascular hepatocellular carcinoma (HCC) - yet associated with only moderate therapeutic effect and the high incidence of HCC recurrence. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib is currently the only approved therapy in hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Patients with advanced hepatocellular carcinoma treated with sorafenib or brivanib in 2008-2011 were included in this retrospective study. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The purpose of the phase 2 study was to determine the response rate of sorafenib and gain further information on the associated toxicities, pharmacokinetics, and pharmacodynamics of sorafenib in children and young adults with relapsed or refractory tumors including rhabdomyosarcoma, Wilms tumor, hepatocellular carcinoma (HCC), and papillary thyroid carcinoma (PTC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of the present study was to assess the association between the efficacy and adverse events (AEs) of transcatheter arterial chemoembolization (TACE) combined with sorafenib in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib demonstrated a survival benefit in the treatment of advanced hepatocellular carcinoma (HCC) in phase III trials. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here, we provide a systemic insight into the potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma depending on abundant previous studies and reports. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We also discuss the perspectives on the use of this molecule, including the role of sorafenib as comparator for the development of new drugs, the combination of sorafenib with additional therapies (such as transarterial chemoembolization for hepatocellular carcinoma) and the use of this treatment in several other advanced refractory solid tumors. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The study aims to evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib vs hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " In hepatocellular carcinoma, sorafenib is the only active medical treatment validated to date. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is currently used for inoperable or advanced stages of hepatocellular carcinoma, as well for hepatocellular carcinoma recurrence when the disease is diffuse or multifocal. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Current clinical trials are designed to identify new antitumor molecules active in hepatocellular carcinoma that could enrich the therapeutic armamentarium in addition to sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The objective of the present study was to investigate the prevalence of pancreatic atrophy among a cohort of patients with hepatocellular carcinoma (HCC) who were treated with sorafenib for \u22652 y. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib was initially approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy, had Child-Pugh A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, had previously received sorafenib (stopped because of progression or intolerance), and had adequate haematological and biochemical parameters. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: To assess the efficacy of continued administration of sorafenib for patients with unresectable hepatocellular carcinoma (HCC) treated with local regional therapy (LRT) after a complete response (CR), also, the adverse events of sorafenib after discontinuation of administration were observed. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib-everolimus combination therapy may be more effective than sorafenib monotherapy for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this phase II study, safety and tolerability of the combination of tigatuzumab and sorafenib was evaluated in patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "sorafenib alone in adults with advanced hepatocellular carcinoma did not meet its primary efficacy end point, although tigatuzumab plus sorafenib is well tolerated in hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine the efficacy of combined continuous sorafenib therapy and drug-eluting bead (DEB) transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The multi-kinase inhibitor sorafenib is now used as standard therapy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study aimed to identify the key pathways and to explore the mechanism of sorafenib in inhibiting hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " While sorafenib (SFN) is the established worldwide standard therapeutic agent for advanced hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) is also considered a favorable treatment for some advanced HCCs. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Biological considerations and early results suggested its activity against hepatocellular carcinoma after progression on sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the only FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The anticancer drug sorafenib has opened a window of hope for patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "While phase 3 studies comparing Y90-radioembolization to chemoembolization in intermediate hepatocellular carcinoma would be difficult to conduct, studies comparing or combining Y90-radioembolization with sorafenib are under way. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib (Nexabar, Bayer, Berlin, Germany), one of multikinase inhibitors, can infrequently downstage advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib, an oral multikinase inhibitor, is the only targeted agent approved for the treatment of patients with hepatocellular carcinoma (HCC) after demonstration to increase overall survival compared to placebo in two randomized phase III study. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The current standard treatment option for advanced hepatocellular carcinoma (HCC) is sorafenib, but its clinical benefit is modest. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib and conventional systemic cytotoxicity chemotherapy are currently being used in parallel for the patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We investigated whether the serum TGF-\u03b21 level was related to the outcomes of patients treated with sorafenib for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We investigated genomic variations associated with responsiveness to sorafenib for patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a novel orally-available multikinase inhibitor blocking several crucial oncogenic signaling pathways, presented survival benefits and became the first-line drug for treatment of patients with Hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of this study was to determine whether skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma (HCC) that is being treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Sorafenib has been shown to significantly improve the overall survival of patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: To investigate the effectiveness and safety of sorafenib after radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the only approved systemic treatment for advanced hepatocellular carcinoma patients and all the recently published randomized controlled trials on new systemic drugs have been unsuccessful. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Following the approval of sorafenib as the first systemic agent for treatment of advanced hepatocellular carcinoma (HCC), there have been an increasing number of targeted treatments under testing for the cancer. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC) treatment with the tyrosine kinase inhibitor (TKI) sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is one of the preferred drugs for the treatment of advanced primary hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, an oral multikinase inhibitor of Raf, VEGF and PDGF receptor signaling is approved for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this study, we investigated a novel c-Met inhibitor, DE605, together with sorafenib in hepatocellular carcinoma cells in vitro and in vivo. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "DE605 and sorafenib synergistically induced apoptosis in hepatocellular carcinoma cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Finally, DE605 and sorafenib significantly inhibited growth of PLC/PRF/5 hepatocellular carcinoma tumor xenografts in athymic nude mice. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Herein, we present this rare case of advanced hepatocellular carcinoma controlled with reduced doses of sorafenib following multidisciplinary therapy, describe our single center experience with sorafenib use in patients with hepatocellular carcinoma, and review previous reports that focused on dose reduction of sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The results of large clinical trials demonstrate that sorafenib prolongs survival and the time to progression of patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multikinase inhibitor commonly used for the treatment of advanced renal cell and hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To date, sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Patients with advanced hepatocellular carcinoma (aHCC) and portal vein tumor thrombus (PVTT) still have a very poor prognosis, even though the oral multikinase inhibitor sorafenib has revolutionized treatment of aHCC in patients with liver cirrhosis (LC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Anti-angiogenic effects of sorafenib lead to impairment of vitamin K uptake and induction of des-\u03b3-carboxyprothrombin release by hepatocellular carcinoma (HCC) cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib increases survival of patients with advanced hepatocellular carcinoma (HCC) by inhibiting RAF kinase and receptor tyrosine kinase activity, but involvement of sorafenib in fibrosis and epithelial-mesenchymal transition (EMT) remains unclear. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: No standard second-line treatments are available for hepatocellular carcinoma patients who fail sorafenib therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Metronomic capecitabine was well tolerated in hepatocellular carcinoma patients who had been treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib may improve progression-free survival (PFS) and overall survival (OS) of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib has become the standard therapy for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is the only drug for patients with advanced-stage hepatocellular carcinoma (HCC) that has been shown to confer a survival benefit to patients with HCC; however, it has many side effects. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of the current study is to explore potential effects of hospital type and volume on outcomes after resection or sorafenib in patients with hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "RESULTS: In the period 2005-2011, 2402 patients were diagnosed with hepatocellular carcinoma: 12% received resection and 9% sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: In low incidence countries, outcome after resection or sorafenib for hepatocellular carcinoma may differ between various hospital types. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " In the last decades the management of hepatocellular carcinoma (HCC) has undergone significant changes following the introduction of novel therapies such as sorafenib, which have improved patient survival. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Use of oral sorafenib, an antiangiogenic chemotherapeutic agent for hepatocellular carcinoma (HCC), is limited by an unfavorable side effect profile. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Tumor lysis syndrome is rare in hepatocellular carcinoma (HCC), but it has been reported more frequently recently in response to treatments such as transcatheter arterial chemoembolization (TACE), radiofrequency thermal ablation (RFTA), and sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, an oral inhibitor of multiple tyrosine kinase receptors, has been widely used as a standard medical treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multikinase inhibitor currently approved in Japan for the treatment of unresectable hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib confers a survival benefit for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) A liver cirrhosis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC), although it is known to cause a variety of dermatologic adverse events. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The purpose of this study was to determine the impact of sorafenib on PI3K/AKT/mTOR signaling pathway and to further define its mechanism for treating hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "hepatic carcinoma", "polarity": 1, "orig_sen": "METHODS: Human SMMC-7721 hepatic carcinoma cells were treated with or without 4 \u03bcmoL/L sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Sorafenib is the standard of care in advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIM: Sorafenib is the medical reference for treatment of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Currently there is no predictor for survival after adjuvant sorafenib in patients with hepatocellular carcinoma (HCC) who have undergone curative resection. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is an oral multikinase inhibitor with clinical activity against hepatocellular carcinoma (HCC) and renal cell carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a potent multikinase inhibitor, lead to a significant improvement in progression free survival and overall survival in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The current study aimed to evaluate the efficacy of sorafenib-based combined therapy against hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib-irinotecan sequential treatment augmented the efficacy of either drug used alone in soliciting HepG2 cells apoptosis in vitro and in suppressing the growth of HepG2 xenografts in vivo.KEYWORDS: hepatocellular carcinoma, irinotecan, sorafenib, synergistic effect. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Current systemic treatment options for patients with hepatocellular carcinoma (HCC) are limited to sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report the long-term survival of a patient with metastatic hepatocellular carcinoma (HCC), successfully treated with transcatheter arterial chemoembolization (TACE)/hepatic arterial infusion chemotherapy (HAIC) combined with long-term administration of sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to determine the effects of matrine (a natural alkaloid) on sorafenib-induced cytotoxicity against hepatocellular carcinoma (HCC) cells, and to explore the molecular mechanisms involved. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The purpose of this study was to assess the efficacy and safety of gemcitabine and oxaliplatin (GEMOX) combined with sorafenib, as first-line therapy, followed by sorafenib as maintenance therapy for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: GEMOX combined with sorafenib as first-line therapy followed by sorafenib as maintenance therapy was effective with manageable toxicity for patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma related to nonalcoholic steatohepatitis during sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is the first successful target therapy effective for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "To our knowledge, this is the first patient reported in the literature with hepatocellular carcinoma related to nonalcoholic steatohepatitis who died of rapid worsening of liver function during sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: This retrospective study was carried out to compare the outcomes between elderly (\u226570 years of age) and nonelderly patients (<70 years of age) with advanced hepatocellular carcinoma (HCC) who received sorafenib combined with transarterial chemoembolization (TACE). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Sorafenib, an oral multikinase inhibitor, is the proved therapy method for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is the only drug to prolong overall survival of the patients with hepatocellular carcinoma (HCC), however, the outcome is still not satisfactory. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this study, six long chain fatty acid esters of quercetin-3-O-glucoside (Q3G) acylated enzymatically and were used for determining their antiproliferative action in hepatocellular carcinoma cells (HepG2) in comparison to precursor compounds and two chemotherapy drugs (Sorafenib and Cisplatin). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Interestingly, Q3G esters showed significantly low toxicity to normal liver cells than Sorafenib (P\u2009<\u20090.05), a chemotherapy drug for hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In a mouse xenograft model of hepatocellular carcinoma, we demonstrated that ONC201 and sorafenib cooperatively and safely triggered tumor regressions. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To assess whether urea-based cream (UBC) has prophylactic benefits on sorafenib-induced hand-foot skin reaction (HFSR) in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Hepatocellular carcinoma (HCC) larger than ten cm belonging to Barcelona Clinic Liver Cancer (BCLC) stage B and C may benefit from hepatic resection (HR), compared to presently recommended management by transarterial chemoembolization and sorafenib, respectively. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To evaluate the feasibility and security of complete remission (CR) of advanced hepatocellular carcinoma (HCC) achieved with sorafenib treatment, and investigate the previously described predictive factors in CR. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Sorafenib is a recommended treatment for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The study is to evaluate the efficacy of sorafenib plus cyproheptadine compared with sorafenib alone in patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: A retrospective cohort study reviewed all consecutive advanced hepatocellular carcinoma cases with Child-Pugh Class A disease starting sorafenib treatment at our hospital from August 2012 to March 2013. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Cyproheptadine may significantly improve survival outcomes of sorafenib-treated advanced hepatocellular carcinoma patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the only recommended treatment for patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Data on survival and safety of sorafenib for hepatocellular carcinoma recurrence after liver transplant are still equivocal. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Additional data from multicentre prospective studies are required to clearly determine if sorafenib is a safe and acceptable treatment in hepatocellular carcinoma recurrence after liver transplant. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: To evaluate the role of antiviral therapy with nucleoside analogs (NAs) in sorafenib-treated patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is an effective anti-angiogenic treatment for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare efficacy of transarterial chemoembolization with and without radiation therapy (RT) versus sorafenib for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Sorafenib is now considered as a standard treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: GIDEON is a non-interventional, prospective, international study that evaluated the safety of sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in daily clinical practice, including Child-Pugh B patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: There have been no established predictors of the outcome on sorafenib therapy for hepatocellular carcinoma (HCC) patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: The study aimed to evaluate the tissue expression of molecules involved in intracellular signalling pathways as predictors of response to sorafenib in advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the therapeutic effect of the hepatic arterial administration of sorafenib in rabbit VX-2 hepatocellular carcinoma (HCC) model. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: It is not clear whether tumor marker responses can predict survival during sorafenib treatment in hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "VEGFA amplification is present in a subset of mouse and human hepatocellular carcinomas (HCCs) that appear to be particularly sensitive to sorafenib treatment, indicating its potential value as a biomarker for HCC treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, randomized, phase III trial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "DISCUSSION: PubMed was used to search the following terms, separately and in combination: acne, acneiform eruption, chloracne, cutaneous adverse events, hepatocellular carcinoma, renal cell carcinoma, skin side effects, and sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Five patients-a woman with liver epithelioid hemangioendothelioma, three men with metastatic renal cell carcinoma, and a man with hepatocellular carcinoma-have developed sorafenib-associated facial acneiform eruption. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The available data were structured as follows: antiangiogenic therapy, c -MET inhibitors, combinations of chemotherapy with sorafenib, immune response modulators, cellular metabolism modulators, mTOR inhibitors, other multi-kinase inhibitors.CONCLUSION: Treatment of advanced hepatocellular carcinoma remains a challenge for oncologists. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a broad tyrosine kinase inhibitor, is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC) but provides limited survival benefits. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Sorafenib is recommended as the treatment of choice for hepatocellular carcinoma (HCC) with extrahepatic spread (EHS). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate the efficacy of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Sorafenib is efficacious, and may prolong OS and TTP in hepatocellular carcinoma with PVTT treated by TACE. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to identify the prognostic factors in patients with advanced hepatocellular carcinoma (HCC) who are refractory or intolerant to sorafenib and to exclude unsuitable candidates from subsequent therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Palliative therapies for hepatocellular carcinoma (HCC) include transcatheter arterial embolic therapies, radiation therapy and systemic chemotherapies such as sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The prognosis of advanced hepatocellular carcinoma (HCC) has remained very poor.It has recently been reported that the molecular targeting agent sorafenib can improve the prognosis of patients with advanced HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: We aimed to evaluate the efficacy and tolerability of hepatic arterial infusion chemotherapy (HAIC) using cisplatin as an alternative to sorafenib for the treatment of hepatocellular carcinoma (HCC) patients who had not responded to transarterial chemoembolization (TACE). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC), the most frequent form of primary liver tumour. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib was the first molecular targeted therapy to be approved for advanced hepatocellular carcinoma and is the benchmark for all other therapies. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is an oral tyrosine kinase inhibitor (TKI) that acts on many targets including RAF kinases, vascular endothelial growth factor (VEGF) 1, 2, 3, platelet derived growth factor and c-kit receptor and is currently FDA approved for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study evaluated sorafenib plasma concentration in a homogeneous group of cirrhotic patients with hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Little data are available on the long-term survival of patients treated with sorafenib for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Advanced-stage hepatocellular carcinoma (HCC) has an extremely poor prognosis although sorafenib, which is the treatment of choice, has provided survival benefits. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transcatheter arterial chemoembolization (TACE) failure or refractoriness is an indication for sorafenib therapy in patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Out of 265 patients with advanced hepatocellular carcinoma who were treated with sorafenib at our hospital, 45 experienced TACE failure or refractoriness and were included in this study and retrospectively analyzed. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Sorafenib is a standard treatment for advanced hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] stage C). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the standard first-line systemic drug for advanced hepatocellular carcinoma (HCC), but it also induces the activation of Akt, which contributes to the mechanisms for the resistance to sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib (Nexavar\u00ae) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: The objective of this study was to evaluate the efficacy of combined therapy using Sorafenib and radiofrequency ablation (RFA) with curative intent for all detectable lesions in patients with Barcelona Clinic Liver Cancer (BCLC) Stage 0-B1 hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is the first and only approved targeted therapy for the treatment of hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Besides functioning as a multiple tyrosine kinase, sorafenib also acts via a kinase-independent mechanism to target signal transducer and activator of transcription 3 (STAT3) signaling in hepatocellular carcinoma cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib administration induces temporary inhibition of tumor growth and a decrease in arterial blood flow in a considerable number of hepatocellular carcinoma (HCC) patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is a molecular-targeting agent showing improved overall survival (OS) for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Recently, we identified sorafenib, an inhibitor of oncogenic kinases, as an inducer of ferroptosis in hepatocellular carcinoma cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " KEY CLINICAL MESSAGE: Sorafenib is the standard treatment of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the role of sorafenib (SFN) in autophagy of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib, a multi-tyrosine kinase inhibitor, is the only chemotherapeutic option for patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the only systemic therapy to demonstrate a significant survival benefit over supportive care in robust randomised controlled trials for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Early evaluation of the response to sorafenib for patients with hepatocellular carcinoma (HCC) remains unclear. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the safety and efficacy of combined therapy with transarterial chemoembolization (TACE) and sorafenib for hepatocellular carcinoma (HCC) with portal venous tumour thrombus (PVTT). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The RP2D was tivantinib 360 mg BID and sorafenib 400 mg BID for all cancer histologies, except in hepatocellular carcinoma (HCC) patients tivantinib was 240 mg BID plus sorafenib 400 mg BID. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib has been demonstrated to improve survival rate in patients with advanced hepatocellular carcinoma (HCC); however, the survival benefit remains modest and the response rates remain poor. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Resistance is one limitation of sorafenib in the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib and hepatic arterial infusion chemotherapy (HAIC) are both indicated for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To study the relationship between adverse events (AEs), efficacy, and nursing intervention for sorafenib therapy in patients with hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the first systemic therapy to demonstrate survival benefit in advanced hepatocellular carcinoma (HCC) in randomized controlled trials with rigorous patient selection. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Sorafenib is recommended as a standard treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The purpose of this study was to build prognostic models capable of estimating the outcomes of individual sorafenib-treated advanced stage hepatocellular carcinoma (HCC) patients based on specific patient and tumor factors. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To determine significant indicators for the efficacy of sorafenib in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aims of the present study were to examine whether unresectable hepatocellular carcinoma (HCC) patients treated with initial dose of sorafenib of 400 mg/day (half-dose group) had comparable treatment efficacy, safety and survival merit as compared with those treated with initial dose of sorafenib of 800 mg/day (standard-dose group) in a multicenter large study. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The antiproliferative effects of the new compounds were investigated in comparison with the parent compounds, phloridzin, aglycone phloretin, the six free fatty acids and chemotherapeutic drugs (sorafenib, doxorubicin and daunorubicin) using human hepatocellular carcinoma HepG2 cells, human breast adenocarcinoma MDA-MB-231 cells and acute monocytic leukemia THP-1 cells along with normal human and rat hepatocytes. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: We compared the benefits of sorafenib therapy with continued transarterial chemoembolization (TACE) in TACE-refractory patients with intermediate-stage hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To prospectively assess treatment response using volumetric functional magnetic resonance imaging (MRI) metrics in patients with hepatocellular carcinoma (HCC) treated with the combination of doxorubicin-eluting bead-transarterial chemoembolization (DEB TACE) and sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Existing therapies such as irradiation or sorafenib have limited success in the treatment of hepatocellular carcinoma (HCC) due to tumor recurrence and metastasis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the approved systemic drug of choice for advanced hepatocellular carcinoma (HCC), but has demonstrated limited benefits because of drug resistance. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: Sorafenib is the only standard therapy for advanced hepatocellular carcinoma, but has a low response rate. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In addition, GSK343 enhanced the anticancer activity of a multikinase inhibitor, sorafenib, in human hepatocellular carcinoma cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The standard treatment for advanced hepatocellular carcinoma (HCC) is sorafenib, a multikinase inhibitor of tumor cell proliferation and angiogenesis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIM: The kinase inhibitor sorafenib is the only approved drug which is effective against late-stage hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Hepatic arterial infusion (HAIC) therapy may be a therapeutic option for advanced hepatocellular carcinoma (HCC) in addition to administration of sorafenib, which is the only currently established standard regimen for this disease. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Our aim was to determine whether single-nucleotide polymorphisms (SNPs) in KDR gene are associated with clinical outcomes after first-line sorafenib therapy in advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We present a 57-year-old Caucasian man with hepatocellular carcinoma (HCC) twice achieving complete remission with reduced dose sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We present our recent observations suggesting that sorafenib, the only medical treatment with proven efficacy against hepatocellular carcinoma, induces ferroptosis, a new anti-oncogenic mode of action of this drug. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This phase II, investigator-initiated, prospective single-arm multinational study (ClinicalTrials.gov registration NCT00990860) evaluated sorafenib in combination with doxorubicin-based transarterial chemoembolization (TACE) in patients with intermediate-stage, unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVES: The benefit of Sorafenib is not well described in patients with peritoneal hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "However, whether ADC could be considered as a measure for monitoring response to sorafenib in hepatocellular carcinoma (HCC) has not been demonstrated. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib in combination with Transarterial chemoembolization (TACE) is increasingly used in patients with unresectable hepatocellular carcinoma (HCC), but the current evidence is still controversial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Hepatocellular carcinoma is a difficult-to-treat cancer and, after numerous phase III trials assessing kinase inhibitors have failed to meet their end points, sorafenib is the only accepted treatment for advanced stages of the disease. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The aim of this study was to assess the early response to sorafenib using ultrasound molecular imaging in a murine model of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "hepatic carcinoma", "polarity": 1, "orig_sen": "Yet, little is known concerning the role of the PI3K/Akt/Snail-dependent pathway in sorafenib\u2011induced invasion and metastasis of hepatic carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " IMPORTANCE: Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "OBJECTIVE: To assess the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "DESIGN, SETTING, AND PARTICIPANTS: EVOLVE-1 was a randomized, double-blind, phase 3 study conducted among 546 adults with Barcelona Clinic Liver Cancer stage B or C hepatocellular carcinoma and Child-Pugh A liver function whose disease progressed during or after sorafenib or who were intolerant of sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS AND RELEVANCE: Everolimus did not improve overall survival in patients with advanced hepatocellular carcinoma whose disease progressed during or after receiving sorafenib or who were intolerant of sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The multikinase inhibitor sorafenib is the only effective drug in advanced cases of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Sorafenib is the standard of care in advanced hepatocellular carcinoma (HCC), however no criteria have been established to select patients likely to benefit from this therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "RESULTS: In vitro growth inhibition results showed that TAI-95 has excellent potency on a wide range of primary liver cancer cell lines (hepatoblastoma or hepatocellular carcinoma) (GI(50) 30-70 nM), which was superior to sorafenib and other cytotoxic agents. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this mini-review, we will discuss MRI findings after Sorafenib treatment in hepatocellular carcinoma and review the feasibility of MRI as an early biomarker in differentiating responders from non-responders after treatment with molecular targeting agents. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Thus, we hypothesized that autophagy may play an important role in hepatocellular carcinoma's resistance to sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Our previous studies have demonstrated that sorafenib can promote the dissemination of hepatocellular carcinoma (HCC) through downregulation of HTATIP2, a suppressor of tumor growth and metastasis that is associated with inhibition of angiogenesis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Since the approval of the multityrosine kinase inhibitor (TKI) sorafenib (Nexavar, Bayer and Onyx) as the standard of care for intermediate to advanced stages of hepatocellular carcinoma (HCC), there has been considerable interest in developing more potent TKIs to improve morbidity and mortality for patients with HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here we report two cases of hepatocellular carcinoma (HCC) that developed sorafenib-induced EM. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: This multicenter, randomized, open-label, phase II trial evaluated the efficacy and safety of AEG35156 in addition to sorafenib in patients with advanced hepatocellular carcinoma (HCC), as compared with sorafenib alone. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report on a 63-year-old man with a history of hepatitis B virus-related hepatocellular carcinoma with a thrombus extending into the inferior vena cava, who received image-guided stereotactic body radiation therapy (SBRT) with helical tomotherapy, followed by sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: We aimed to compare clinical outcomes and safety after sorafenib therapy between patients with Barcelona Clinic Liver Cancer (BCLC) stage B or C hepatocellular carcinoma (HCC) aged \u226575 years (aged group, n=179) and those with BCLC stage B or C HCC aged <75 years (control group, n=279). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the standard systemic therapy for unresectable or recurrent hepatocellular carcinoma (HCC) but adds minimal increase in survival. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In the current study, we examined clonogenic survival, DNA damage, and cell cycle distribution in hepatocellular carcinoma (HCC) cell lines treated with LDR in combination with varying doses and schedules of 5-fluorouracil (5-FU), gemcitabine, and sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Presently, Sorafenib is a first-line drug, targeted for hepatocellular carcinoma (HCC) but effective in only a small portion of patients and can induce hypoxia. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib is the only drug approved by the Food and Drug Administration for metastatic hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is used in patients with intermediate or advanced stage hepatocellular carcinoma (HCC) before or after of transarterial chemoembolization (TACE). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Since 2008, systemic therapy with the multikinase inhibitor sorafenib has become available worldwide and has become the standard of care for unresectable/non-ablatable or advanced-stage hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Collectively, TTK plays an important role in proliferation and sorafenib resistance and could act as a potential therapeutic target for human hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Thus, we show that rationally designed core-shell nanoparticles can effectively combine clinically relevant single-agent drugs for exerting synergistic activity against liver cancer.FROM THE CLINICAL EDITOR: Transferrin-targeted core-shell nanomedicine encapsulating doxorubicin and sorafenib was studied as a drug delivery system against hepatocellular carcinoma, resulting in enhanced and synergistic therapeutic effects, paving the way towards potential future clinical applications of similar techniques. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To retrospectively analyze the efficacy and safety of transcatheter arterial chemoembolization (TACE) in combination with sorafenib for the treatment of patients with intermediate-advanced hepatocellular carcinoma (HCC) and assess the prognostic impact of baseline characteristics. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, an oral multi-kinase inhibitor, has been approved for treatment of advanced renal-cell and hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Radioembolization as part of first-line therapy in metastatic colorectal tumors is being tested in large international trials combined with FOLFOX6 and bevacizumab, as well as in hepatocellular carcinoma with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Clinical trials suggest that combining transcatheter arterial chemoembolization with sorafenib in patients with advanced hepatocellular carcinoma shows a superior safety and tolerability profile. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Patients with advanced hepatocellular carcinoma, treated by transcatheter arterial chemoembolization and sorafenib subsequently, between February 2010 and September 2012 in our hospital, were retrospectively analyzed. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Combining sorafenib and transcatheter arterial chemoembolization was safe and effective for advanced hepatocellular carcinoma patients with extrahepatic spread but without portal vein tumor thrombi. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: There have been no established predictive factors of responders to sorafenib in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib, a multikinase inhibitor, has been shown to halt the growth of hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To clarify whether histone deacetylase inhibitors histone deacetylase inhibitors (HDACIs) can sensitize hepatocellular carcinoma (HCC) cells to sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multi-kinase inhibitor approved for hepatocellular carcinoma, but rarely causes tumor regression in patients with chronic liver diseases. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: The purpose of the present study was to compare the efficacies of transarterial chemoembolization (TACE) combined with sorafenib versus TACE monotherapy for treating patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is a promising drug for advanced hepatocellular carcinoma (HCC); however, treatment may be discontinued for multiple reasons, such as progressive disease, adverse events, or the cost of treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: Currently, the only standard systemic treatment for advanced hepatocellular carcinoma is sorafenib monotherapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The study was conducted to assess the efficacy and safety of the novel combination of sorafenib and gemcitabine in the treatment of advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Between March 2008 and October 2010, patients with advanced pathologically proven hepatocellular carcinoma who had not received previous systemic therapy and had Child-Pugh liver function class A or B received sorafenib plus gemcitabine. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: The combination of sorafenib and gemcitabine in advanced hepatocellular carcinoma is generally well tolerated and has modest clinical efficacy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Currently, sorafenib is the only US Food and Drug Administration-approved chemotherapeutic for hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Liver transplantation (LT) is an established treatment for hepatocellular carcinoma (HCC), and sorafenib (SFN) is a validated treatment for patients harboring advanced tumors. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and particularly for those who are unsuitable to receive life-prolonging transarterial chemo-embolization. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib represents the first effective targeted therapy for advanced stage hepatocellular carcinoma (HCC); however, adequate patient stratification regarding sorafenib-responsiveness is still missing. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib, a multikinase inhibitor that targets angiogenesis in hepatocellular carcinoma (HCC), has become a standard treatment for advanced-stage HCC and has shown survival benefits in recent clinical trials. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Patients with hepatocellular carcinoma (HCC) who receive an initial full dose of sorafenib (800\u2009mg/day) often require a decreased dose (400\u2009mg/day) or discontinuation of therapy because of severe adverse events. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: Early assessment of hepatocellular carcinoma (HCC) response during sorafenib (SO) treatment is challenging, since tumor necrosis, extension and radiological appearance can be inhomogeneous. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib, the drug used as first line treatment for hepatocellular carcinoma (HCC), is metabolized by cytochrome P450 (CYP) 3A4-mediated oxidation and uridine diphosphate glucuronosyl transferase (UGT) 1A9-mediated glucuronidation. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of this study was to investigate the prognostic significance of blood NLR in patients with intermediate-advanced hepatocellular carcinoma (HCC) who received transcatheter arterial embolization (TAE) combined with Sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Sorafenib has been proved to prolong survival of patients with advanced hepatocellular carcinoma (HCC), but with moderate efficacy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We describe herein a hepatocellular carcinoma patient presenting with recurrent psychotic symptoms in the course of the BASIL trial (assessing BAY86-9766 plus sorafenib for the treatment of liver cancer). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Combination therapy of sorafenib and transarterial chemoembolization (TACE) showed benefits for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Sorafenib and transarterial (90) Y-radioembolization (TARE) are possible treatments for Barcelona Clinic Liver Cancer (BCLC) intermediate-advanced stage hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the only systemic treatment that has shown a significant benefit in overall survival (OS) and in progression-free survival (PFS) in advanced hepatocellular carcinoma (HCC) patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We conducted a retrospective analysis of whether the development of hypertension during sorafenib treatment of advanced hepatocellular carcinoma could be a predictor of anti-cancer efficacy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: The study included 38 patients with advanced hepatocellular carcinoma who had received sorafenib for at least 1 month between January 2010 and December 2012. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Hypertension within 2 weeks of initiation of therapy may be a predictor of the anti-cancer efficacy of sorafenib when used for the treatment of advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the standard treatment of patients with advanced hepatocellular carcinoma (HCC), with demonstrated outcome benefits in randomized clinical trials. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Several pilot studies have demonstrated the effectiveness of combination therapy with pyrimidine fluoride and interferon for advanced hepatocellular carcinoma.This study aimed to determine the recommended dose of capecitabine combined with peginterferon \u03b1-2a (Phase I) and evaluate its safety and efficacy for sorafenib-refractory advanced hepatocellular carcinoma (Phase II). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The multi-kinase inhibitor (MKI) sorafenib can be an effective palliative therapy for patients with hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with sorafenib (hereafter, TACE-sorafenib) in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the standard first-line systemic drug for advanced hepatocellular carcinoma (HCC), but the acquired resistance to sorafenib results in limited benefits. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: There are no clinical data/markers to predict improved survival in patients with hepatocellular carcinoma treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: We prospectively studied 147 hepatocellular carcinoma patients (97% cirrhotic, 82% Child-Pugh A, BCLC-B 77, BCLC-C 69) treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To explore the efficacy and safty of sorafenib in Child-Pugh class B to class C hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the first drug currently approved to treat advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The management of hepatocellular carcinoma (HCC) has substantially changed in the past few decades, the introduction of novel therapies (such as sorafenib) have improved patient survival. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Interestingly, Q3G exhibited significantly lower toxicity to normal cells (primary human and rat hepatocytes and primary lung cells) than sorafenib (p<0.05), a chemotherapy drug for hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is a non-selective multiple kinase inhibitor with proven antiproliferative effects in thyroid, renal and hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To retrospectively compare radiofrequency ablation (RFA) combined with the multikinase inhibitor sorafenib (hereafter, sorafenib-RFA) and RFA alone in the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Are some patients with hepatocellular carcinoma just too old to be treated? More specifically, should the age of a patient influence the way sorafenib is prescribed? A new study has tried to address these questions, providing helpful information to guide clinicians making these decisions. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This phase 2 study evaluated the efficacy of radiation therapy (RT) with concurrent and sequential sorafenib therapy in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), may underestimate activity and does not predict survival in patients with hepatocellular carcinoma (HCC) treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: A large number of studies have tried to combine sorafenib with TACE for patients with unresectable hepatocellular carcinoma (HCC) and the results were controversial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The value of serum cholinesterase (ChE) level as a predictive marker in sorafenib therapy for advanced hepatocellular carcinoma (HCC) has not yet been investigated. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multi-kinase inhibitor that has been proven effective for the treatment of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib (BAY 43-9006) is an orally administered multi-level kinase inhibitor, approved for treatment of solid tumors such as renal cell carcinoma, hepatocellular carcinoma and recently for metastatic thyroid carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Identification of individual sorafenib resistance mechanisms may be useful for rational choice of an appropriate combination of targeted drugs for retardation of HCC progression and improving the efficacy of therapy  Hepatocellular carcinoma (HCC) is a malignant tumor characterized by easy metastasis and frequent recurrence. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "An open-label, single arm, investigator-initiated Phase II study (NCT0071279) was conducted at four Asia-Pacific centers to evaluate the safety and efficacy of sequential radioembolization-sorafenib in patients with hepatocellular carcinoma (HCC) not amenable to curative therapies. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the sole molecular-targeted agent showing a survival benefit in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: The human hepatocellular carcinoma cell line HepG2 MCSs were used as in vitro models to investigate the effects of celecoxib combined with 5-fluorouracil or sorafenib or gefitinib treatment on cell growth, apoptosis, and signaling pathway. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of the combination of sorafenib and transarterial chemoembolization (TACE)in the treatment of primary hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a tyrosine kinase inhibitor, is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate in greater detail the efficacy and safety of sorafenib for the treatment of hepatocellular carcinoma (HCC) in patients with established cirrhosis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Small molecule inhibitors of the mitogen-activated protein kinase (MAPK) pathway, such as sorafenib, represent novel treatment options for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib, a multikinase inhibitor as a standard of care for advanced hepatocellular carcinoma, may lead endothelial cells to an unstable state by blocking the signaling pathway of vascular endothelial growth factor receptor, which may result in the disruption of the architecture and integrity of the microvasculature, and eventually increase the risk of hemorrhage. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CASE PRESENTATION: Here we report a unique case of hemobilia occurring in a 55-year-old Korean man with hepatitis B virus-related hepatocellular carcinoma on Barcelona Clinic Liver Cancer advanced stage after seven days of treatment with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Sorafenib may increase the risk of biliary bleeding in hepatocellular carcinoma patients who were primed with irradiation, by blocking the signaling pathway of the vascular endothelial growth factor receptor. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Therefore, sorafenib should be used with caution in patients with advanced hepatocellular carcinoma, especially when combined with radiation therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Sorafenib is the standard systemic therapy for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: These findings suggest that MPT0E028 in combination with sorafenib has significant anti-hepatocellular carcinoma activity in preclinical models, potentially suggesting a novel therapeutic strategy for patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Although sorafenib improves survival in patients with hepatocellular carcinoma (HCC), doses have to be reduced in quite a few patients because of adverse events. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The prognosis of patients with advanced hepatocellular carcinoma (HCC) is poor despite treatment with sorafenib or other anti-angiogenic targeted-therapies. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: The purpose of this study was to assess the clinical outcome and identify prognostic factors following treatment of patients with advanced hepatocellular carcinoma (HCC) and extrahepatic metastasis with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The anti-hepatocellular carcinoma (HCC) drug sorafenib was encapsulated inside the nanoparticles. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To test the hypothesis that use of the response evaluation criteria in cancer of the liver (RECICL), an improved evaluation system designed to address the limitations of the response evaluation criteria in solid tumors 1.1 (RECIST1.1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Published studies have not investigated the suitability of Response Evaluation Criteria in Solid Tumors (RECIST), European Association for the Study of the Liver (EASL) criteria, and modified RECIST (mRECIST) for assessing the response of patients with hepatocellular carcinoma to treatment with sorafenib combined with transarterial chemoembolization. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The antiangiogenic multikinase inhibitor sorafenib was the first systemic agent to demonstrate a significant improvement in the overall survival of patients with advanced hepatocellular carcinoma (HCC), thereby introducing molecularly-targeted therapy in a therapeutic field of unmet needs. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, the first-line systemic drug for advanced hepatocellular carcinoma (HCC), has demonstrated limited benefits with very low response rates. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The multi-kinase inhibitor Sorafenib increases the survival of patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: PubMed, Medline, the Cochrane Library, trip database and Google Scholar were searched using the terms \"Hepatocellular carcinoma\" OR \"Hepatoma\" or \"Liver cancer\" AND \"systemic anticancer therapy\" AND \"Sorafenib\" and specifying only English literature. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study evaluated the feasibility of CT perfusion parameters for the early efficacy prediction of sorafenib in the treatment of hepatocellular carcinoma (HCC) in rats. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aims of this study were to evaluate the frequency of dose-limiting toxicities and to find the recommended dose of combination chemotherapy with sorafenib and transcatheter arterial infusion (TAI) using cisplatin for patients with advanced hepatocellular carcinoma (HCC), for whom surgical resection, local ablation therapy, or transcatheter arterial chemoembolization were not indicated. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Sorafenib, a multi-targeted tyrosine kinase inhibitor, is a first-line systemic treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The success of sorafenib has spurred an explosive increase of clinical trials testing novel molecular targets and other agents in the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report a case of multiple intrahepatic recurrence of hepatocellular carcinoma( HCC) that was successfully treated with transcatheter arterial chemoembolization( TACE) and sorafenib therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The multikinase inhibitor, sorafenib (Nexavar\u00ae, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, an orally-available kinase inhibitor, is the only medical treatment with a proven efficacy against Hepatocellular Carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib, an inhibitor of a number of kinases targeting the Raf/MEK/ERK pathway, is a promising new chemotherapeutic agent in human medicine that has been approved since 2006 for the therapy of renal cell carcinoma and since 2007 for the treatment of hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase and the vascular endothelial growth factor receptor, in 2007 for treating advanced hepatocellular carcinoma (HCC) has generated considerable enthusiasm in drug development for this difficult-to-treat disease. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study aimed to investigate the feasibility of combined transarterial chemoembolization and radiotherapy (TACE+RT) in comparison with sorafenib for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Sorafenib is considered a standard of care in advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In the present study, we investigated in vitro whether ATRA modulates the response of human hepatocellular carcinoma (HCC) cells to sorafenib, the only proven oral drug for advanced HCC, and the underlying mechanisms. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "(5) Despite this in vitro binding data sorafenib has profound in vivo effects on tumor cells in renal carcinoma and hepatocellular carcinoma patients; cells which are not per se addicted to high activity oncogene signals that are targets of sorafenib/regorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This study was undertaken to compare response evaluation criteria in solid tumours (RECIST) 1.1 and modified RECIST (mRECIST) in patients with unresectable hepatocellular carcinoma (HCC) on sorafenib, and to describe HCC enhancement changes before and after sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this study, we investigated noninvasive imaging protocols to monitor responses to sorafenib, a multikinase inhibitor approved for treatment of renal cell and hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) is a global, prospective, non-interventional study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in real-life practice, including Child-Pugh B patients who were excluded from clinical trials. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib, an oral multikinase inhibitor, is the only systemic agent proven to be effective in patients with hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here, we report that SC-60, a dimer-based sorafenib derivative, overcomes the resistance of sorafenib and shows a better anti-hepatocellular carcinoma effect in vitro and in vivo. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Importantly, SC-60 exhibited significant survival benefits compared with sorafenib in a hepatocellular carcinoma orthotopic model via targeting the SHP-1/STAT3-related signaling pathway. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In summary, dimer derivative of sorafenib, SC-60, is a SHP-1 agonist and may be a potent reagent for hepatocellular carcinoma-targeted therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib--a broad kinase inhibitor--is a standard therapy for advanced hepatocellular carcinoma (HCC) and has been shown to exert antifibrotic effects in liver cirrhosis, a precursor of HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Recently, the oral multikinase inhibitor sorafenib has been used to treat advanced hepatocellular carcinoma (aHCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The current study aimed to explore whether the BIM deletion polymorphism predicts the treatment efficacy of sorafenib for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "For patients with early resectable disease, surgical resection or transplantation is considered a potentially curative modality for hepatocellular carcinoma (HCC); on the other hand, for patients with unresectable or metastatic disease, treatment is essentially palliative and prior to the approval of sorafenib, there was no globally approved systemic treatment for patients presenting with unresectable or metastatic HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY 86-9766 in monotherapy and in combination with sorafenib in orthotopic and subcutaneous hepatocellular carcinoma (HCC) models with different underlying etiologies in two species. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is currently recommended as first-line therapy for patients with intermediate or advanced hepatocellular carcinoma (HCC) per Barcelona Clinic Liver Cancer staging. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "An angiostatic therapy with sorafenib is considered one of the promising approaches for chemoprevention of hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this study, we evaluated the role of synthetic dsRNA as a TLR3 synergist and by combining with sorafenib in anti-hepatocellular carcinoma (HCC) in vitro and in vivo. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Despite the established efficacy of sorafenib in advanced hepatocellular carcinoma (HCC), a significant number of sorafenib-treated patients experience disease progression. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We investigated the effect of EMT-related SRF, focusing on its promotion of chemoresistance against sorafenib in hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Antiangiogenic therapy, especially treatment with sorafenib, is the primary treatment for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Although sorafenib is accepted as the standard of care in advanced hepatocellular carcinoma (HCC), its therapeutic benefit is marginal. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "After the hepatocellular carcinoma was confirmed, adjuvant therapy (sorafenib) was initialized. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multi-targeted kinase inhibitor, which is the current standard treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of this study was to compare the safety profile between renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) patients receiving sorafenib under real-life practice conditions. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Sorafenib is the reference therapy for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: A new predictive biomarker for determining prognosis in patients with hepatocellular carcinoma (HCC) who receive sorafenib is required, because achieving a reduction in tumor size with sorafenib is rare, even in patients who have a favorable prognosis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The management of hepatocellular carcinoma (HCC) has substantially changed in the past few decades, the introduction of novel therapies (such as sorafenib) have improved patient survival. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND GOALS: Several studies have demonstrated that sorafenib is effective in the treatment of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The purpose of this study was to identify the correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib by analyzing medical records retrospectively. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To assess the safety and feasibility of the targeted delivery of the antiangiogenic drug sorafenib to the liver using transarterial chemoembolization methodology as a novel approach to hepatocellular carcinoma (HCC) therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Transarterial chemoembolization with sorafenib in Lipiodol is an effective methodology for the localized delivery of this drug to the liver and has possible practical implications in therapeutic interventions for the treatment of hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The purpose of this study is to assess clinical efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) on patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The combination of sorafenib, TACE, and RFA proved both safe and effective in the treatment for unresectable hepatocellular carcinoma patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: We previously reported that expressions of the pro-angiogenic cytokines angiopoietin-2 (Ang-2), follistatin, granulocyte colony-stimulating factor, hepatocyte growth factor, leptin, platelet-derived growth factor-BB, platelet endothelial cell adhesion molecule-1, and vascular endothelial growth factor were associated with the response to sorafenib in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "BACKGROUND: Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "KEYWORDS: Hepatocellular carcinoma, chemoembolization, radiofrequency, sorafenib, hepatitis C, Hepatitis B. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Sorafenib is an effective systemic agent for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib (SO) was the first targeted agent to produce significant improvements in overall survival in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the overall survival (OS) and progression-free survival (PFS) with associated adverse events (AE) in patients with unresectable hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) + sorafenib vs TACE alone. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma (HCC), has opened a window of hope after searching for effective agents to combat HCC for decades. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a malignant tumour that is characterized by extensive vascular remodelling and responsiveness to treatment with the anti-angiogenic multikinase inhibitor sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare the time to progression (TTP) and overall survival (OS) in patients with advanced-stage hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment combined with transarterial chemoembolization (TACE) versus sorafenib monotherapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Two global phase III trials showed that sorafenib prolonged the survival of patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib, an oral multityrosine kinase inhibitor, has been approved for treatment of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The current status of treatment with sorafenib, and factors affecting the duration of treatment in patients started on sorafenib for hepatocellular carcinoma from July 2009 until April 2011 in the Department of Gastroenterology at Kobe City Medical Center General Hospital, were examined. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Therefore, it was considered that these factors improved the effect of treatment with sorafenib in patients with hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib represents the standard of care targeted therapy for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the standard of care for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "For several years, sorafenib has been approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following first-line sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Currently, oral sorafenib is the treatment of choice for metastatic hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: The outcomes of sorafenib therapy in patients with advanced hepatocellular carcinoma (HCC) and impaired liver function remain unresolved. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " After years of therapeutic nihilism due to the inefficacy of conventional cytotoxic chemotherapy, the multikinase inhibitor sorafenib was the first agent to demonstrate a significant improvement in the survival of patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The efficacy of sorafenib for hepatocellular carcinoma (HCC) patients refractory to transcatheter arterial chemoembolization (TACE) has not yet been clarified. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib improves overall survival (OS) of patients with hepatocellular carcinoma (HCC) in the absence of objective response. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report on a case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "He was diagnosed as rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Despite the successful FDA approval of sorafenib as the standard of care therapy in patients with advanced hepatocellular carcinoma (HCC), its clinical benefits have been modest. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To explore the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: The combined use of TACE and sorafenib is both safe and efficacious in the treatment of advanced hepatocellular carcinoma with tumor thrombosis in portal vein. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is currently approved for the treatment of advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The objective of this phase I trial was to establish the safety and toxicity profile of sorafenib in high-risk patients with hepatocellular carcinoma who have undergone orthotopic liver transplantation. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AIMS: We previously demonstrated the pro-metastasis effect of sorafenib in hepatocellular carcinoma (HCC), which is mediated by down-regulation of tumor suppressor HTATIP2. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Despite the fact that the hepatocellular carcinoma (HCC) represents a major health problem, very few interventions are available for this disease, and only sorafenib is approved for the treatment of advanced disease. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patients with well-preserved liver function (Child-Pugh A class) and advanced-stage HCC (BCLC-C) or in patients with HCC progressing after locoregional therapies, with a high grade of recommendation. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The recommendation of sorafenib as standard of care in advanced hepatocellular carcinoma has lent support to the increased use of antiangiogenic therapies. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The combination of sorafenib and erlotinib was not superior to sorafenib alone, which suggests no positive interaction between antiangiogenics and tyrosine kinase inhibitors in the treatment of advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Sorafenib induces early vascularity reduction in patients with hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Antiangiogenic therapy, specially sorafenib, has become the standard of care for patients with advanced hepatocellular carcinoma (HCC), however, the improvement in survival time is not satisfactory. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Liver resection can be considered in some hepatocellular carcinoma (HCC) patients who received sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally, and its prevalence and impact are even more profound because sorafenib is the only systemic therapy proven to prolong survival in patients with advanced disease. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of this study was to compare radiological and pathological changes and test the adjunct efficacy of Sorafenib to Y90 as a bridge to transplantation in hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Sorafenib, an oral multikinase inhibitor, is the first agent that has demonstrated an improved overall survival benefit in advanced hepatocellular carcinoma, setting a new standard for first-line treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The purpose of this study was to investigate whether sorafenib could enhance radiosensitivity and the possible mechanisms of sorafenib-mediated radiosensitization in human hepatocellular carcinoma cell line SMMC-7721. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Interestingly, pretreatment of mitogen-activated protein kinase kinases/extracellular signal-regulated kinase (MEK/ERK) signaling inhibitor U0126 had a similar effect as that of sorafenib pretreatment in hepatocellular carcinoma cells, whereas pretreatment of phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling inhibitor LY294002 in the same cells had no effect on radiosensitization. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Our data provided experimental support for the possible combination of sorafenib with radiation for the treatment of hepatocellular carcinoma and other cancers. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Sorafenib is an unselective inhibitor of multiple kinases which has demonstrated clinical advantage in renal cancer and hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Both are illustrated with analyses of overall survival from the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol trial. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here, we report a pharmacokinetic interaction between sorafenib and the CYP3A4 inducer prednisolone in a patient with hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The efficacy of sorafenib against hepatocellular carcinoma (HCC) has been extensively reported. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Before the sorafenib era, advanced but liver-confined hepatocellular carcinoma (HCC) was treated by liver-directed therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: By carrying out a meta-analysis of randomized controlled trials that compared sorafenib or combined chemotherapy with placebo or combined chemotherapy, the effectiveness of sorafenib in hepatocellular carcinoma was evaluated in the present study, which also provided clinical practice guidelines of evidence-based-medicine. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: We reviewed PubMed citations concerning sorafenib treating hepatocellular carcinoma in randomized controlled trials from Jan 2000 to July 2012. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Compared with controls, sorafenib was shown to significantly increase overall survival (OS), time to progression (TTP), and disease control rates (DCR), but not the time to symptom progression (TTSP) in hepatocellular carcinoma patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Sorafenib exerts significant curative effects in hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To examine the effect of branched-chain amino acid (BCAA) therapy for patients with unresectable hepatocellular carcinoma (HCC) treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: We investigated whether continuous sorafenib administration keeps suppressing the growth of hepatocellular carcinoma (HCC) after first progressive disease (PD), and whether it prolongs patients' survival. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Few studies have reported that the effect of sorafenib on advanced human hepatocellular carcinoma (HCC) is taking place via the inhibition of NF-\u03baB signal transduction. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Currently, only one drug, sorafenib, is FDA approved for the treatment of advanced hepatocellular carcinoma (HCC), achieving modest objective response rates while still conferring an overall survival benefit. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We investigated the antiproliferative effects of sorafenib in combination with pegylated interferon-\u03b12b (PEG-IFN-\u03b12b) on human hepatocellular carcinoma (HCC) cells in vitro and in vivo. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib has proven survival benefits in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: This prospective pilot study investigated the feasibility of perfusion computed tomography parameters as surrogate markers of angiogenesis and early response following sorafenib administration in patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: To evaluate the effectiveness and safety of sorafenib combined with transarterial chemoembolization (TACE) in patients with advanced primary hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODOLOGY: A retrospective analysis of 65 patients with advanced primary hepatocellular carcinoma who had been administered sorafenib for more than one month and treated by TACE was performed. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Sorafenib combined with TACE is a safe and effective treatment of advanced primary hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Preclinical studies show that sorafenib, a multitarget kinase inhibitor, displays anti-proliferative, anti-angiogenic, and pro-apoptotic properties in hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIM: Sorafenib is currently the only medical treatment with proven efficacy against hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Sorafenib is a promising treatment for hepatocellular carcinoma (HCC) but recent toxicity concerns suggest that new strategies for its use are needed. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The potential for increased efficacy with combined transarterial chemoembolization and sorafenib is a topic of increased interest to specialists who care for patients with unresectable hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Despite the availability of several treatment opportunities, diagnosis is still made in an advanced phase, limiting application of most therapeutic choices that currently are based on the Barcelona Clinic Cancer Liver Classification and include surgical resection, orthotopic liver transplantation and ablative methods for very early and early disease, arterial chemoembolization for intermediate stages and systemic therapy with sorafenib for advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib (SO) was the first systemic agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC); international guidelines now recommend SO as a first-line treatment in patients with unresectable HCC who are not eligible for locoregional therapies and maintain preserved liver function. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Down-regulation of SLC22A1 encoding the organic cation transporter-1 (OCT1) may affect the response of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CGC) to sorafenib, a cationic drug. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety, activity, pharmacokinetics (PK), and biomarkers of the mammalian target of rapamycin inhibitor, temsirolimus, combined with sorafenib in hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Data on the efficacy and safety of sorafenib in combination with transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) are lacking. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The multikinase inhibitor sorafenib is currently the treatment of reference for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of this study was to evaluate the efficacy of sorafenib, compared to best supportive care (BSC), in two cohorts of patients which presented with hepatocellular carcinoma (HCC) recurrence after LT. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is an orally active tyrosine kinase inhibitor used in the treatment of renal and hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K (BKM-120) or both (BEZ-235 and GDC-0980) in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) cells characterized for acquired resistance to sorafenib or sunitinib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: The combination of the TACE and sorafenib proved both safe and effective in the treatment of Chinese patients with unresectable hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is a multikinase inhibitor with antiangiogenic and antiproliferative properties, approved for the treatment of hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "It is worth noting that the antitumor activities of compounds 2c, 2d and 2f are more potent than that of sorafenib on pancreatic cancer cells Mia-PaCa-2 and SW1990, and the activities of compounds 3f and 3g are 2-3 times than that of sorafenib on human hepatocellular carcinoma HepG2 cell line. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Sorafenib and S-1 (one mixed formulation containing 5-FU prodrug and dihydropyrimidine dehydrogenase inhibitor) were two effective agents against hepatocellular carcinoma (HCC), but whether they had synergistic effects remained unclear. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The multikinase inhibitor sorafenib has demonstrated an overall survival benefit in phase III hepatocellular carcinoma (HCC) trials and has become the new standard of care for advanced stages of this disease. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The standard therapy for advanced hepatocellular carcinoma (HCC) is sorafenib, with most patients experiencing disease progression within 6 months. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: In 2007, sorafenib was the first drug able to improve overall survival in patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To determine the value of early alterations of the tumor markers \u03b1-fetoprotein (AFP) and des-\u03b3-carboxy prothrombin (DCP) for predicting the outcomes of patients with advanced hepatocellular carcinoma (HCC) who receive sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We investigated the molecular mechanisms underlying the effect of sorafenib and SC-59, a novel sorafenib derivative, on hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Elevated Glasgow Prognostic Score (GPS) has been related to poor prognosis in patients with hepatocellular carcinoma (HCC) undergoing surgical resection or receiving sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib, a multikinase inhibitor approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, has been reported inhibitory on the function of dendritic cells. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Des-\u03b3-carboxyprothrombin (DCP) is known to be increased by the use of sorafenib for the treatment of hepatocellular carcinoma (HCC), despite its therapeutic efficacy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sorafenib is the first agent to demonstrate a survival benefit in the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) vs\u2005TACE alone for the treatment of patients with unresectable intermediate or advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Despite the successful approval and extensive application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Early prediction of tumour response and major adverse events (AEs), especially liver failure, in patients with hepatocellular carcinoma (HCC) is essential for maximizing the clinical benefits of sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib has been approved in the indication of unresectable hepatocellular carcinoma, but there are many cases in which administration of the drug is discontinued due to severe side effects. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "She was diagnosed with unresectable hepatocellular carcinoma (HCC) with PVTT, and sorafenib in combination with intermittent cisplatin(CDDP) hepatic arterial infusion chemotherapy(HAIC)was performed. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is an oral multikinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To evaluate the efficacy of sorafenib monotherapy, we enrolled 188 patients with hepatocellular carcinoma (HCC) who had undergone sorafenib monotherapy during a 3-year period from May 2009 to June 2012. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the only drug approved for the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To investigate the volumetric iodine-uptake (VIU) changes by dual-energy CT (DECT) in assessing the response to sorafenib treated hepatocellular carcinoma (HCC) patients, compared with AASLD (American Association for the Study of Liver Diseases) and Choi criteria. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Accurate staging of hepatocellular carcinoma (HCC) is critical for guiding optimal treatment, and the presence of extrahepatic metastases (EHM) can seriously affect the optimal choice of treatment in the sorafenib era. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGF\u03b2 and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In a trial examining the use of sorafenib after transarterial chemoembolization in Korean and Japanese patients with advanced hepatocellular carcinoma, the compliance and dose intensity of the drug were quite low compared with other trials. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Hepatocellular carcinoma (HCC) is a difficult to treat cancer characterized by poor tumor immunity with only one approved systemic drug, sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is the only approved agent recommended by the American Association Study of Liver Disease guidelines for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Few data are available on the safety and efficacy of sorafenib in HIV-infected patients with unresectable hepatocellular carcinoma (HIV-u-HCC) and concomitant highly active antiretroviral therapy (HAART). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Impact of patient and tumour baseline characteristics on the overall survival is not well characterized in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib was shown in clinical trial to enhance survival in hepatocellular carcinoma (HCC) patients, but with minimal tumor shrinkage. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "AREAS COVERED: This paper covers the preclinical data, the Phase I studies as monotherapy or in combination with sorafenib, and a Phase II study as second-line systemic treatment in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS) with Sonazoid in evaluating early response to sorafenib for hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib, an oral multikinase inhibitor, was approved for the treatment of advanced hepatocellular carcinoma (HCC), but has not been adequately evaluated for safety and effectiveness in Japanese patients with advanced HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We investigated the in vitro and in vivo effect of sorafenib combined with irradiation on hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " A multi-kinase inhibitor, sorafenib, was recently approved and is currently recommended for the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but its use is hampered by the occurrence of drug resistance. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib has been used to treat advanced hepatocellular carcinoma (HCC), but the underlying molecular mechanisms remain controversial and why some patients do not respond to this therapy is poorly understood. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is currently the only approved systemic therapy shown to have efficacy in the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study investigates the effectiveness and safety of sorafenib in a heterogeneous cohort of Child-Pugh A, B and C patients with advanced hepatocellular carcinoma in a clinical-practice scenario. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Adult patients with hepatocellular carcinoma and treated with sorafenib 800 mg/day were eligible for this multicentric retrospective observational study. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Although sorafenib has been approved for treating advanced hepatocellular carcinoma (HCC), its high cost, frequent adverse events, and unsatisfactory efficacy remain unresolved. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib, a multikinase inhibitor that inhibits angiogenesis and carcinogenesis, has been used for patients with advanced hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Sorafenib improves survival in advanced hepatocellular carcinoma (HCC), but the demonstration of its efficacy and safety is limited to Child-Pugh A cirrhotic patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study was performed to identify clinical predictors for better survival in patients with advanced hepatocellular carcinoma (HCC) under sorafenib treatment. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib has become the standard first-line treatment for patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "DATA SOURCES: A computer-based systematic search from January 2005 to June 2011 with \"sorafenib\" and \"advanced hepatocellular carcinoma\" as search terms was performed for possible clinical trials. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: The aim of this study was to assess the safety and efficacy of sorafenib, with or without everolimus, in the treatment of recurrent hepatocellular carcinoma (HCC) after an orthotopic liver transplantation (OLT). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib has shown survival benefits in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class A liver function. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The molecular mechanisms and cellular targets of sorafenib, a multikinase inhibitor used for the treatment of hepatocellular carcinoma (HCC), remain to be fully characterized. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: The current standard treatment for advanced hepatocellular carcinoma (HCC) is sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND PURPOSE: Previously, we have shown that sorafenib sensitizes hepatocellular carcinoma (HCC) to apoptosis induced by TNF-related apoptosis-inducing ligand (TNFSF10; TRAIL). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Antiangiogenic agents can sometimes promote tumor invasiveness and metastasis, but little is known about the effects of the antiangiogenic drug sorafenib on progression of hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " In May 2007, sorafenib (Nexavar\ufffd) was approved for \"unresectable hepatocellular carcinoma (HCC)\", and was the first molecular targeted agent for use in HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is presently the only effective therapy in advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The response rate to sorafenib in hepatocellular carcinoma (HCC) is relatively low (0.7%-3%), however, rapid and drastic tumor regression is occasionally observed. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Sorafenib is the standard treatment of patients with advanced hepatocellular carcinoma, regardless of the liver functional reserve. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVES: Sorafenib has been shown to improve survival rate of hepatocellular carcinoma (HCC) patients significantly. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "As a member of this group, Sorafenib has already been approved for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma not suitable for locoregional treatment, and it is currently under investigation for advanced non small cell lung cancer (NSCLC), either alone or in combination with other biological/cytotoxic agents. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is a multi-kinase inhibitor currently approved in Japan for unresectable and/or metastatic renal cell carcinoma and unresectable hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib currently sets the new standard for advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: The 28% progression-free survival rate at 27 weeks was not significantly higher than the recent historical control rate of 20% observed on the placebo arm of the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol trial (P=0.28). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Patients with advanced hepatocellular carcinoma who were treated with sorafenib at Queen Mary Hospital, Hong Kong, China, were analyzed retrospectively. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma (HCC), but it is not known whether sorafenib is equally active in all HCC. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: In both SHARP and Asia-Pacific Study, sorafenib was proved to improve the overall survival of the patients with hepatocellular carcinoma. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is currently approved for advanced hepatocellular carcinoma (HCC) and is presently being studied as an adjuvant treatment for HCC following resection. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: In Japan, sorafenib is now the first-line therapy for individuals with advanced hepatocellular carcinoma (HCC), but no other treatment is available for such patients. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Some patients with advanced hepatocellular carcinoma (HCC) progressing under sorafenib remain eligible for further systemic therapy. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Little is known about acute interstitial pneumonia (AIP) induced by sorafenib therapy in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "PATIENTS AND METHODS: Sorafenib plasma concentrations were determined by liquid chromatography, every 2 weeks, in consecutive hepatocellular carcinoma patients treated with sorafenib. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "RESULTS: Fifteen hepatocellular carcinoma patients with Child-Pugh A cirrhosis, in whom sorafenib dosing remained unchanged from initiation of treatment to disease progression, were eligible for this analysis. "}, {"drug": "sorafenib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib is an oral tyrosine kinase inhibitor approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. "}, {"drug": "idarubicin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "SETTING: This is a phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads performed in cirrhotic patients with hepatocellular carcinoma. "}, {"drug": "idarubicin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To present in vitro loading and release characteristics of idarubicin with ONCOZENE (CeloNova BioSciences, Inc, San Antonio, Texas) drug-eluting embolic (DEE) agents and in vivo pharmacokinetics data after transarterial chemoembolization with idarubicin-loaded ONCOZENE DEE agents in patients with hepatocellular carcinoma. "}, {"drug": "idarubicin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Clinical and 24-hour pharmacokinetics data were recorded after transarterial chemoembolization with idarubicin-loaded ONCOZENE DEE agents in four patients with unresectable hepatocellular carcinoma. "}, {"drug": "idarubicin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: A phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads was performed in cirrhotic patients with hepatocellular carcinoma (HCC). "}, {"drug": "idarubicin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "A recent in vitro study demonstrated that idarubicin, an anthracycline, was by far the most cytotoxic drug on human hepatocellular carcinoma (HCC) cell lines. "}, {"drug": "Axitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study aimed to evaluate the utility of dynamic contrast-enhanced ultrasound (DCE-US) in measuring early tumor response of advanced hepatocellular carcinoma to axitinib. "}, {"drug": "Axitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "DCE-US is potentially useful in measuring early tumor response of advanced hepatocellular carcinoma to axitinib, but a larger trial is needed. "}, {"drug": "Axitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The efficacy and safety of axitinib, a potent and selective vascular endothelial growth factor receptors 1-3 inhibitor, combined with best supportive care (BSC) was evaluated in a global, randomized, placebo-controlled phase II trial in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). "}, {"drug": "LMWH", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Low molecular weight heparin nanoparticles (LMWH) modified by glycyrrhetinic acid (GA) (LMWH-GA) and further decorated by lactobionic acid (LA) (LA-LMWH-GA) were reported as novel hepatocellular carcinoma (HPC)-targeted carriers to overcome multidrug resistance (MDR) of doxorubicin (DOX). "}, {"drug": "LMWH", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this study, GA grafted low molecular weight heparin (GA-LMWH) was prepared and self-assembled into micelles in aqueous solution to improve the solubility and antitumor effects against hepatocellular carcinoma. "}, {"drug": "LMWH", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "GA-LMWH micelles were administered intravenously and significantly improved liver function, decreased cell lesions in hepatic tissue, inhibited the expression of CD105 and prolonged survival time of hepatocellular carcinoma model compared with groups treated with normal saline or GA solution. "}, {"drug": "LMWH", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We evaluated \"second generation\" LMWH bemiparin and its in vitro anti-tumor effects on HepG2 hepatocellular carcinoma and MIA PaCa-2 cancer cells. "}, {"drug": "LMWH", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To explore the effects of low molecular weight heparin (LMWH) on cisplatin (DDP)- induced apoptosis in human\u00a0hepatocellular\u00a0carcinoma\u00a0cell and the underlying mechanisms.\u2029 METHODS: Hepatocellular carcinoma SMMC-7721 cells were divided into a control group, a LMWH group, a DDP group and a LMWH plus DDP group. "}, {"drug": "Dasatinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "All the synthesized compounds were evaluated for their in vitro anticancer activity against four cancer cell lines, namely human hepatocellular carcinoma (HepG2), human medulloblastoma (Daoy), human cervical cancer (HeLa), and human colon cancer (HT-29), by using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and dasatinib as the reference drug. "}, {"drug": "Octreotide", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To explore the effects of SOM230, octreotide and lanreotide on hepatocellular carcinoma cell line Bel-7402 In vivoand In vitro, and to analyze the differences of their therapeutic efficacy with relevant mechanisms. "}, {"drug": "Octreotide", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To investigate the effect of Lawsonia inermis total methanolic extract (LIE) and octreotide (OC) on hepatocellular carcinoma (HCC) progression, depending on somatostatin receptor 2 (SSTR-2) and Alfa fetoprotein (AFP) perturbations. "}, {"drug": "Octreotide", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To validate the efficacy of an innovative multimodality therapy with transcatheter arterial embolization (TAE) plus octreotide and celecoxib in reducing neoangiogenesis and prolonging the survival of rabbits with hepatocellular carcinoma. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In the advanced and metastatic setting, only two targeted drugs have been approved by the Food &amp; Drug Administration (FDA), which are sorafenib for hepatocellular carcinoma and erlotinib for PDA. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To evaluate the efficacy and safety of erlotinib for the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study aimed to identify biomarkers predicting prognosis and/or response to sorafenib, with or without erlotinib, in hepatocellular carcinoma patients from the phase III SEARCH trial. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Baseline plasma HGF, VEGFA, KIT, and VEGFC correlated with clinical outcomes in hepatocellular carcinoma patients treated with sorafenib with or without erlotinib. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "BACKGROUND: Early clinical studies of bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) have a tolerable toxicity and a promising clinical outcome. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, randomized, phase III trial. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Previously, we found that PP2A activity determined the anticancer effect of bortezomib and erlotinib in hepatocellular carcinoma (HCC) cells. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We previously showed erlotinib, a selective EGFR antagonist, inhibited the growth of sensitive hepatocellular carcinoma cells by inhibiting the cancerous inhibitor of protein phosphatase 2A (CIP2A) pathway. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The drug combination was also tested in a panel of hepatocellular carcinoma cells (HCC), a cancer type known to be refractory to erlotinib. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: The bevacizumab/erlotinib combination was reported with high clinical activity for advanced hepatocellular carcinoma (HCC) by a phase II study conducted in the USA. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The combination of sorafenib and erlotinib was not superior to sorafenib alone, which suggests no positive interaction between antiangiogenics and tyrosine kinase inhibitors in the treatment of advanced hepatocellular carcinoma. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "There are no other reports about erlotinib-induced leukocytoclastic vasculitis (LV) in the erlotinib-bevacizumab regimen for bone metastasis, from a relapsed hepatocellular carcinoma (HCC) in liver-transplanted patients. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here, we identify that cancerous inhibitor of protein phosphatase 2A (CIP2A) is a major determinant mediating erlotinib-induced apoptosis in hepatocellular carcinoma (HCC). "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here, a series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma were evaluated. "}, {"drug": "Erlotinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the combination of erlotinib and bevacizumab in subjects with hepatocellular carcinoma (HCC) who are not candidates for local therapy. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Patients receiving ribavirin experienced more episodes of ascites and headache but less recurrence of hepatocellular carcinoma (HCC), and were prescribed more diuretics and cardiopulmonary drugs. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In patients with hepatitis C virus-induced liver cirrhosis, interferon and ribavirin combination therapy provide a favorable long-term prognosis, including lower rates of liver-related and non-liver-related deaths, hepatic decompensation, and hepatocellular carcinoma, particularly in those who have successful eradication of the virus after therapy. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Adjuvant pegylated interferon plus ribavirin treatment (PegIFN/RBV) reduces recurrence and prolongs survival in early stage hepatocellular carcinoma (HCC) patients with chronic hepatitis C (CHC) infection receiving resection or ablation. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "However, previously published data deriving from the use of pegylated-interferon and ribavirin lead to hypothesizing that we are going to observe, in the future, a reduction in mortality and in the incidence of hepatocellular carcinoma, as well as a regression of fibrosis for people previously affected by hepatitis C. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study undertaken to identify suitable candidates for peg-interferon plus ribavirin (PEG-IFN/RBV) treatment by evaluating hepatocellular carcinoma (HCC) risk in patients with chronic HCV treated or not with PEG-IFN/RBV.This large-scale retrospective study was conducted on 1176 patients with chronic HCV without a history of HCC (treatment group [n\u200a=\u200a489] and no-treatment group [n\u200a=\u200a687]). "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We sought to compare the hepatocellular carcinoma recurrence-free survival of a historical cohort treated with pegylated interferon/ribavirin and an untreated cohort with a cohort treated with direct-acting antivirals. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Healthcare costs and clinical outcomes (number of liver-related deaths, quality-adjusted life-years [QALYs], life-years [LYs] spent in sustained virologic response [SVR] or with decompensated cirrhosis, hepatocellular carcinoma, or liver transplant) were compared among five treatment strategies (no antiviral therapy; IFN\u2009+\u2009ribavirin\u2009+\u2009protease inhibitor for fibrosis stages F2-F4, IFN-based DAAs for stages F2-F4, IFN-free DAAs for stages F2-F4, and IFN-free DAAs for stages F0-F4). "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "RESULTS: For genotype 1 treatment-naive HCV patients, for OMB/PTV/r\u2009+\u2009DSV\u2009\u00b1\u2009RBV, PegIFN\u2009+\u2009ribavirin (PegIFN/RBV), sofosbuvir\u2009+\u2009PegIFN/RBV, telaprevir\u2009+\u2009PegIFN/RBV, boceprevir\u2009+\u2009PegIFN/RBV, lifetime risk of decompensated liver disease was 5.6%, 18.9%, 7.4%, 11.7%, and 14.9%; hepatocellular carcinoma was 5.4%, 9.2%, 5.7%, 7.0%, and 7.4%; and death from liver disease was 8.7%, 22.2%, 10.4%, 14.8%, and 17.6%, respectively. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC). "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study was conducted to test the hypothesis that peripheral absolute monocyte counts (AMC) could impart an increased risk of hepatocellular carcinoma (HCC) development in hepatitis C virus (HCV)-infected patients after a failed peginterferon/ribavirin (PR) combination therapy. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC). "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The subjects consisted of patients with chronic hepatitis C (n\u2009=\u2009553, 72.9%), liver cirrhosis (n\u2009=\u2009127, 16.7%), and hepatocellular carcinoma (n\u2009=\u200979, 10.4%), and were treated usually using pegylated interferon alpha and ribavirin. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Our goal was to evaluate the impact of IFN-\u03b2 plus ribavirin (RBV) treatment on the suppression of hepatocellular carcinoma (HCC). "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Pegylated interferon-alpha plus ribavirin combination (PegIFN/RBV) therapy possesses positive effect in the secondary prevention of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The use of pegylated interferon (Peg-IFN) plus ribavirin combination therapy for chronic hepatitis C patients who received curative treatment for hepatocellular carcinoma is controversial. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Ninety-nine chronic hepatitis C patients who received curative resection or radiofrequency ablation for primary hepatocellular carcinoma, met the Milan criteria and were treated with Peg-IFN plus ribavirin therapy were enrolled (75 males, 24 females; mean age, 65.0\u2009\u00b1\u20095.9 years; 79 HCV genotype 1, 20 genotype 2). "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "However, there is controversy regarding how polymorphisms in IFNL3 affect the risk for development of hepatocellular carcinoma (HCC) in patients treated with pegylated interferon and ribavirin. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: In a phase 2, open-label study, 61 patients with HCV of any genotype and cirrhosis (Child-Turcotte-Pugh score, \u22647) who were on waitlists for liver transplantation for hepatocellular carcinoma, received up to 48 weeks of sofosbuvir (400 mg) and ribavirin before liver transplantation. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: We assessed the effects of sustained viral response (SVR), after treating with interferon-ribavirin (IF-RB), on mortality, liver-related (LR) events (decompensation, hepatocellular carcinoma), HIV progression, and liver stiffness in HIV/hepatitis C virus (HCV)-coinfected patients with nonadvanced liver fibrosis. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "HCV steatosis has a remarkable clinical impact in as much as it is an acknowledged risk factor for accelerated fibrogenesis; for impaired treatment response to interferon and ribavirin; and development of hepatocellular carcinoma. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Although the incidence of hepatocellular carcinoma (HCC) has been shown to be reduced after pegylated glycol-interferon plus ribavirin (Peg-IFN/RBV) therapy in patients with chronic hepatitis C, the risk factors for the development of HCC are not fully understood. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We report our experience using the combination of telaprevir, pegylated interferon alfa-2a (PegIFN alfa-2a), and ribavirin in three patients with HCV-associated hepatocellular carcinoma (HCC) awaiting LT. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To determine the frequency of development of hepatocellular carcinoma in patients with chronic liver disease secondary to hepatitis C who had achieved sustained virological response with Interferon and Ribavirin therapy. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Whether peginterferon \u03b1 and ribavirin combination therapy reduces risk of hepatocellular carcinoma (HCC) or improves survival in patients dual-infected with hepatitis C virus (HCV) and hepatitis B virus (HBV) is unknown. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: The effects of pegylated interferon (PegIFN) \u03b1 and ribavirin (RBV) treatment of chronic hepatitis C on the incidence of hepatocellular carcinoma (HCC) have not been well established. "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Recent reports show that R70Q and L/C91M amino acid substitutions in the core from different hepatitis C virus (HCV) genotypes have been associated with variable responses to interferon (IFN) and ribavirin (RBV) therapy, as well to an increase of hepatocellular carcinoma (HCC) risk, liver steatosis and insulin resistance (IR). "}, {"drug": "Ribavirin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Substitution of amino acid 70 and/or 91 in the core region of hepatitis C virus (HCV) genotype 1b (HCV-1b) is an important predictor of hepatocellular carcinoma (HCC), but its impact on HCC in nonresponders to interferon (IFN) and ribavirin (RIB) combination therapy is not clear. "}, {"drug": "Thalidomide", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Transcatheter arterial chemoembolization (TACE) and thalidomide have been used for treating primary hepatocellular carcinoma(HCC). "}, {"drug": "Thalidomide", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To correlate between signal parameters using dynamic contrast-enhanced magnetic resonance imaging (DCEMRI) and outcomes of hepatocellular carcinoma (HCC) receiving radiotherapy with or without concomitant thalidomide. "}, {"drug": "Thalidomide", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of the present study was to investigate the inhibitory effects of thalidomide in the hepatocellular carcinoma nude mouse model in order to provide new insights into a comprehensive clinical intervention for hepatocellular carcinoma. "}, {"drug": "Thalidomide", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We reported two cases of hepatocellular carcinoma (HCC) with lung metastases who were treated with a combination of thalidomide and cyproheptadine. "}, {"drug": "Vismodegib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The study was influenced by the high number of patients with hepatocellular carcinoma with advanced cirrhosis; rendering it difficult to draw any causal relationships between vismodegib exposure and the serious adverse events. "}, {"drug": "Carboplatin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODOLOGY: We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: We aimed to evaluate the short- and long-term surgical outcomes of salvage hepatectomy for recurrent hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) and/or transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To assess the value of conventional transarterial embolization/chemoembolization (cTAE/TACE) therapy via extrahepatic arteries for patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: The aim of this study is to evaluate efficacy and safety of transarterial chemoembolization (TACE) with N-butyl 2-cyanoacrylate (NBCA) for the treatment of hepatocellular carcinoma (HCC) with arterioportal shunts (APS). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Transarterial chemoembolization (TACE) is a good choice for hepatocellular carcinoma (HCC) treatment when surgery and liver transplantation are not feasible. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: We retrospectively evaluated a total of 72 patients with hepatocellular carcinoma that underwent TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: This study was designed to evaluate the efficacy and safety of combination transarterial chemoembolization (TACE) followed by radiotherapy (RT) and hyperthermia (CERT) in hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Methods: From August 2016 to May 2017, there were 13 patients including 11 males and 2 females with primary hepatocellular carcinoma who underwent TBPVE+ TACE , among whom there were 11 cases with a history of HBV infection.Average age of the 13 patients was (60.8\u00b16.2)years. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Conclusions: TBPVE could induce a rapid growth of the liver remnant but still with the concern of inducing the growth of neoplasms at the same time.To combine TACE in TBPVE therapy not also can the growth of neoplasms be prevented but also inducing its shrinking.This method might be a new mode for the treatment of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To review the initial imaging responses after drug-eluting embolic trans-arterial chemoembolization (DEE-TACE) delivered with the Surefire Infusion System \u00ae for the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the long-term therapeutic outcomes of repeated radiofrequency ablation (RFA) with that of transarterial chemoembolisation (TACE) in patients with local tumour progression (LTP) after initial RFA treatment for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "PATIENTS CONCERNS: A 74-year-old male with primary biliary cirrhosis and hepatocellular carcinoma who underwent transarterial chemoembolization (TACE) developed a high fever on post-TACE day 14. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: Transarterial chemoembolization (TACE) is the most common treatment for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We aim to investigate the effects of postoperative adjuvant transarterial chemoembolization (TACE) on survival and recurrence in hepatocellular carcinoma (HCC) patients after radical resection. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To study the impact of lipiodol deposition in the lesion of hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) on the necrosis area of percutaneous microwave coagulation therapy (PMCT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The objective of our study was to assess the value of CT texture analysis for prediction of therapeutic response of hepatocellular carcinoma (HCC) to transcatheter arterial chemoembolization (TACE) with pretherapeutic dynamic CT. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVES: Combination of transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) has become an effective alternative therapy for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: As prognosis of patients with metastatic hepatocellular carcinoma (HCC) is mainly determined by intrahepatic HCC progression, local treatment with TACE may result in improved OS, although it is not recommended. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The purpose of this study was to analyze retrospectively the efficacy of TACE and its impact on OS in patients with metastatic hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study sought to develop an effective and reliable nomogram for predictions of recurrence for postoperative adjuvant transarterial chemoembolization (PA-TACE) in patients with hepatitis B virus-related (HBV) hepatocellular carcinoma (HCC).The nomogram was established based on data obtained from a retrospective study on 235 consecutive patients with HBV HCC who received PA-TACE as an initial therapy from 2006 to 2010 in our center. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " According to the current European Association for the Study of Liver guidelines, transarterial chemoembolization (TACE) is the recommended first-line therapy for patients with intermediate-stage (Barcelona Clinic Liver Cancer-B class) hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the utility of the portal venous phase on multiphasic computed tomography (CT) after treatment of hepatocellular carcinoma (HCC) with trans-arterial chemoembolisation (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This prospective study investigated the superiority of transarterial chemoembolization (TACE) with miriplatin over TACE with epirubicin regarding overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "There is also a review of key prospective and retrospective studies evaluating the use of Y-90 SIRT, specifically Y-90 resin microspheres in unresectable HCC, which led to the development of the SARAH trial.METHODS: To identify relevant publications, the PubMed database was queried using one or more of the following search terms alone or in combination with Boolean operators: epidemiology, hepatocellular, hepatocellular cancer, hepatocellular carcinoma, unresectable, radioembolisation, selective internal radiation therapy, SIR-Spheres, yttrium 90, TACE, and sorafenib. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This randomized, double-blind, placebo-controlled trial evaluated dexamethasone efficacy in preventing fever, anorexia, and nausea/vomiting, the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Patients with intermediate to advanced hepatocellular carcinoma (HCC) are most commonly treated with transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: We compared survival outcomes in 313 patients with unresectable hepatocellular carcinoma (HCC) treated with two different transcatheter arterial chemoembolization (TACE) regimens: triple-drug TACE or single-drug TACE using drug-eluting beads. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We present a patient who developed painful retiform purpura on the right flank shortly after TACE for treatment of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Objective: To investigate the effect of transcatheter arterial chemoembolization(TACE)combined with thymosin alpha1(T\u03b11)on the autophagy of immune cells from advanced hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Conclusions: TACE combined with T\u03b11 significantly increase the level of autophagy in the immune cells of patients with advanced primary hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Transarterial chemoembolisation (TACE) is the most widely used locoregional treatment for patients with an unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare effectiveness of transarterial chemoembolization (TACE) combined with microwave ablation (MWA; TACE-MWA) with TACE alone for treating hepatocellular carcinoma (HCC) tumors \u22645\u00a0cm. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: The appropriate selection of hepatocellular carcinoma (HCC) patients who are eligible for transarterial chemoembolization (TACE) remains a challenge. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To investigate whether bevacizumab compromises early response assessment after Transarterial Chemoembolization (TACE) in patients with hepatocellular carcinoma by 3D quantitative European Association for the Study of the Liver (qEASL) criteria in comparison to other imaging-based criteria. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To analyze long-term outcomes in patients bridged/downstaged to orthotopic liver transplantation (OLT) by transarterial chemoembolization (TACE) or yttrium-90 radioembolization (Y90) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Transcatheter arterial chemoembolization (TACE) has been recognized as a treatment option for patients with intermediate hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " RATIONALE AND OBJECTIVES: This study aimed to evaluate the potential role of computed tomography texture analysis (CTTA) of arterial and portal-venous enhancement phase image data for prediction and accurate assessment of response of hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization (TACE) by comparison to liver perfusion CT (PCT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background A novel strategy to combine conventional transcatheter arterial chemoembolization (TACE) and TACE during portal vein occlusion (TACE-PVO) in the presence of high-flow arterioportal shunt (APS) has been developed to treat hepatocellular carcinoma (HCC) with portal invasion. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: We did a multicentre, randomised, placebo-controlled, phase 3 trial (TACE 2) in 20 hospitals in the UK for patients with unresectable, liver-confined hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "INTERPRETATION: The addition of sorafenib to DEB-TACE does not improve progression-free survival in European patients with hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "To the authors' knowledge, its role in combination with TACE for the treatment of patients with inoperable hepatocellular carcinoma (HCC) is unclear. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 \u03bcm drug eluting beads in patients not eligible for curative treatment. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To prospectively monitor changes in tumor perfusion of hepatocellular carcinoma (HCC) in response to doxorubicin-eluted bead based transarterial chemoembolization (DEB-TACE) using perfusion-CT (P-CT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM/BACKGROUND: The ultimate aim of any treatment for hepatocellular carcinoma (HCC) is to improve overall survival (OS); however, the clinical significance of time to progression (TTP) after transarterial chemoembolization (TACE) is unclear. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Traditional treatments for intermediate or advanced stage hepatocellular carcinoma (HCC) such as transarterial chemoembolization (TACE) and anti-angiogenesis therapies were developed to starve tumor blood supply. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the prognostic value of the radiological response after transarterial chemoembolization (TACE) and inflammatory markers in patients affected by hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) and sorafenib (SOR) are well-established treatments for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Purpose: The prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) is often uncertain. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: The purpose of this meta-analysis was to compare the efficacy of transarterial chemoembolisation (TACE) and iodised oil infusion chemotherapy without embolisation (TAI) in patients with hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This nationwide population-based cohort study evaluated the association between acute kidney injury (AKI) and transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE), a well-established treatment for unresectable hepatocellular carcinoma (HCC), blocks the arterial blood supply to the tumor, which can be short-lived as development of collateral neovessels, leading to the failure of treatment. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Repeat transcatheter arterial chemoembolization (TACE) becomes more challenging for patients with intrahepatic biloma following TACE for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine the value of CT perfusion (CTP) for early response assessment after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is a well-established treatment for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This prospective study was to investigate the value of [(11)C]-acetate PET and [(18)F]-FDG PET in the evaluation of hepatocellular carcinoma (HCC) before and after treatment with transarterial chemoembolization (TACE) and vascular endothelial growth factor (VEGF) antibody (bevacizumab). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) remains controversial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To retrospectively evaluate the feasibility and safety of repeated transarterial chemoembolization (TACE) three or more times using miriplatin-lipiodol (M-LPD) suspension (repeated M-LPD TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study was designed to compare the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Transarterial chemoembolization (TACE) is indicated for Barcelona Clinic Liver Cancer (BCLC) B hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is a common treatment modality to locally manage hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The purpose of this study is to determine the efficacy and tolerability of transarterial chemoembolization (TACE) using polyethylene glycol (PEG) drug-elutable microspheres loaded with doxorubicin for treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " In this issue of Radiology, Gade et al ( 1 ) describe a unique mechanism of hepatocellular carcinoma (HCC) cells for surviving ischemia induced by transarterial embolization (TAE)/transarterial chemoembolization (TACE) in a state of cell cycle arrest-a function that may serve as a defensive shield against conventional chemotherapeutic agents. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The objective of this study was to evaluate the sensitivity of dual phase cone-beam computed tomography (CBCT) in detecting small (<3 cm in diameter) hepatocellular carcinoma (HCC) tumors during transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: This study aimed to investigate the factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization (B-TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To investigate clinical features and results of follow-up in patients with arterial injury during transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To investigate the impact of the first transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) on health-related quality of life (HRQoL) and identify predictors for low HRQoL following TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Although the transcatheter arterial chemoembolization (TACE) was demonstrated to be an alternative treatment of hepatocellular carcinoma with favorable oncological effect, the benefit of postoperative adjuvant TACE was still controversial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of this study was to evaluate the effect of postoperative TACE in hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: To identify predictors of a therapeutic effect after transarterial chemoembolisation using drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Intermediate-stage hepatocellular carcinoma (HCC), for which trans-arterial chemoembolization (TACE) constitutes the standard of care, is a patient subgroup with significant heterogeneity in clinical outcome. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: To assess the diagnostic efficacy of contrast-enhanced ultrasonography (CEUS) in the context of intrahepatic progression\u00a0(IHP) of hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Objective: To evaluate the efficacy and safety of drug-eluding beads transarterial chemoembolization (DEB-TACE) in treatment of unrecectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Recurrence of hepatocellular carcinoma (HCC) after transarterial chemoembolisation (TACE) is common due to neoangiogenesis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To investigate the effects of lentiviral vector-mediated shRNA suppressing CXCR7 on tumour invasion and metastasis in hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of the present study was to compare the effectiveness of transarterial chemoembolization (TACE), TACE combined with Jie-du granules (JD), and TACE combined with sorafenib (SOR) for treating patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To retrospectively analyze the safety and efficacy of 350-560\u200a\u03bcm gelatin sponge particles combined with single-chemotherapy drug transcatheter arterial chemoembolization (Gs-TACE) for the treatment of elderly hepatocellular carcinoma without surgical resection.Thirty elderly hepatocellular carcinoma patients without surgical resection, who received Gs-TACE in our hospital, were selected. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We conducted a retrospective study to evaluate the safety and efficacy of transarterial chemoembolization (TACE) combined with computed tomography-guided 125iodine implantation (TACE-125iodine) in hepatocellular carcinoma (HCC) patients with type B portal vein tumor thrombus (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is recommended for patients with intermediate-stage (Barcelona Clinic Liver Cancer criteria B [BCLC-B]) hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "However, their roles in determining the treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) remain unknown. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Transcatheter arterial chemoembolization (TACE) and thalidomide have been used for treating primary hepatocellular carcinoma(HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To retrospectively compare the initial response, local recurrence, and complication rates of radiofrequency ablation (RFA) vs microwave ablation (MWA) when combined with neoadjuvant bland transarterial embolization (TAE) or drug-eluting microsphere chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Transcatheter arterial chemoembolization (TACE) is the first-line treatment for intermediate stage hepatocellular carcinoma (HCC) and prolongs survival in HCC patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to explore the antitumour effect of the DNA repair inhibitor, DT01 (the cholesterol conjugated form of Dbait), as an adjunct treatment to enhance the therapeutic efficacy of transarterial chemoembolization (TACE) in pre-clinical models of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is considered a standard local-regional treatment for intermediate-stage hepatocellular carcinoma (HCC) and the most common bridging therapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study aimed to validate the prognostic value of inflammation scores for patients with hepatocellular carcinoma (HCC) who were treated with TACE combined with H101. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Although the efficacy of transcatheter arterial chemoembolization (TACE) has been recommended as first-line therapy for nonsurgical patients with hepatocellular carcinoma (HCC), it is difficult to accurately predict the efficacy of TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: There is no approved therapy for patients with failed transarterial chemoembolization (TACE) and progression of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Adjuvant transarterial chemoembolization (TACE) is a major option for postoperative hepatocellular carcinoma (HCC) patients with recurrence risk factors. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: The aim of this study was to assess the feasibility of computed tomography (CT) perfusion in early follow-up after transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is a therapeutic procedure often performed for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of adjuvant transarterial chemoembolization (TACE) after curative hepatectomy in improving the survival of patients with primary hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To explore the threshold of intravoxel incoherent motion (IVIM) parameters, apparent diffusion coefficient [ADCtotal and ADC(0,500) ] ratios 24-48 hours after transarterial chemoembolization (TACE) to assess early response in patients with unresectable hepatocellular carcinoma (HCC) and to compare the association between diffusion-weighted imaging with the intravoxel incoherent motion (IVIM-DWI) and mRECIST with survival. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare the response to transcatheter arterial chemoembolization (TACE) between hepatocellular carcinoma (HCC) with paradoxical uptake on the hepatobiliary phase (HBP) (HCCpara) and HCC with defect on the HBP (HCCdef), and to identify some imaging features that can differentiate between two groups. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: We investigated the outcomes of early-stage hepatocellular carcinoma (HCC) patients who showed a complete response (CR) to initial transarterial chemoembolization (TACE), with a focus on the role of scheduled TACE repetition. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Purpose To identify early biomarkers for the prediction of the therapeutic response in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) and sorafenib (referred to as TACE plus sorafenib) and establish an effective prognostic nomogram. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: There is limited information on the use of stereotactic body radiotherapy (SBRT) as a bridge to liver transplantation for hepatocellular carcinoma and no study comparing its efficacy to transarterial chemoembolization (TACE) and radiofrequency ablation (RFA). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We aimed to ascertain the safety and efficacy of SBRT on an intention-to-treat basis compared with TACE and RFA as a bridge to liver transplantation in a large cohort of patients with hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Transarterial chemoembolization (TACE) is an established treatment for intermediate stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE)-induced complete pathological response (CPR) is known to improve postresection outcomes of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Introduction: Local ablative therapy and trans arterial chemoembolization (TACE) are applied to ablate non resectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Objective: Hepatocellular carcinoma with portal vein thrombosis is considered a relative contraindication for transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Transarterial chemoembolization (TACE) or sorafenib is recommended for hepatocellular carcinoma BCLC stages B and C respectively. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with percutaneous microwave ablation (MWA) in the treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The objective of this study was to evaluate the effectiveness on argon-helium cryoablation combined with transcatheter arterial chemoembolization (TACE) in treating advanced hepatocellular carcinoma (HCC) and its influence factor. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the incidence and condition of necrotic tumor excretion into the biliary system in patients with hepatocellular carcinoma (HCC) >5\u00a0cm treated with conventional transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background/Aims: To investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The aim of this study was to evaluate the prognostic significance of parametric response mapping (PRM) analysis for hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Several scoring systems that guide patients' treatment regimen for transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) have been introduced, but none have gained widespread acceptance in clinical practice. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: We aimed to evaluate the combining effects of transarterial chemoembolization (TACE) and open local thermal microwave ablation in a hepatocellular carcinoma animal model. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: This investigation shows improved results of TACE followed by microwave ablation as treatment of hepatocellular carcinoma in a rat model, compared with single therapy regimen regarding the inhibition of growth rate and reduction of VEGF-level in peritumoral tissue. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The benefits of transarterial chemoembolization plus sorafenib (TACE-S) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remain controversial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To develop the treatment algorithm from multivariate survival analyses (MVA) in patients with Barcelona clinic liver cancer (BCLC) C (advanced) Hepatocellular carcinoma (HCC) patients treated with Trans-arterial Chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Combinations of transarterial chemoembolization (TACE) and radical therapies (pretransplantation, resection and radiofrequency ablation) for hepatocellular carcinoma (HCC) have been reported as controversial issues in recent years. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The aim of the study was to correlate tumor stiffness (TS) measured with MR elastography (MRE) with degree of tumor enhancement and necrosis on contrast-enhanced T1-weighted imaging (CE-T1WI) in hepatocellular carcinomas (HCC) treated with Yttrium-90 radioembolization (RE) or transarterial chemoembolization plus radiofrequency ablation (TACE/RFA). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To test the predictive performance of the Metroticket calculator for survival after liver transplantation (LT) of patients with hepatocellular carcinoma (HCC) undergoing prior transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Retrospective analysis of our cases(98 procedures of[transcatheter arterial chemoembolization: TACE]or TAI for liver tumors performed at the Department of General Surgery, Chiba University from 2012 to 2015)revealed that serum biliary enzymes levels 7 days after TACE were significantly higher in patients with metastatic liver tumors than those in patients with hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We investigatedwhether it is possible to estimate the treatment effect(TE)of TACE for hepatocellular carcinomas(HCCs). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemo-embolisation (TACE) is recommended for patients with BCLC intermediate stage hepatocellular carcinoma (stage B), particularly in patients with good underlying liver function and minimal symptoms. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The present study aimed to compare the overall and recurrence-free survival rates following hepatic resection (HR) and transcatheter arterial chemoembolization (TACE) in patients with Barcelona Clinic Liver Cancer (BCLC) classified intermediate-stage Child-Pugh A hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We report one case with advanced hepatocellular carcinoma (HCC), who received apatinib combined with transhepatic arterial chemotherapy and embolization (TACE), and chemotherapy respectively. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The purpose of this study is to evaluate the efficacy of transcatheter arterial chemoembolization (TACE) combined with computed tomography-guided radiofrequency ablation (CT-RFA) in the treatment of hepatocellular carcinoma (HCC) using magnetic resonance diffusion weighted imaging (MR-DWI) and CT perfusion imaging (CT-PI). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Conventional trans-arterial chemoembolization (cTACE) for intermediate stage hepatocellular carcinoma (HCC) achieves a partial response in up to 72% of patients and improves median survival. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background and Aims: Intermediate stage hepatocellular carcinoma (HCC) can be treated by transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Hepatic damage during transarterial chemoembolization (TACE) is a critical complication in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the factors that influence survival of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) following transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Preoperative transcatheter arterial chemoembolization (TACE) is administered to improve long-term outcome after surgical resection of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Numerous studies have tried to combine transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) with radiotherapy (RT) for the treatment of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) is the mainstay of treatment for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To assess the value of transarterial embolization/chemoembolization (TAE/TACE) therapy via adrenal artery for patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study sought to develop a reliable and easy-to-use scoring model to guide the decision to perform postsurgical adjuvant transarterial chemoembolization (PA-TACE) in patients with hepatitis B-related hepatocellular carcinoma (HCC).The study included 235 consecutive patients with hepatitis B-related HCC undergoing PA-TACE at our medical center. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: We compared overall survival (OS) of patients with a solitary large (>5\u2009cm) hepatocellular carcinoma (HCC) treated surgically or by transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is a proven catheter-based locoregional therapy for treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Aim was to assess the therapeutic value of portal vein stenting (PVS) combined with iodine-125 seed ((125)I seed) strand endovascular implantation followed by transcatheter arterial chemoembolization (TACE) for treating patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate the safety and efficacy of transcatheter arterial chemoembolization (TACE) with embospheres for the treatment of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The current study aimed to evaluate the efficacy and outcomes of three-dimensional conformal radiotherapy (3DCRT) combined with transarterial chemoembolization (TACE) for treating patients with hepatocellular carcinoma involving portal vein tumor thrombus. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Between January 2000 and December 2013, a total of 182 hepatocellular carcinoma patients with portal vein tumor thrombus were retrospectively analyzed: 68 patients were treated by 3DCRT alone (group A), 74 by TACE alone (group B), and 40 by a combination of 3DCRT + TACE (group C). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: These results suggest that combining 3DCRT with TACE may provide better OS than either technique alone in hepatocellular carcinoma patients with portal vein tumor thrombus. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This meta-analysis was conducted to compare transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation (RFA) with TACE alone for hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In conclusion, the use of TACE plus RFA for intermediate stage hepatocellular carcinoma can attain higher tumor response rates and improve survival rates than TACE alone. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To investigate the incidence and outcome of major complication following conventional transarterial embolization/chemoembolization (TAE/TACE) therapy for hepatocellular carcinoma (HCC).From May 2010 to May 2016, all patients with major complication following conventional TAE/TACE for HCC were included. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Purpose To compare the outcomes of radiation segmentectomy (RS) and transarterial chemoembolization (TACE) combined with microwave ablation (MWA) in the treatment of unresectable solitary hepatocellular carcinoma (HCC) up to 3 cm. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Transcatheter arterial chemoembolization (TACE) is the treatment of choice for intermediate-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) and sorafenib combination treatment for unselected hepatocellular carcinoma (HCC) is controversial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is an effective palliative intervention that is widely accepted for the management of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This case suggests that, in patients with tumor thrombi due to hepatocellular carcinoma, thrombus control and long-term survival are achievable with TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study explored the predictive values of diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) in evaluating the efficacy of transcatheter arterial chemoembolization (TACE) for patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Portal vein thrombosis (PVT) is a common complication after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) is the standard therapy for Barcelona Clinic Liver Cancer (BCLC) classification intermediate stage B hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To investigate the prognosis of transarterial chemoembolization (TACE) followed by hepatic resection (HR) in large/multifocal hepatocellular carcinoma (HCC), the medical records of consecutive HCC patients who underwent TACE between January 2006 and December 2010 were retrospectively analyzed. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The purpse of this study was to evaluate the ability of various radiologic response criteria to predict patient outcomes after trans-arterial chemo-embolization with drug-eluting beads (DEB-TACE) in patients with advanced-stage (BCLC C) hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The aim of the study was to compare transcatheter arterial chemoembolization (TACE) plus (131)I-labelled metuximab with TACE alone for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is a widely used standard treatment for patients with hepatocellular carcinoma (HCC) who are not suitable candidates for curative treatments. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Treatment response to drug-eluting bead chemoembolization (DEB-TACE) is well established for patients with hepatocellular carcinoma (HCC); however, few studies have evaluated tumor imaging characteristics associated with treatment responses. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study explored the predictive value of serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) levels combined with enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma (HCC) patients after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The survival following transarterial chemoembolization (TACE) alone is still low in unresectable hepatocellular carcinoma (HCC) with almost patients developing disease progression after treatment. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate whether combined transarterial chemoembolization (TACE) with radiofrequency ablation (RFA) or percutaneous ethanol injection (PEI) for hepatocellular carcinoma (HCC) have superior efficacy to transarterial chemoembolization (TACE) alone a retrospective review was conducted. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: During January 2009 to March 2013, 108 patients with hepatocellular carcinoma underwent TACE or combined therapies (TACE+RFA or TACE+PEI). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the main treatment for intermediate stage hepatocellular carcinoma (HCC) with Barcelona Clinic Liver Cancer classification because of its exclusive arterial blood supply. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Hepatocellular carcinoma (HCC) of intermediate stage consists of diverse tumor and patient factors in terms of tumor number, size and liver function resulting in various outcomes given by transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: We examined early predictors of the outcome in hepatocellular carcinoma (HCC) patients after transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The study aims to analyze the oncologic outcomes of living donor liver transplantation (LDLT) after combined transarterial chemoembolization (TACE) and radiotherapy for hepatocellular carcinoma (HCC) with major vascular invasion. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The goal of this study is to evaluate the outcomes of combined transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) in terms of the frequency of aggressive intrasegmental recurrence. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Objective: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with cryoablation in patients with unresectable large hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This meta-analysis aimed to update and re-evaluate the efficacy and safety of cTACE compared with those of DEB-TACE in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Transcatheter arterial chemoembolization (TACE) is one of the most effective therapeutic options for hepatocellular carcinoma (HCC) and it is important to protect residual liver function after treatment as well as the effect. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Contrast-enhanced sonography increases negative enhancement in the Kupffer phase after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The standard treatment option that is available for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) is transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to investigate the value of microRNA (miR) gene polymorphisms in evaluating the efficacy of transcatheter arterial chemoembolization (TACE) in primary hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the efficacy of radiofrequency ablation (RFA) and transarterial chemoembolisation (TACE) as a first-line treatment for isolated intrahepatic recurrent hepatocellular carcinoma (IIR-HCC) after liver transplantation (LT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) has mostly been used in hypervascular tumours such as hepatocellular carcinoma, and may be an effective palliative treatment in patients with metastatic liver cancer. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To conduct a quantitative analysis of microcirculation blood perfusion in patients with hepatocellular carcinoma (HCC) before and after transcatheter arterial chemoembolisation (TACE) using contrast-enhanced ultrasound (CEUS). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the principal therapy for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Patients with hepatocellular carcinoma (HCC), a fatal cancer, have benefited significantly from TACE (transcatheter arterial chemoembolization) and immunotherapy treatments. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " It remains controversial whether transarterial chemoembolization (TACE) should be performed in patients with advanced-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Hepatocellular carcinoma (HCC) is usually managed by the transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Data from a total of 13 cases of spontaneous rupture of hepatocellular carcinoma hemorrhage, who were treated with GSM-TACE at the Affiliated Zhongshan Hospital of Dalian University (Dalian, China) between August 2010 and June 2014, were collected. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In conclusion, GSM-TACE of various diameters is a safe and effective method in the treatment of spontaneous rupture of hepatocellular carcinoma hemorrhage. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) with that of multiphase computed tomography (CT) in the evaluation of tumor response to transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the feasibility, efficacy, and safety of microwave ablation (MWA) in the treatment of hepatocellular carcinoma associated with Budd-Chiari syndrome (BCS) after transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To assess the efficacy and safety of metronomic S-1 chemotherapy combination with transcatheter arterial chemoembolization (TACE) for the treatment of Barcelona Clinic Liver Cancer (BCLC) Stage B hepatocellular carcinoma (HCC) refractory to TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The mRECIST and dermatologic adverse events (AEs) can be used to assess the patient response to transarterial chemoembolization (TACE) and/or sorafenib for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Use of gadobenate dimeglumine-enhanced liver magnetic resonance (MR) for evaluation of hepatocellular carcinoma tumor response after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Forty-five patients with hepatocellular carcinoma were imaged with multiphase gadobenate dimeglumine-enhanced MR examination at baseline and 1-month follow-up after TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Major liver resection for hepatocellular carcinoma (HCC) ideally involves preoperative portal venous embolization (PVE) coupled with preoperative transarterial chemoembolization (TACE) to improve postoperative course and oncological results. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This study aims to evaluate immediate changes in perfusion parameters in hepatocellular carcinoma (HCC) to transarterial chemoembolization (TACE) in C-arm computed tomography (CT) and volume perfusion CT (VPCT) and prediction of midterm tumor response. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the usefulness of cone-beam computed tomography (CBCT) for monitoring the transcatheter arterial chemoembolization (TACE) of hepatocellular carcinomas supplied by the cystic artery. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) is an effective therapy for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This study aimed to compare the short-term efficacy of transarterial chemoembolization (TACE) with epirubicin-loaded superabsorbent polymer embolics (SAP) and conventional TACE in TACE-na\u00efve patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: We aimed to systematically evaluate the influence of preoperative transarterial chemoembolization (TACE) for resectable hepatocellular carcinoma (HCC) on long-term prognosis and perioperative safety. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Transcatheter arterial chemoembolization (TACE) is a standard therapy for the treatment of intermediate-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial radioembolization (TARE) has emerged as a newer regional therapy to transarterial chemoembolization (TACE) for treatment of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We explored the hypothesis that sorafenib may improve the effect of transarterial chemoembolization (TACE) in patients with recurrent hepatocellular carcinoma (HCC) and that longer sorafenib duration was associated with additional survival benefits. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate drug-eluting beads (DEB) for transarterial chemoembolization (TACE) in patients with Barcelona Clinic Liver Cancer (BCLC) A to D suffering from hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 ((90)Y)-radioembolization for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The aim of this study was to investigate the role of dynamic contrast-enhanced magnetic resonance imaging (MRI) in evaluation of blood flow changes related to transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) procedures in patients with hepatocellular carcinoma (HCC) lesions. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to investigate the efficacy of Jianpi Ligan decoction (JLD) as an adjuvant therapy for patients with unresectable hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Post-procedural pain is frequent after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), and is only partially prevented by treatment selectivity. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To evaluate the clinical outcome and safety of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with segmental or subsegmental portal vein tumour thrombus (sPVTT) in patients with preserved hepatic function, and to address the efficacy of additional chemoinfusion after TACE (TACE+CI). "}, {"drug": "TACE", "disease": "Intrahepatic cholangiocarcinoma", "polarity": 0, "orig_sen": "Factors associated with disease-free survival (DFS) included intrahepatic cholangiocarcinoma (ICC) tumor size (P\u200a=\u200a0.002) and use of postoperative prophylactic transcatheter arterial chemoembolization (TACE) treatment (P\u200a=\u200a0.015). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study sought to establish an effective and reliable prognostic nomogram to guide the decision for post-surgical adjuvant transarterial chemoembolization (PA-TACE) in patients with hepatitis B virus-related (HBV) hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: This study aims to evaluate clinical outcomes of patients with hepatocellular carcinoma who underwent transarterial chemoembolization (TACE) using drug-eluting beads (DEB). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "So, we conducted this study to explore the effect of miR-126 expression on angiogenesis in hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: The effect of transcatheter arterial chemoembolization (TACE) is not necessarily sufficient in patients with multiple hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: This study evaluated long-term outcomes of salvage surgery as additional therapy following downstaging of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) in patients with initially unresectable HCC. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "IMPLICATIONS FOR PRACTICE: The results of this study suggest that salvage liver resection after downstaging of unresectable hepatocellular carcinoma in patients with a complete response to transarterial chemoembolization (TACE) has a comparable long-term outcome in this good-prognosis group. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To quantify the arterial flow change during transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using digital subtraction angiography, quantitative color-coding analysis (d-QCA), and real-time subtraction fluoroscopy QCA (f-QCA). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate the long-term oncological outcome of patients with resectable hepatocellular carcinoma (HCC) undergoing sequential transarterial chemoembolization (TACE) and portal vein embolization (PVE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Transcatheter arterial chemoembolization (TACE) in combination with external beam radiotherapy (EBRT) results in improved survival due to better local control in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To compare the treatment outcomes of sorafenib plus transarterial chemoembolization (TACE) vs TACE alone in patients with hepatocellular carcinoma (HCC) and hepatic vein tumor thrombus (HVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: PCMT combining with TACE is safe and more effective in one-year survival than PCMT alone for the treatment of primary hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To perform a quantitative, volumetric analysis of therapeutic effects of trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To compare transarterial chemoembolization (TACE)-related hepatic toxicities of conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) in patients with intermediate-stage hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To assess safety, feasibility and effectiveness of transarterial chemoembolization with degradable-starch-microspheres (DSM-TACE) in the treatment of patients with advanced hepatocellular carcinoma (HCC) dismissing or ineligible for multikinase-inhibitor chemotherapy administration (Sorafenib) due to unbearable side effects or clinical contraindications. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This study was designed to evaluate the safety and efficacy of transarterial chemoembolization (TACE) combined with intra-IVC implantation of an irradiation stent for the treatment of hepatocellular carcinoma (HCC) complicated by inferior vena cava tumor thrombosis (IVCTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is frequently used for treatment of unresectable hepatocellular carcinoma (HCC) and can also be used for case of liver metastases from rectal cancer. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study aims to find out the safety and efficiency of postoperative adjuvant transarterial chemoembolization (TACE) and radiotherapy (RT) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "PATIENTS AND METHODS: In a retrospective analysis, 32 patients with hepatocellular carcinoma who received either DEB or a cTACE were compared regarding survival time, disease recurrence, and side effects such as pain and fever. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Several studies have suggested that surgical resection (SR) can provide a survival benefit over transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) at the intermediate stage according to the Barcelona Clinic Liver Cancer (BCLC) staging system. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The purpose of this retrospective study was to evaluate the impact of obesity on radiologic outcomes in patients with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the efficacy and safety of yttrium-90 radioembolization (Y90RE) and transarterial chemoembolization (TACE) in hepatocellular carcinoma patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Both iodine-125 implantation and transarterial chemoembolization (TACE) are feasible options for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIM: Sorafenib and chemoembolization of the liver (TACE) have both produced increased survival in hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVES: Transcatheter arterial chemoembolization (TACE) is the first-line treatment for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "SETTING: This is a phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads performed in cirrhotic patients with hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: The efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib for patients with hepatocellular carcinoma (HCC) have been explored by many studies, but the results were controversial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Transarterial chemoembolization (TACE) is used to treat intermediate stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of this study is to examine the safety and efficacy of Cinobufacini injection in transarterial chemoembolization (TACE) for treatment of huge hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Assessment for retreatment with TACE (ART) score evaluates whether hepatocellular carcinoma (HCC) patients can benefit from transcatheter arterial chemoembolization (TACE) retreatments. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: Our study sought to compare the overall survival in patients with hepatocellular carcinoma (HCC) and portal venous thrombosis (PVT), treated with either conventional trans-arterial chemoembolization (cTACE) or drug-eluting beads (DEB) TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Transarterial administration of integrin inhibitor loaded nanoparticles combined with TACE evidently retards tumor growth and intrahepatic metastases compared with TACE alone or TACE plus integrin inhibitor in an animal model of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report a case of resected hepatocellular carcinomas (HCCs) after drug-eluting bead transarterial chemoembolization (DEB-TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Doxorubicin-loaded drug-eluting beads TACE (DEB-TACE) has been developed to maximize the therapeutic efficacy of conventional trans-catheter arterial chemo-embolization (cTACE) in patients with hepatocellular carcinoma (HCC); however, its cost-effectiveness (CE) still needs to be assessed. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: The aim of this study is to clarify the usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization (B-TACE) using miriplatin for patients with four or fewer hepatocellular carcinoma (HCC) nodules. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) is variable, despite a myriad of prognostic markers. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND Transarterial chemoembolization (TACE) has been used alone or in combination with three-dimensional conformal radiation therapy (3DCRT) for treating hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Three-dimensional conformal radiotherapy in combination with transarterial chemoembolization (TACE) has been beneficial in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to investigate whether the level of serum microRNA-199a/b-3p (miR-199a/b-3p) can serve as a predictor of treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) frequently causes feeding artery stenosis or occlusion that may interfere with repeated treatment. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of the study is to assess the effectiveness of the additional injection of Survivin siRNA to the routine protocol of Transarterial Chemoembolization (TACE) for the treatment of hepatocellular carcinoma in a rat model. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: The additional injection of Survivin siRNA to the routine TACE protocol increased the inhibition of the hepatocellular carcinoma growth in a rat animal model compared to regular TACE protocol. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To evaluate the efficacy and safety of dendritic cells (DCs) co-cultured with cytokine-induced killer cell (CIK) immunotherapy combined with transcatheter arterial chemoembolization (TACE) or TACE plus local ablation therapy for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) is the most common palliative therapy for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "These results suggest that a novel anionic pH-sensitive copolymer has been developed with a potential application as a liquid radiopaque embolic solution for TACE of HCC.STATE OF SIGNIFICANCE: Transcatheter arterial chemoembolization (TACE) has been widely used as a palliative treatment therapy for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In this report, we aim to assess the efficacy and safety of raltitrexed plus oxaliplatin (OXA)-based transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (uHCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) is a well-recognized procedure for management of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate whether plain cone-beam computed tomography (CT) immediately after conventional transcatheter arterial chemoembolization (c-TACE) can help to predict tumor response semiquantitatively in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To investigate the clinical features, risk factors, and bacterial spectrum of liver abscess following transarterial chemoembolization (TACE) and evaluate the therapeutic effect of percutaneous catheter drainage (PCD) on the abscesses.A retrospective review of patient charts was performed in 3613 patients who suffered from liver malignancies (2832 patients with hepatocellular carcinoma and 781 with metastatic hepatic tumor) and had undergone 11,054 TACE procedures from January 2005 to October 2013. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To retrospectively compare the outcome of chemolipiodolization with or without embolization in transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in Patients with hepatocellular carcinoma (HCC) within the Milan criteria. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) and sorafenib are the therapeutic standard for intermediate and advanced stage hepatocellular carcinoma (HCC) patients respectively. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Unlike systemic chemotherapy for hematological malignancies with hepatitis B virus (HBV) infection, transarterial chemoembolization (TACE) for HBV-related hepatocellular carcinoma (HCC) has only recently been reported to cause HBV reactivation and subsequent hepatitis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study investigated the effectiveness of a new strategy, repeated radiofrequency (RF) ablation combined with ablated lesion elimination following transarterial chemoembolization (TACE)/transarterial embolization (TAE), for solitary huge hepatocellular carcinoma (SHHCC) 10\u200acm or larger. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Although the Barcelona Clinic Liver Cancer (BCLC) staging system suggests that patients with stage B hepatocellular carcinoma (HCC) should be treated with transcatheter arterial chemoembolization instead of surgical treatment, recent studies indicated that the prognosis of surgical resection for patients with BCLC stage B HCC was better than that of TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CKI, combined with transarterial chemoembolization (TACE), is believed to increase the therapeutic efficacy of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization(TACE) is the palliative treatment of choice for patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: A total of 156 patients with hepatocellular carcinoma treated from June 2006 to September 2012 in Shengli Oilfield Central Hosptial were divided into control group(RFA, TACE) and research group(RFA, TACE, CIK). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the efficacy of transcatheter arterial chemoembolisation (TACE) compared with surgical intervention and sorafenib for treatment of hepatocellular carcinoma (HCC) in patients with tumor thrombus extending to the main portal vein. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total number of 35 patients with hepatocellular carcinoma who had undergone TACE were enrolled into the study. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to evaluate the clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization (TACE) on hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The intermediate-stage hepatocellular carcinoma patients who received either TACE-S or TACE-alone treatment were consecutively included into analysis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To clarify the hemodynamic changes under balloon occlusion of the hepatic artery and to identify predictors of the short-term therapeutic effect (TE) after balloon-occluded transcatheter arterial chemoembolization using miriplatin (B-TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Occasionally, transarterial chemoembolization (TACE) may be selected for preoperative management of resectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma (HCC) recommends transarterial chemoembolization (TACE) as the first line therapy for stage B patients and sorafenib treatment for stage C patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) is the most widely used treatment modality for patients with hepatocellular carcinoma who are not eligible for surgery. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To evaluate the safety/efficacy and explore biomarkers for a rationally designed combination of sunitinib and transarterial chemoembolization (TACE) in a prospective phase 2 study of advanced hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To perform a meta-analysis examining the efficacy of transcatheter arterial chemoembolization (TACE) alone or in combination with radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), or high-intensity focused ultrasound (HIFU) for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVES: To compare the impact of concurrent TACE\u2009+\u2009sorafenib versus TACE alone on overall survival (OS) and time to progression (TTP) in patients with unresectable hepatocellular carcinoma (uHCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the prognostic significance of serum GGT in patients with hepatitis C virus-related hepatocellular carcinoma (HCV-HCC) treated with transcatheeter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: The clinicopathological data of 110 patients with hepatitis C virus-related stage B hepatocellular carcinoma, who received TACE treatment from January 2008 to May 2011, were retrospectively analyzed. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: The level of serum GGT before TACE is an independent prognostic factor for patients with stage B HCV-related hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Currently, it is not entirely clear whether hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) is involved in the regulation of COX-2 expression and epithelial-to-mesenchymal transition (EMT), and whether these events affect the prognosis of hepatocellular carcinoma (HCC) patients treated with transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate technical feasibility and treatment results of sequential transcatheter arterial chemoembolization (TACE) and cone-beam computed tomography-guided percutaneous radiofrequency ablation (CBCT-RFA) for small hepatocellular carcinoma (HCC) in the caudate lobe. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Embolotherapies used in the treatment of hepatocellular carcinoma (HCC) include bland embolization, conventional transarterial chemoembolization (cTACE) using ethiodol as a carrier, TACE with drug-eluting beads and super absorbent polymer microspheres (DEB-TACE), and selective internal radiation therapy (SIRT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Furthermore, ARMs improve embolization efficiency which may lead to improved disease response from TACE for patients with hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate overall survival (OS) in unresectable American Joint Committee on Cancer (AJCC) stage I/II hepatocellular carcinoma (HCC) treated with drug-eluting-bead transarterial chemoembolization (DEB-TACE) versus best supportive care. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: We evaluated the prognostic value of pretreatment (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) in patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A hepatocellular carcinoma (HCC) who had received curative treatment or transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate the potential prognostic roles of polymorphisms in the X-ray repair cross-complementing group 1 (XPCC1), xeroderma pigmentosum group D (XPD) and excision repair cross-complementing group 1 (ERCC1) genes for patients with hepatocellular carcinoma (HCC) receiving transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Objectives This study evaluated the objective response to and toxicity of trans-arterial chemo-embolisation (TACE) followed by radiotherapy and hyperthermia (CERT) in hepatocellular carcinoma patients with portal vein tumour thrombosis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study explored the potential of computed tomography (CT) textural feature analysis for the stratification of single large hepatocellular carcinomas (HCCs) > 5 cm, and the subsequent determination of patient suitability for liver resection (LR) or transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The purpose of this study is to investigate the outcomes of conventional transarterial chemoembolization (TACE) treatment of hepatocellular carcinoma (HCC) in contemporary clinical practice. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This study aimed to evaluate the effect of stereotactic ablative radiotherapy (SABR) after incomplete transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of the present study was to investigate whether baseline serum IGF-1 levels are associated with time to progression (TTP) and overall survival (OS) in patients with hepatocellular carcinoma (HCC) who have undergone transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Purpose To conduct a single-center, open-label, randomized, controlled trial to compare the effectiveness and safety of (a) ginsenoside Rg3 combined with transcatheter arterial chemoembolization (TACE) and (b) TACE alone in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Adjuvant transcatheter arterial chemoembolization (TACE) is associated with better outcome and reduced tumor recurrence in hepatocellular carcinoma (HCC) patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The purpose of this review is to report the results of large hepatocellular carcinoma (>5 cm or more nodules in the same lobe) management using sequential transarterial chemoembolization (TACE) and portal vein embolization (PVE) before major liver resections. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Here we present the first case of ALPPS done after double TACE procedure in a 64-years-old female patient with extensive hepatocellular carcinoma of the right liver lobe. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) are effective treatments for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: We compared the recurrence of hepatocellular carcinoma (HCC) and the survival of patients who received radiofrequency ablation (RFA) after transarterial chemoembolization (TACE) with patients treated with TACE or RFA alone. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background There has been no consensus as to which system, either the Cancer of the Liver Italian Program (CLIP) or the Japan Integrated Staging (JIS) system, is suitable to predict the prognosis of hepatocellular carcinoma (HCC) patients who underwent transcatheter arterial chemoembolization (TACE) as initial therapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Combination therapy of sorafenib and transarterial chemoembolization (TACE) has shown benefits in treating advanced hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the relationship between portal vein tumor thrombosis (PVTT) response and clinical outcomes in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization followed by radiotherapy (TACE-RT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This meta-analysis aimed to analyze the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To explore the surgical risk, perioperative outcome and the response of patients with hepatocellular carcinoma (HCC) after preoperative transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "A total of 105 patients (82 patients with selective and dynamic region-specific vascular occlusion to perform hepatectomy for patients with complex hepatocellular carcinoma) was included in this study, in which 35 patients underwent TACE therapy, and a 1:2 matched control group of 70 subjects. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Transarterial chemoembolization with doxorubicin-eluting beads (DC Bead\u00ae; DEB-TACE) is effective in patients with Barcelona clinic liver cancer stage B hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The patient was diagnosed with a hepatocellular carcinoma (HCC), and transcatheter arterial chemoembolization (TACE) was selected for HCC because of the patient's condition. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Here, we describe the surgical treatment of a patient with hepatocellular carcinoma(HCC)with portal vein tumor thrombus (PVTT) after irradiation and transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study aimed to assess the analgesic effect of parecoxib sodium for postoperative pain control in patients with inoperable hepatocellular carcinoma (HCC) undergoing TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "\u2022 Parecoxib helps improve quality-of-life after TACE for patients with inoperable hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Purpose To compare computed tomography (CT) image quality and diagnostic performance among three reconstruction techniques - ASIR, MBIR, and filtered back projection (FBP) - after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinomas (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: The survival outcome of patients with unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) who received transarterial chemoembolization (TACE) combined with radiotherapy (RT) remains unclear. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " In this study, we sought to evaluate the efficacy of transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation (RFA; experimental group) versus RFA treatment (control group) in patients receiving palliative treatment for hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is used to treat various types of hypervascular tumors such as hepatocellular carcinoma and renal cancer. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This study aimed to compare sequential treatment by transcatheter arterial chemoembolization (TACE) and percutaneous radiofrequency ablation (RFA) with partial hepatectomy for hepatocellular carcinoma (HCC) within the Milan criteria. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Studies highlighting the use of TACE with DEBs for the treatment of hepatocellular carcinoma (HCC) have shown similar or better results compared to conventional TACE with lipiodol. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study evaluated the factors impacting overall survival (OS) and time to progression (TTP) in patients with unresectable hepatocellular carcinoma (HCC) who received transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) using lipiodol-based regimens, including the administration of an anticancer-in-oil emulsion followed by embolic agents, is widely used in the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "multi-lesion assessment on baseline MRI using 1D- and 3D-based measurements to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) before transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Enrolled patients were diagnosed with unresectable non-metastatic hepatocellular carcinoma and underwent multiple TACEs between June 2006 and December 2007 (N\u2009=\u2009153). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate transarterial chemoembolization (TACE) use prior to and concomitantly with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) across different global regions. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: To prospectively assess the use of microwave ablation (MWA) to treat hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) after transarterial chemoembolization (TACE), and to evaluate factors that significantly affect treatment outcomes. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study aimed to assess the prognostic value of (18)F-FDG uptake in hepatocellular carcinoma (HCC) patients who had transarterial chemoembolization (TACE) or concurrent intraarterial chemotherapy with external-beam radiotherapy (CCRT) and to compare the prognosis between patients treated with TACE and those with CCRT according to (18)F-FDG uptake.METHODS: Two hundred fourteen intermediate-to-advanced-stage HCC patients without extrahepatic metastasis who underwent staging (18)F-FDG PET/CT before TACE (153 patients) or CCRT (61 patients) were recruited from 7 hospitals. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: Patients with intermediate-stage hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE) are considered to be candidates for sorafenib. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The aim of this retrospective study was to evaluate the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with surgery in the treatment of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Postoperation TACE treatment modality was superior to surgery alone for the treatment of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To improve patient comfort and reduce complications, clinical benefit of a transradial approach for transcatheter arterial chemoembolization (TACE) was evaluated in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: The purpose of this study was to evaluate the predictive value of recurrence for serum hypoxia inducible factor-1\u03b1 (HIF-1\u03b1), C-reaction protein (CRP) in hepatocellular carcinoma patients after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "PATIENTS AND METHODS: Fifty-eight hepatocellular carcinoma patients treated with TACE were included in this study from February 2010 to January 2013 as the case group. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The serum level of HIF-1\u03b1 and CRP was significantly higher in hepatocellular carcinoma patients than that of benign liver disease patients (P < 0.05); The recurrence predictive sensitivity and specificity of HIF-1\u03b1 for hepatocellular carcinoma patients after TACE chemoembolization was 76.60% and 81.82% with the area under the curve (AUC) receiver operating characteristic (ROC) curve of 0.85; The recurrence predictive sensitivity and specificity of CRP for hepatocellular carcinoma patients after TACE was 65.96% and 63.64% with the AUC/ROC of 0.74. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transcatheter arterial chemoembolization (TACE) is a widely used and well-established treatment for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background Arterial dissections during transcatheter arterial chemoembolization (TACE) procedures are not rare and can limit the successful treatment of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Gelatin sponge particles are commonly used in the conventional transarterial chemoembolization (c-TACE) as an adjuvant embolizing agent for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: It is critical to follow up hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) in clinical practice. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: C-arm computed tomography (CT) guided intervention is an increasingly applied technique in transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of this study was to assess the relevance of TACE in hepatocellular carcinoma (HCC) patients before liver transplantation. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the safety and efficiency of transcatheter arterial chemoembolization (TACE) and subsequent radiofrequency ablation (RFA) combined with cytokine-induced killer (CIK) cells transfusion for early-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This study was performed to evaluate the accumulation of lipiodol emulsion (LE) and adverse events during our initial experience of balloon-occluded trans-catheter arterial chemoembolization (B-TACE) for hepatocellular carcinoma (HCC) compared with conventional TACE (C-TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Both B-TACE and angiography-assisted CT were performed for 27 hepatocellular carcinomas. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate and compare outcome of stereotactic body radiation therapy (SBRT), yttrium-90 radioembolization, radiofrequency ablation (RFA), or transarterial chemoembolization (TACE) as bridge to liver transplant (LT) in patients with hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This retrospective study investigated the clinical application of sequential therapy with transarterial chemoembolization (TACE) and CT-guided radiofrequency ablation (RFA) using a bipolar needle in treating hepatocellular carcinoma (HCC) tumors of different sizes. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) is performed worldwide for patients with intermediate-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To improve the efficacy of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), this study evaluated the prevalence and causes of extrahepatic arteries (EHAs) and identified feeding arteries in HCCs in three independent clinical groups in a single inverventional radiology center. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This study aimed to assess the prognostic impact of preoperative transcatheter arterial chemoembolization (TACE) on long-term survival outcomes in patients undergoing resection of small solitary hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The feasibility of transcatheter arterial chemo-embolization (TACE) combined with intratumoral injection of cisplatin as treatment for hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate whether ultrasound-guided RNA interference (RNAi) targeting hypoxia-inducible factor-1alpha (HIF-1\u03b1) can enhance the efficacy of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS AND METHODS: Rats with orthotopic hepatocellular carcinoma were randomized to four groups and treated as follows: 1) control; 2) siHIF-1\u03b1; 3) TACE; 4) siHIF-1\u03b1+TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: HIF-1\u03b1 RNAi, which was administered in vivo in liver tumors under ultrasound guidance, improved the efficacy of TACE in treating hepatocellular carcinoma in an animal model. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the cytotoxic effects of 11 anticancer agents against VX2 and HepG2 cells in order to establish candidate drugs that can be tested preclinically on VX2 tumor model for transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The ART (Assessment for Retreatment with Transarterial chemoembolization) score was recently developed to determine patients who may benefit from multiple sessions of TACE for treatment of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The ART score, clinical characteristics, and outcomes of 82 patients with hepatocellular carcinoma who received multiple TACE sessions at Taipei Veterans General Hospital from September 2007 to July 2013 were analyzed. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To explored the value of 3D C-arm CT (CACT) guidance system in performing radiofrequency ablation (RFA) following transarterial chemoembolizationon (TACE) for hepatocellular carcinomas. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: There is no consensus regarding the selection of treatment options for hepatocellular carcinoma (HCC) after initial transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study evaluated the safety and objective response of combining 131I-labeled-metuximab (Licartin) with transarterial chemoembolization (TACE) in the treatment of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) is the conventional treatment for patients with unresectable hepatocellular carcinoma (HCC), but few studies to date have demonstrated the use of TACE as an examination method for uneasily detected HCC. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: To develop an individual prognostic calculator for patients with unresectable hepatocellular carcinoma (HCC) undergoing trans-arterial chemo-embolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the effectiveness of Jian Pi Li Qi (JPLQ) decoction in improving quality of life of patients with hepatocellular carcinoma (HCC) following transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate whether balloon-occluded transcatheter arterial chemoembolization (b-TACE) can produce a more dense accumulation of iodized oil in various stages of hepatocellular carcinoma (HCC), from single to uncountable, to overcome inferior local control. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Transarterial chemoembolization (TACE) is recommended as a first-line therapy for hepatocellular carcinoma (HCC) patients ineligible for curative therapy and without portal invasion. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study aims to explore the clinical effectiveness of a combination therapy of transarterial chemoembolization (TACE) and percutaneous microwave coagulation therapy (PMCT) in treating hepatocellular carcinoma (HCC) abutting the diaphragm. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is one of the standard locoregional treatments for intermediate stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: The aim of this study was to analyze the correlation between 18-FDG positron emission tomography (PET)/computed tomography (CT), histological necrosis, and prognosis after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) patients undergoing orthotopic liver transplantation (OLT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This analysis was conducted to evaluate the efficacy and safety of Trans-arterial Chemo- Embolization (TACE) in treating Elderly patients with Hepatocellular Carcinoma (EHPC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) is the most common procedure for the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To explore the risk factors, treatment and outcomes of biloma after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We reviewed the clinical parameters of 189 hepatocellular carcinoma (HCC) patients and investigated the prognostic significance of lymphocyte-related scores in HCC patients following transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The prevalence of osteoporosis and trabecular microstructural changes using clinical MDCT-based microstructural analysis in patients after TACE with the interventional-CT system to treat hepatocellular carcinoma have been demonstrated here. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the standard of care for treatment of intermediate hepatocellular carcinoma (HCC), however, key molecules involved in HCC cell survival and tumor metastasis post-TACE remain unclear. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: The aim of this study was to assess clinical utility of the quantitative perfusion parameter called parenchymal blood volume (PBV), as derived from C-arm-based computed tomography (CT), for immediate posttreatment assessment of drug-eluting bead (DEB) transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The clinical outcomes in hepatocellular carcinoma (HCC) patients receiving surgical resection (SR) or transarterial chemoembolization (TACE) are diverse. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To retrospectively evaluate the incidence of each extrahepatic collateral artery (EHCA) supplying to hepatocellular carcinoma (HCC) in sessions of transcatheter arterial chemoembolization (TACE) and its therapeutic frequency. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " RATIONALE AND OBJECTIVES: To assess patient radiation dose reduction and the image quality of a new X-ray imaging technology during repetitive transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to determine the clinical benefit of transhepatic arterial chemoembolization (TACE) with or without recombinant human adenovirus type 5 (H101) administration for the treatment of patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To study predictive factors for hepatic decompensation after transarterial chemoembolisation (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To identify clinical and imaging features associated with complete response (CR) to first session of transarterial chemoembolization (TACE) with drug-eluting beads (DEB) in patients with hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: The prognosis of hepatocellular carcinoma (HCC) treated with hepatic resection may be improved by the adjunctive use of transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The survival benefit of combining sorafenib and transarterial chemoembolization (TACE) therapy compared with sorafenib monotherapy for patients with advanced hepatocellular carcinoma (HCC) and main portal vein tumor thrombosis (MPVTT) is unclear. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To determine whether the use of radiofrequency ablation (RFA) plus transcatheter arterial chemoembolization (TACE) is more effective than the use of RFA alone for patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To explore the value of artificial hydrothorax microwave coagulation combined with transcatheter arterial chemoembolization (TACE) therapy in the treatment of ultrasound-invisible malignant tumors in the hepatic dome (mainly hepatocellular carcinoma/HCC) and the perioperative care for the patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) and transarterial embolization (TAE) have improved the survival rates of patients with unresectable hepatocellular carcinoma (HCC); however, the optimal TACE/TAE embolic agent has not yet been identified. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The prognosis of hepatocellular carcinoma (HCC) patients receiving transcatheter arterial chemoembolization (TACE) is far from being identified. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " RATIONALE AND OBJECTIVES: The aim of this study was to determine the optimal arterial phase delay for computed tomography imaging of hepatocellular carcinoma (HCC) before and after transarterial chemoembolization (TACE) using a low iodine dose protocol. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate balloon-occluded arterial stump pressure (BOASP), which is responsible for effective balloon-occluded transarterial chemoembolization (B-TACE), at each hepatic arterial level before B-TACE using a 1.8-French tip microballoon catheter for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The practice guideline of the American Association for the Study of Liver Diseases currently recommends transarterial chemoembolization (TACE) for the treatment of intermediate-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is commonly used for the treatment of locally advanced hepatocellular carcinoma (HCC) by its dual effects of chemotherapy and ischemic hypoxia. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To evaluate the outcomes of preoperative transarterial chemoembolization (TACE) for resectable hepatocellular carcinoma (HCC) with portal vein invasion. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Presently, there is no level one evidence that other TACE techniques are superior to Lipiodol TACE for intermediate stage hepatocellular carcinoma (HCC), which includes patients with preserved liver function and nonsurgical large or multinodular HCC without distant metastases. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " For patients with advanced hepatocellular carcinoma (HCC), official guidelines recommend palliative treatments such as transarterial chemoembolization (TACE) but not hepatic resection (HR). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) have been used for patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate the reactivation of the hepatitis B virus (HBV) following transarterial chemoembolization (TACE) in Chinese hepatocellular carcinoma (HCC) patients with low serum HBV DNA level, and to analyze the factors related to HBV reactivation in HCC patients with low serum HBV DNA level. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) is the most common treatment for patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) with regional lymph node metastases. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Optimal administration of transarterial chemoembolization (TACE), the standard approach for intermediate-stage hepatocellular carcinoma (HCC), requires clinical and technical expertise. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Recent studies have shown that the combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) may offer a survival advantage compared to monotherapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PROPOSE: To evaluate the safety and efficacy of endovascular brachytherapy (EVBT) with iodine-125 ((125)I) seed strand implantation combined with stent placement and transarterial chemoembolization (TACE) to treat hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To study the comparative short-term safety and efficacy of transcatheter arterial chemoembolization (TACE) with drug-eluting LC Beads loaded with doxorubicin (DEBDOX), doxorubicin-eluting QuadraSpheres (hqTACE), and conventional TACE using ethiodized oil for superselective C-arm computed tomography (CT)-guided treatment of hepatocellular carcinoma (HCC) after the onset of drug shortages. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the efficacy of hepatic resection (HR) and transarterial chemoembolization (TACE) for patients with solitary huge (\u2265 10 cm) hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We compared the benefits of sorafenib with that of hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (ad-HCC) refractory to transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in treatment of patients with hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS AND METHODS: During January 2009 to March 2012, 80 patients with hepatocellular carcinoma underwent TACE, with or without RFA. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: A number of cohort studies have compared the outcomes of transarterial chemoembolization (TACE) and hepatic resection (HR) in the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To identify the role of serum MicroRNA-335 (miR-335) in determining the treatment response to Trans-arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) and their prognosis after TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "What are the possible reasons for the failure? What we should expect in the near future?  RATIONALE AND BACKGROUND: Transarterial chemoembolization (TACE) is the most frequently used palliative therapy for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the efficacy and safety of radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) for treatment of patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the current standard of care for patients with large or multinodular hepatocellular carcinoma (HCC), preserved liver function, absence of cancer-related symptoms and no evidence of vascular invasion or extrahepatic spread (i.e., those classified as intermediate stage according to the Barcelona Clinic Liver Cancer staging system). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "She then underwent subsequent TACE, resulting in remission of her primary hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: To investigate the value of changes in alpha-fetoprotein (AFP) levels for the prediction of radiologic response and survival outcomes in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) who received combined treatment of 3-dimensional conformal radiotherapy (3D-CRT) and transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To report the results of combined therapy with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for early stage hepatocellular carcinoma (HCC) considered infeasible for ultrasound (US)-guided RFA in comparison with those of TACE monotherapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, hepatic resection and transarterial chemoembolization (TACE) should be recommended in patients with hepatocellular carcinoma (HCC) within and beyond the BCLC stage A, respectively. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial-chemo-embolization (TACE) is used for palliation of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The present study aimed to investigate changes in cellular immune function and regulatory T cells (Tregs) in patients with hepatocellular carcinoma (HCC) prior to and following transcatheter arterial chemoembolization (TACE) and their clinical significance. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: A systematic review and meta-analysis were performed to compare the post-recurrence survival with hepatic re-resection versus transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after initial resection. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: For intermediate hepatocellular carcinoma (HCC), transcatheter arterial chemoembolization (TACE) therapy is recommended in the guidelines as a monotherapy, although TACE is a non-curative therapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of this study is to analyze the efficacy of B-TACE for patients with one or two hepatocellular carcinoma (HCC) nodules compared with conventional super-selective TACE using a microcatheter (C-TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The purpose of this study is to evaluate the efficacy of hypofractionated radiation therapy (RT) in the treatment of unresectable hepatocellular carcinoma (HCC) after failure of transarterial chemoembolization (TACE) or in cases of refractory HCC, and to investigate biliary complications after hypofractionated RT. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) is an important option as the majority of patients present with advanced disease. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of the present study was to assess the association between the efficacy and adverse events (AEs) of transcatheter arterial chemoembolization (TACE) combined with sorafenib in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "RESULTS: TACE-induced bile duct injuries occurred in 30 out of 348 patients with liver metastatic tumors (8.6%) and in 10 out of 1992 patients with hepatocellular carcinoma (HCC) (0.5%). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: The therapeutic effect of transarterial chemoembolization (TACE) against hepatocellular carcinoma (HCC) is usually assessed using multidetector computed tomography (MDCT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Seventeen patients with 18 hepatocellular carcinoma (HCC) underwent TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUNDS/AIMS: Both preoperative transcatheter arterial chemoembolization (TACE) alone and portal vein embolization (PVE) alone have a detrimental prognostic effect on the post-resection outcomes in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the downstaging rates in hepatitis C virus-patients with hepatocellular carcinoma (HCC), treated with degradable starch microspheres transcatheter arterial chemoembolization (DSM-TACE), to reach new-Milan-criteria (nMC) for transplantation. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To investigate the efficacy and safety of conventional transarterial chemoembolization (TACE) (cTACE) in combination with bevacizumab or a placebo in patients with hepatocellular carcinoma (HCC) in a randomized controlled double-blind phase II trial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The purpose of this study was to investigate the utility of MRI findings after drug-eluting beads (DEB) - transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma in predicting time to progression (TTP). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of this study was to investigate the frequency and characteristics of cerebral lipiodol embolism (CLE) in patients with hepatocellular carcinoma (HCC) receiving transarterial embolization/chemoembolization (TAE/TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the standard of care for the treatment of patients with an intermediate (Barcelona Clinic Liver Cancer [BCLC] B) hepatocellular carcinoma and to bridge patients with an early cancer to liver transplantation (LT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine the efficacy of combined continuous sorafenib therapy and drug-eluting bead (DEB) transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study was undertaken to assess the long-term outcome of transcatheter arterial chemoembolization (TACE) after radiofrequency ablation (RFA) combined with a combined therapy for Chinese patients with intermediate (stage B) hepatocellular carcinoma (HCC) of single block type, and evaluate the survival rate for 1, 3, 5, and 7 years. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "His medical history was remarkable for multifocal hepatocellular carcinoma (HCC) treated with selective transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Transcatheter arterial chemoembolization (TACE) plus thermal ablation has been widely used recently in the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To investigate the relationship between the improved stability of an anticancer drug-lipiodol emulsion and pharmacokinetic (PK) profile for transarterial chemoembolisation (TACE) of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "KEY POINTS: \u2022 Transarterial chemoembolisation (TACE) regimens that improve survival in hepatocellular carcinoma are needed. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To compare the overall survival of patients with hepatocellular carcinoma (HCC) who were treated with lipiodol-based conventional transarterial chemoembolization (cTACE) with that of patients treated with drug-eluting bead transarterial chemoembolization (DEB-TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: To compare the efficacy and safety profile of doxorubicin-loaded drug-eluting beads (DEB) to the conventional TACE (C-TACE) in the management of nonresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: The hepatoma arterial-embolization prognostic (HAP) score predicts survival outcome in patients with hepatocellular carcinoma (HCC) treated with trans-arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Hepatocellular carcinoma (HCC) with a tumor thrombus in the inferior vena cava (IVC) and right atrium (RA) rarely occurs and is usually associated with extremely poor prognosis, we carried out this study to evaluate the efficacy and safety of a combination of trans-arterial chemoembolization (TACE) and external beam radiation therapy (EBRT) in the treatment of HCC with a tumor thrombus in the IVC and RA. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIM: We examined tumor marker levels to assess in more detail transcatheter arterial chemoembolization (TACE)-refractory hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the recommended treatment for patients suffering from intermediate, B stage, hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To investigate the influence of region-of-interest (ROI) placement on 3D tumour enhancement [Quantitative European Association for the Study of the Liver (qEASL)] in hepatocellular carcinoma (HCC) patients treated with transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: The aim of our study was to determine the diagnostic value of a novel image analysis method called parametric response mapping (PRM) for prediction of intrahepatic recurrence of hepatocellular carcinoma (HCC) treated with conventional transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the prognostic ability of inflammation scores for patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate the value of quantitative iodine-based material decomposition images with gemstone spectral CT imaging in the follow-up of patients with hepatocellular carcinoma (HCC) after transcatheter arterial chemoebolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: The goal of the study was to evaluate the efficacy and safety of balloon-occluded transarterial chemoembolization (B-TACE) of hepatocellular carcinoma (HCC) using miriplatin (a lipophilic anticancer drug) and gelatin particles. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Our results suggest that B-TACE with miriplatin is a useful treatment for hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Transarterial chemoembolization (TACE) is used for treating unresectable hepatocellular carcinoma (HCC), but its efficacy still needs to be improved. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To quantitatively measure the hemodynamic change of hepatic artery before and after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) by quantitative color-coding analysis (QCA). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUNDS & AIMS: We aimed to generate and validate a novel risk prediction model for patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To study the influence of the sequence of three-dimensional conformal radiotherapy (3DCRT) and transcatheter arterial chemoembolization (TACE) on the efficacy and toxicity of treatment in patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Intermediate-stage hepatocellular carcinoma (HCC), defined according to the Barcelona Clinic Liver Cancer (BCLC) staging system, is a heterogeneous condition with variable clinical benefits from transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the outcomes of hepatic resection and transarterial chemoembolization (TACE) for solitary hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer (BCLC) staging system. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare survival and recurrence in hepatocellular carcinoma (HCC) patients who did or did not receive adjuvant transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report an unusual case of Clostridium perfringens liver abscess formation after transcatheter arterial chemoembolization (TACE) for large hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Although potentially very useful in optimizing patient selection and follow-up, the individual response to transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) is generally unpredictable. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND STUDY AIM: Trans-arterial chemoembolisation (TACE) became the treatment of choice for multinodular hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " RATIONALE AND OBJECTIVES: To validate the concordance of a semiautomated multimodality lesion segmentation technique between contrast-enhanced magnetic resonance imaging (CE-MRI), cone-beam computed tomography (CBCT), and multidetector CT (MDCT) in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Some genetic alterations of glutathione S-transferase omega 2 (GSTO2) have been reported to increase the risk of many malignancies, including hepatocellular carcinoma (HCC); however, their prognostic capability remained unresolved in HCC patients treated with transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Tumor lysis syndrome is rare in hepatocellular carcinoma (HCC), but it has been reported more frequently recently in response to treatments such as transcatheter arterial chemoembolization (TACE), radiofrequency thermal ablation (RFTA), and sorafenib. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate whether transarterial chemoembolization (TACE) before liver transplantation (LT) improves long-term survival in hepatocellular carcinoma (HCC) patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Transarterial chemoembolization (TACE) using chemotherapy agents-doxorubicin and cisplatin-is an accepted treatment option for locally advanced hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The current standard of care for patients with large or multinodular noninvasive hepatocellular carcinoma is conventional transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study aims to investigate the efficacy of adjuvant transarterial chemoembolization (TACE) with or without antiviral therapy for patients with hepatocellular carcinoma (HCC) after radical hepatectomy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) is an important treatment modality for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the value of C-arm Lipiodol computed tomography (CT) for intra-procedural hepatocellular carcinoma (HCC) lesion detection during transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial Chemoembolization (TACE) is the standard procedure for intermediate stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Treatment of primary hepatocellular carcinoma (HCC) with transcatheter hepatic arterial chemoembolization (TACE) and three-dimensional conformal radiotherapy (3D-CRT) achieves good short-term but poor long-term survival. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Reports of hepatocellular carcinoma (HCC) rupture after TACE are limited. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate whether neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) predict survival and metastasis in patients after transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (RHCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the efficacy and safety of transarterial chemoembolization (TACE)-based multimodal treatment in patients with large hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Although transcatheter arterial chemoembolization (TACE) has been widely used as a palliative treatment for unresectable hepatocellular carcinoma (HCC), its actual efficacy and prognostic usefulness have not been clarified in past studies. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: We showed that in treatment of patients with unresectable hepatocellular carcinoma, TACE significantly improved the disease and the overall survival rate. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Advanced hepatocellular carcinoma (HCC) and chronic hepatitis B infection were diagnosed and treated by twice-repeated transcatheterarterial chemoembolization (TACE) followed by administration of entecavir. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " In 35 patients who underwent balloon-occluded transarterial chemoembolization (B-TACE) for hepatocellular carcinoma (HCC) since January 2013, 5 patients (14%) had postoperative cholangitis, 1 of whom required drainage of a liver abscess. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report the long-term survival of a patient with metastatic hepatocellular carcinoma (HCC), successfully treated with transcatheter arterial chemoembolization (TACE)/hepatic arterial infusion chemotherapy (HAIC) combined with long-term administration of sorafenib. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The second case is a 69-year-old man who underwent TACE at the age of 68 years because of multiple hepatocellular carcinoma tumors with a maximum diameter of 15 mm. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Continuous hepatic artery infusion chemotherapy for hepatocellular carcinoma (HCC) refractory to trans-arterial chemoembolization ( TACE) sometimes adversely affects the quality of life (QOL) of patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: To establish an effective prognostic nomogram for patients with unresectable hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the efficacy and safety of supplemental transcatheter arterial chemoembolization (TACE) through the extrahepatic collateral omental artery (OA) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: The aim of this study was to compare the survival in elderly hepatocellular carcinoma (HCC) patients treated with curative modalities (radiofrequency ablation (RFA), percutaneous ethanol injection (PEIT) and surgery) to those treated with transcatheter arterial chemoembolization (TACE) and supportive care. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) has been used to treat unresectable massive hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transcatheter arterial chemoembolization (TACE) is an effective first-line therapy for intermediate stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: We aimed to compare contrast-enhanced ultrasound (CEUS) with contrast-enhanced computed tomography (CECT) for evaluating the treatment response to transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the clinical value of 320-detector row CT in transcatheter arterial chemoembolization (TACE) treatment for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: This retrospective study was carried out to compare the outcomes between elderly (\u226570 years of age) and nonelderly patients (<70 years of age) with advanced hepatocellular carcinoma (HCC) who received sorafenib combined with transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is an important therapeutic option for patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total of 89 patients with hepatocellular carcinoma (HCC) were recruited in 3 groups: Group I, 30 HCC patients receiving sorafinib; Group II, 30 HCC patients with best supportive care; and Group III include 29 patients undergoing transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To investigate magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) of hepatocellular carcinoma (HCC) immediately post-doxorubicin drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) therapy as an early imaging biomarker of therapy response. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: The study aims to determine the effects of doxorubicin drug-eluting bead transarterial chemoembolization (DEB-TACE) therapies on health-related quality of life (HRQOL) in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolisation (TACE), having demonstrated survival benefits, is the treatmentof choice in intermediate-stage hepatocellular carcinoma, although there is great heterogeneity in its clinical application. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: To investigate the prognostic significance of pathologic response (PR) after transarterial chemoembolization (TACE) in cirrhotic patients resected or transplanted for hepatocellular carcinoma (HCC), and to identify predictors of complete pathologic response (CPR). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of our study was to elucidate the survival of single hepatocellular carcinoma (HCC) and also to clarify whether TACE plus sequential curative therapy provides benefits in single HCC. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the survival of hepatocellular carcinoma (HCC) patients received prophylactic use of transcatheter arterial chemoembolization (TACE) after radical resection. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: It was commonly accepted that chemotherapeutic cytotoxicity was the main cause for hepatic failure in hepatocellular carcinoma patients after repeated transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUNDS & AIMS: The aim of this study is to evaluate the prognostic significances of not only the initial and the best response during repeated transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), but if eligible, also the time point of achieving treatment responses. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: For large hepatocellular carcinoma, combined method was superior to TACE+RFA and comprehensive treatment can improve the local-control rate. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report an extremely rare case of pulmonary lipiodol embolism with acute respiratory distress syndrome (ARDS) after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To clarify the value of postoperative adjuvant transcatheter arterial chemoembolization (TACE) for resectable multiple hepatocellular carcinoma beyond the Milan criteria. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: This retrospective study enrolled 135 HCC patients with resectable multiple hepatocellular carcinoma beyond the Milan criteria, and those patients underwent a hepatectomy with/without postoperative adjuvant TACE from Jan. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: As a bridge to liver transplantation or downstaging therapy for hepatocellular carcinoma (HCC) patients, preoperative transarterial chemoembolization (TACE) has potential risks in causing damage to hepatic artery (HA), resulting in severe postoperative complications. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: It was the aim of this study to find an optimal therapeutic regimen of transarterial chemoembolization (TACE) by comparing the efficacy of chemoembolization with different anticancer agents in hepatocellular carcinoma (HCC) patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Herein, we reported that asparagus polysaccharide and its embolic agent form, asparagus gum, significantly inhibited liver tumor growth with transcatheter arterial chemoembolization (TACE) therapy in an orthotopic hepatocellular carcinoma (HCC) tumor model, while significantly inhibiting angiogenesis and promoting tumor cell apoptosis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Adjuvant transcatheter arterial chemoembolization (TACE) protects against hepatocellular carcinoma (HCC) and is associated with reduced disease recurrence and improved outcome after surgery. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To retrospectively compare treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) using gelatin sponges or microspheres plus lipiodol-doxorubicin vs. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "PURPOSE: To assess early results of TACE in patients with hepatocellular carcinoma (HCC) using CEUS and VPCT. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Portal vein thrombosis is considered a relative contraindication for transarterial chemoembolization (TACE) in hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The purpose of our study was to evaluate the efficacy of TACE treatment in patients with hepatocellular carcinoma with portal vein (PV) thrombosis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: TACE is a promising procedure in unresectable hepatocellular carcinoma with PV thrombosis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) has been the standard treatment modality in patients with intermediate stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: We aimed to evaluate the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) using miriplatin plus epirubicin in unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the standard treatment for patients with Barcelona Clinic Liver Cancer-intermediate stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to compare the long-term outcome of patients with a solitary large (> 5 cm) hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage A who received liver resection (LR) or transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of this study was to investigate the neutrophil-lymphocyte ratio (NLR), which is one of the systemic inflammation markers, in the prognosis of hepatocellular carcinoma (HCC) after treatment of transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Purpose To test and compare the association between radiologic measurements of lesion diameter, volume, and enhancement on baseline magnetic resonance (MR) images with overall survival and tumor response in patients with unresectable hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: We investigated the optimal radiologic method for measuring hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE) in order to assess suitability for liver transplantation (LT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Transarterial chemoembolization (TACE) is used to treat hepatocellular carcinoma (HCC), but it is a challenge to predict patient survival. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) using a drug-eluting bead (DEB-TACE) for hepatocellular carcinoma (HCC) is a new treatment method. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: This retrospective study was aimed to investigate the efficacy of prophylactic agents in hepatocellular carcinoma (HCC) patients receiving TACE and compare the difference between lamivudine and entecavir. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To analyze prognostic factors for survival after transarterial chemoembolization (TACE) combined with microwave ablation (MWA) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: The aim of this retrospective study was to evaluate the feasibility and treatment effects of transcatheter arterial chemoembolization (TACE) for recurrent intrahepatic hepatocellular carcinoma (HCC) after liver transplantation. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Transcatheter arterial chemoembolization (TACE) has been shown to increase survival in patients with unresectable hepatocellular carcinoma (HCC), however toxicity from commonly used agents limits its use in unresectable disease. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate the efficacy of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Sorafenib is efficacious, and may prolong OS and TTP in hepatocellular carcinoma with PVTT treated by TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate related clinical factors of hepatocellular carcinoma (HCC) patients received transcatheter arterial chemoembolization (TACE) complicated with hepatogenous diabetes (HD). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: This retrospective study aimed to compare the efficacy of and tolerance to two center-related conventional transarterial chemoembolization (TACE) strategies in the management of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: We aimed to evaluate the efficacy and tolerability of hepatic arterial infusion chemotherapy (HAIC) using cisplatin as an alternative to sorafenib for the treatment of hepatocellular carcinoma (HCC) patients who had not responded to transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare transcatheter arterial chemoembolization (TACE) and 3D conformal radiotherapy (3D-CRT) with TACE monotherapy in hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: This meta-analysis demonstrated that TACE combined with 3D-CRT was better than TACE monotherapy for patients with HCC, which needs to be confirmed by large multicenter trials\uff0e  AIM: To compare conventional transarterial chemoembolization (c-TACE) with microsphere embolization in hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Given that transarterial chemoembolization (TACE) is usually a repeated procedure for treatment of hepatocellular carcinoma (HCC), repeated radiologic response assessments rather than a single time point assessment may have different clinical implications through the repeated course of TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " According to the Barcelona Clinic Liver Cancer (BCLC) guidelines, transarterial chemoembolization (TACE) is recommended for BCLC stage B hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Transarterial chemoembolization (TACE) is the standard of care for intermediate stage hepatocellular carcinoma (HCC) and it is the most commonly used treatment for HCC worldwide. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the efficacy of combined PET/CT in the detection of viable tumour in patients with hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: To compare selective internal radiation therapy (SIRT) with transarterial chemoembolization (TACE), the standard-of-care for intermediate-stage unresectable, hepatocellular carcinoma (HCC), as first-line treatment. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the recommended treatment of intermediate stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The cells of hepatocellular carcinoma (HCC) treated by TACE suffered various hypoxia and hyponutrition. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: The aim of this retrospective study was to evaluate the feasibility and treatment effects of transcatheter arterial chemoembolization (TACE) for recurrent intrahepatic hepatocellular carcinoma (HCC) after liver transplantation. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Transcatheter arterial chemoembolization (TACE) has been shown to increase survival in patients with unresectable hepatocellular carcinoma (HCC), however toxicity from commonly used agents limits its use in unresectable disease. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transcatheter arterial chemoembolization (TACE) failure or refractoriness is an indication for sorafenib therapy in patients with advanced hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Out of 265 patients with advanced hepatocellular carcinoma who were treated with sorafenib at our hospital, 45 experienced TACE failure or refractoriness and were included in this study and retrospectively analyzed. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " In the 2010 version of the Japan Society of Hepatology (JSH) consensus-based treatment algorithm for the management of hepatocellular carcinoma (HCC), transarterial chemoembolization (TACE) failure/refractoriness was defined assuming the use of superselective lipiodol TACE, which has been widely used worldwide and particularly in Japan, and areas with lipiodol deposition were considered to be necrotic. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: To test the hypothesis that the hypoxia marker carbonic anhydrase IX (CAIX), and the cholangiocytic/progenitor markers cytokeratin (CK) 19 and epithelial cell adhesion molecule (EpCAM), may be expressed in areas of hypoxia in hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The purpose of this study was to investigate the overall survival, efficacy, and safety of small (100-300 \u00b5m) versus large (300-500 and 500-700 \u00b5m) doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: Drug eluting beads (DEBs) theoretically improve the efficacy and safety of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "A 51-year-old Caucasian male with chronic hepatitis B virus-associated cirrhosis and unresectable hepatocellular carcinoma (HCC) presented to the Interventional Radiology Unit for TACE to achieve tumor necrosis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) is accepted worldwide as an effective treatment for patients with unresectable hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Conventional transarterial chemoembolization (cTACE) is widely used for treating patients with inoperable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The ART score (a point score for the assessment of retreatment with transarterial chemoembolization, TACE) has been recently developed in Austria to differentiate patients who may benefit from multiple sessions of TACE for hepatocellular carcinoma (HCC) treatment. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To prospectively compare SIRT and DEB-TACE for treating hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is a common treatment for patients with hepatocellular carcinoma (HCC) who are awaiting liver transplantation (LT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) and radioembolization (RE) are frequently used to treat patients with hepatocellular carcinoma who cannot receive curative therapies. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Evidence supporting the use of RE derives from consistent, large-cohort series involving patients with more advanced hepatocellular carcinoma, not suitable for TACE or for those who have failed TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We conducted a cohort study to investigate the prognostic significance of vascular endothelial growth factor (VEGF) polymorphisms in hepatocellular carcinoma (HCC) patients after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Hypoxia-induced vascular endothelial growth factor (VEGF) upregulation and angiogenesis following treatment of hepatocellular carcinoma (HCC) with transarterial embolization (TAE) or transarterial chemoembolization (TACE) may be mediated by ginsenoside Rg3, an anti-angiogenic saponin extracted from ginseng. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transcatheter arterial chemoembolization (TACE) has been used to curtail tumor vasculature and delay tumor progression in hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "However, the association between functional single nucleotide polymorphisms (SNPs) in one of TCA cycle key gene isocitrate dehydrogenase (IDH) and the overall survival of hepatocellular carcinoma (HCC) patients treated with transcatheter arterial chemoembolization (TACE) has never been investigated. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "stage B or C, based on the Barcelona Clinic Liver Cancer classification of hepatocellular carcinoma (HCC), transarterial chemoembolization (TACE) may be offered as a treatment of palliative intent. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The objective of our study was to compare the effectiveness of radiofrequency ablation (RFA) for viable hepatocellular carcinoma (HCC) including areas of retained oil after transarterial chemoembolization (TACE) versus RFA treatment of viable HCC alone for ablation coverage. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The purpose of this study was to determine the prevalence of osteoporosis and trabecular microstructural changes in patients after transarterial chemoembolization (TACE) for hepatocellular carcinoma therapy using an interventional-CT system. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolisation (TACE) is a standard treatment for unresectable, intermediate stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) and TACE alone for hepatocellular carcinoma (HCC), Pubmed, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI) and Wanfang Datebases were searched for the randomized controlled trials (RCTs) and retrospective cohort studies from the establishment of the databases to January 2014. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the safety and efficacy of combined therapy with transarterial chemoembolization (TACE) and sorafenib for hepatocellular carcinoma (HCC) with portal venous tumour thrombus (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The purpose of this study was to investigate the efficacy and toxicity of radiation therapy (RT) following incomplete transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Data of patients with hepatocellular carcinoma, who had previous TIPS implantation and received TACE between January 2010 and December 2012, were reviewed retrospectively. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study was conducted to compare long-term survival between patients with unresectable infiltrating hepatocellular carcinoma (HCC) who were treated with transarterial chemoembolization (TACE) and those who received conservative treatment (best supportive care). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of this study was to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) using warmed and nonwarmed miriplatin for hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The combination of systemic antiangiogenic therapy and transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC) is the subject of several ongoing clinical trials. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the technical feasibility and safety considerations of balloon-occluded transarterial chemoembolization (B-TACE) using a newly developed 1.8-French (Fr) tip microballoon catheter for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This study aimed to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) in combination with three-dimensional conformal radiotherapy (3D-CRT) in the treatment for locally advanced unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: A total of 115 patients with compensated liver cirrhosis underwent RFA combined with TACE at a time-interval of 0-2 d for the treatment of hepatocellular carcinoma (HCC) < 5.0 cm. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS AND METHODS: CTRIPA performed on 104 patients treated with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma in our hospital between August 2007 and July 2013 were reviewed. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical effect of radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare clinical outcome and safety of transcatheter arterial chemoembolization (TACE)\u2009+\u2009portal vein embolization (PVE) with TACE alone in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: We compared the benefits of sorafenib therapy with continued transarterial chemoembolization (TACE) in TACE-refractory patients with intermediate-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To prospectively assess treatment response using volumetric functional magnetic resonance imaging (MRI) metrics in patients with hepatocellular carcinoma (HCC) treated with the combination of doxorubicin-eluting bead-transarterial chemoembolization (DEB TACE) and sorafenib. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The aim of this study was to compare the efficacy of sunitinib combined with transarterial chemoembolization (TACE) versus TACE alone for treating patients with advanced-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The aim of this meta-analysis is to evaluate the clinical efficacy of cinobufacini combined with transcatheter arterial chemoembolization (TACE) in the treatment of advanced hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS AND METHODS: By searching Medline, the Cochrane central register of controlled trials, EMBSE, ESMO, Wanfang and Chinese National Knowledge Infrastructure (CNKI) databases, the open published clinical trials compared the clinical efficacy of cinobufacini plus TACE versus TACE only in patients with advanced hepatocellular carcinoma were collected. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: This meta-analysis demonstrated that cinobufacini combined with TACE can significantly increase the objective response rate and 2-year survival rate compared with TACE only in patients with advanced hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " A woman in her eighties underwent transcatheter arterial chemoembolization (TACE) with cisplatin (CDDP) for recurrence of hepatocellular carcinoma (HCC) with lymph node involvement and associated hepatitis C. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: Repeat transarterial chemoembolization (TACE) is a common intervention performed for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To compare the long-term survival of hepatocellular carcinoma (HCC) patients within the Milan criteria who underwent hepatic resection (HR) or transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Patients with single hepatocellular carcinoma (HCC) usually undergo transarterial chemoembolization (TACE) if they are not candidates for curative surgical or ablative therapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Out of 158 patients who received miriplatin using B-TACE for hepatocellular carcinoma, 49 patients with a single lesion at either stage I or II (according to the Liver Cancer Study Group of Japan) were evaluated in comparison with 48 matched patients who received miriplatin using conventional TACE (C-TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Few groups have studied the impact of pretransplant transarterial chemoembolization (TACE) in the outcomes of liver transplant recipients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) using iodized oil (Lipiodol(\u00ae)) (Lp-TACE) as a carrier of chemotherapeutic agents has been routinely performed to control hepatocellular carcinomas (HCC) in Japan, and its use has yielded fairly beneficial therapeutic results. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This phase II, investigator-initiated, prospective single-arm multinational study (ClinicalTrials.gov registration NCT00990860) evaluated sorafenib in combination with doxorubicin-based transarterial chemoembolization (TACE) in patients with intermediate-stage, unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Sorafenib in combination with Transarterial chemoembolization (TACE) is increasingly used in patients with unresectable hepatocellular carcinoma (HCC), but the current evidence is still controversial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) is commonly used to treat advanced hepatocellular carcinoma (HCC), but less is known regarding safety and efficacy of TACE in patients with HCC and portal vein tumour thrombosis (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: We investigated the therapeutic effects of three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolisation (TACE) for hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The two intraarterial techniques used in the treatment of hepatocellular carcinoma (HCC) are the transarterial chemoembolization (TACE) and radioembolization (RE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: We aimed to retrospectively examine the tolerability and efficacy of transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Significant proportion of Hepatocellular Carcinoma (HCC) cases are diagnosed in stage B of Barcelona Clinic Liver Cancer (BCLC) algorithm, in which the standard of care is Transcatheter Arterial ChemoEmbolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) is recommended as a treatment for unresectable hepatocellular carcinoma (HCC) in patients with normal underlying liver function. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: The role of radiofrequency ablation (RFA) remains uncertain in patients with viable hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: The aim of our study was to compare clinical outcomes between elderly patients aged \u226575 years (elderly group, n=66) with intermediate hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) and younger patients aged <75 years (control group, n=84) with intermediate HCC undergoing TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study was conducted to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) combined with transarterial chemoembolization (TACE) for huge (\u226510 cm) hepatocellular carcinomas (HCCs). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) in patients with infiltrative hepatocellular carcinoma (HCC) and to identify the prognostic factors associated with patient survival. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate safety, efficacy, survival and recurrence-free survival of transarterial chemoembolization (TACE) with drug eluting (DC) beads combined with MR-guided radiofrequency (RF) ablation for the treatment of hepatocellular carcinomas (HCC) larger than 3 cm. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) is the first-line therapy recommended for patients with intermediate hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Miriplatin (MPT) is a novel platinum complex used in TACE that shows promise for the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the efficacy and safety of lobaplatin-transcatheter arterial chemoembolization (TACE) combined with radioactive 125I seed implantation in treatment of primary hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Transarterial chemoembolization (TACE) is one of the standard treatments recommended for intermediate stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) and transarterial embolization (TAE) are commonly used as first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and have been shown to improve overall survival (OS). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The routine use of transarterial chemoembolization (TACE) prior to resection for hepatocellular carcinoma (HCC) is not recommended, although its use in the transplant setting is gaining popularity. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the prognostic significance of (18)F-FDG PET-CT SUVmax value in 85 patients with hepatocellular carcinoma (HCC) before transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: The SUVmax value of the primary intrahepatic tumor can be used as an important prognostic factor to predict the effect of TACE in patients with hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the diagnostic performance of three-dimensional ( 3D three-dimensional ) quantitative enhancement-based and diffusion-weighted volumetric magnetic resonance (MR) imaging assessment of hepatocellular carcinoma ( HCC hepatocellular carcinoma ) lesions in determining the extent of pathologic tumor necrosis after transarterial chemoembolization ( TACE transarterial chemoembolization ). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS AND METHODS: This institutional review board-approved retrospective study included 17 patients with HCC hepatocellular carcinoma who underwent TACE transarterial chemoembolization before surgery. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: This radiologic-pathologic correlation study demonstrates the diagnostic accuracy of 3D three-dimensional quantitative MR imaging techniques in identifying pathologically measured tumor necrosis in HCC hepatocellular carcinoma lesions treated with TACE transarterial chemoembolization . "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS AND METHODS: From December 2010 to December 2011, a pilot study was conducted including nine patients (mean age 66.6 years; SD 8.3 years; seven men) undergoing TACE with drug-eluting beads for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: We aimed to establish an objective point score to guide the decision for the first treatment with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The purpose of the present study was to evaluate whether diffusion-weighted imaging (DWI) can be used to assess hepatocellular carcinoma (HCC) viability following transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of the present study was to investigate the value of apparent diffusion coefficients (ADCs) measured with magnetic resonance (MR) diffusion-weighted imaging (DWI) in evaluating liver fibrosis and curative effects on hepatocellular carcinoma (HCC) following transcatheter arterial chemoembolization (TACE) with low doses of chemotherapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To assess the prognostic role of baseline clinical, biochemical and radiological characteristics of patients with hepatocellular carcinoma (HCC) treated with the first transarterial chemoembolization (TACE) procedure. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) can reduce tumor progression and help achieve good locoregional effect in hepatocellular carcinoma (HCC) patients with intrahepatic multiple recurrence (IHMR) after liver resection (LR). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIM: Transarterial chemoembolization (TACE) is the recommended treatment for patients with Barcelona stage B hepatocellular carcinoma; however, community practice varies from these American Association for the Study of Liver Diseases guidelines. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "AIMS: We aim to investigate the survival effect of postoperative adjuvant TACE on the prognosis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients (stage B, the Barcelona Clinic Liver Cancer staging). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the overall and cumulative incidence, degree, interval change and predictors of hepatic arterial injury (HAI) after cisplatin and Gelfoam\u00ae (Upjohn, Kalamazoo, MI)-based transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Transarterial chemoembolization (TACE) is an effective treatment for patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Transcatheter arterial chemoembolization (TACE) and transarterial infusion chemotherapy (TAI) are the main therapeutic strategies for treatment of advanced hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: The purpose of the present study was to determine whether lamivudine in combination with transarterial chemoembolization (TACE) could reduce hepatitis B virus (HBV) activation and improve the survival of patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Sorafenib is used in patients with intermediate or advanced stage hepatocellular carcinoma (HCC) before or after of transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " In Europe, trans-arterial chemoembolization (TACE) is usually given to patients with Barcelona Clinic Liver Cancer (BCLC) \"intermediate stage\" hepatocellular carcinoma (HCC), and is associated with a modest improvement in median overall survival. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Early local recurrence and no early local recurrence groups drawn from 134 patients who were initially diagnosed with hepatocellular carcinoma (HCC) and showed a complete response (CR) to TACE treatment between January 1, 2006, and January 31, 2012, were analyzed by univariate and multivariate analyses. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transcatheter arterial chemoembolisation (TACE) is the treatment of choice for intermediate stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Patient demographic characteristics, history of TACE for treatment of hepatocellular carcinoma, OLT data, and biliary stricture data were obtained. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Selective TACE treatment of hepatocellular carcinoma in pretransplant patients does not increase the rate of posttransplant biliary strictures. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "These findings corroborate the safety of TACE in the treatment of hepatocellular carcinoma in potential OLT patients as a bridge to transplantation. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To compare the effectiveness of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for treating small (\u22642\u2009cm) hepatocellular carcinomas (HCCs). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: The effect of preoperative transcatheter arterial chemoembolization (TACE) on the short- and long-term outcome of resectable hepatocellular carcinoma (HCC) is controversial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: There was a continuing controversy on whether the adoptive transfusion of cytokine-induced killer cells (CIK) therapy should have been recommended to reduce the recurrence and metastasis of hepatocellular carcinoma (HCC) after minimally invasive therapy such as TACE (transarterial chemoembolization) or TACE plus RFA (radiofrequency ablation) treatment. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: We retrospectively evaluated the local tumor control and safety of transcatheter arterial chemoembolization (TACE) followed by stereotactic body radiation therapy (SBRT) for small hepatocellular carcinoma (HCC) in this pilot study. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To retrospectively analyze the efficacy and safety of transcatheter arterial chemoembolization (TACE) in combination with sorafenib for the treatment of patients with intermediate-advanced hepatocellular carcinoma (HCC) and assess the prognostic impact of baseline characteristics. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the short-term safety and efficacy of the new generation of 70-150 \u00b5m drug-eluting beads (M1 DEB) in patients with hepatocellular carcinoma undergoing transarterial chemoembolization (TACE) as a primary therapy or as a bridge to liver transplantation (LT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: Surgical resection (SR) and transarterial chemoembolization (TACE) have been commonly applied for patients with huge hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Although transcatheter arterial chemoembolization (TACE) is the most common treatment option in patients with hepatocellular carcinoma (HCC), its clinical benefits remain still controversial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the well-known treatment for hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is considered as the standard therapy for patients with intermediate-stage hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To explore the clinical efficacy of dendritic cell-cytokine induced killer cell (DC-CIK) immunotherapy combined with transcatheter arterial chemoembolization (TACE) for treatment of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Thirty patients with hepatocellular carcinoma treated with TACE combined with DC-CIK cell therapy and 38 patients treated with TACE alone (control group) were compared for progression-free survival time, overall survival time, quality of life, and treatment-related adverse events. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To compare the long-term survival of patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) undergoing either liver resection or transarterial chemoembolization (TACE) after propensity score matching (PSM). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate the feasibility and accuracy of multidetector computed tomography (MDCT) angiography for assessment of subsegmental tumor-feeding vessels in transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: The purpose of the present study was to compare the efficacies of transarterial chemoembolization (TACE) combined with sorafenib versus TACE monotherapy for treating patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: We aimed to compare the effect of using different embolic agents such as gelfoam and polyvinyl alcohol (PVA) on survival, tumor response, and complications in transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: New tracking navigation imaging software was used to evaluate the usefulness of three dimensional (3D) CT angiography for transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) could achieve a better survival benefit than conservative treatment for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: In this study, we try to investigate the possible causes of failed TACE when it is served as a down-staging therapy for advanced hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODOLOGY: Two hundred and seventy eight patients had diagnoses of unresectable hepatocellular carcinoma but had the possibility to accept a resection if they accepted the successful use of TACE as a down-staging therapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of this meta-analysis was to compare the effectiveness of combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) with that of RFA alone in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the feasibility and technical aspects of transcatheter arterial chemoembolization (TACE) for non-resectable hepatocellular carcinoma (HCC) using a 3.5-French (Fr) catheter system. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Combination therapy of sorafenib and transarterial chemoembolization (TACE) showed benefits for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To assess the beneficial and harmful effects of transarterial embolization (TAE) or transarterial chemoembolization (TACE) for curative resection of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: A phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads was performed in cirrhotic patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "A retrospective analysis was carried out on patients with unresectable hepatocellular carcinoma who received TAE or TACE at the Tri-Service General Hospital (Taiwan) between January 2005 and December 2008. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: It is unclear whether hepatic resection (HR) or transarterial chemoembolization (TACE) is associated with better outcomes for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage A. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) followed by radiotherapy (RT) in treatment-na\u00efve patients with locally advanced hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with sorafenib (hereafter, TACE-sorafenib) in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To assess the usefulness of intravoxel incoherent motion diffusion weighted imaging (IVIM-DWI) for predicting lipiodol uptake in patients with hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We aim to investigate the clinical characteristics and prognostic factors of Hepatocellular Carcinoma (HCC) patients treated by transarterial chemoembolization (TACE) in Chinese cohort. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the first line treatment for patients with intermediate stage hepatocellular carcinoma but is also increasingly being used for patients on the transplant waiting list to prevent further tumor growth. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In the current article, we review the use of TACE and TAE for hepatocellular carcinoma and we focus on the evidence for their use. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate the efficacy, survival and prognosis of transarterial chemoembolization (TACE) alone and TACE in combination with multimodality therapy for huge hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To determine appropriate imaging criteria for early response evaluation in patients with hepatocellular carcinoma treated with transarterial chemoembolization (TACE) using drug-eluting beads. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Application of mRECIST criteria at the 1-month follow-up computed tomography may be a reliable early predictor of outcome response in patients with hepatocellular carcinoma treated with TACE using drug-eluting beads. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Balloon-occluded transarterial chemoembolization (B-TACE) is able to achieve denser accumulation of Lipiodol emulsion (LE) in hepatocellular carcinoma (HCC) than conventional TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Transcatheter arterial chemoembolization (TACE) is a standard treatment for hepatocellular carcinoma (HCC) and/or some unresectable liver metastasis tumors. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To compare radiofrequency ablation (RFA) or microwave ablation (MWA) and transcatheter arterial chemoembolization (TACE) with RFA or MWA monotherapy in hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: A large number of studies have tried to combine sorafenib with TACE for patients with unresectable hepatocellular carcinoma (HCC) and the results were controversial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: The aim of this randomized comparative trial (RCT) is to compare partial hepatectomy (PH) with transcatheter arterial chemoembolization (TACE) to treat patients with resectable multiple hepatocellular carcinoma (RMHCC) outside of Milan Criteria. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The purpose of this study was to evaluate the clinical efficacy, toxicity and adverse effects of stereotactic body radiotherapy (SBRT) combined with transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "To determine the prognostic value of Tregs, we conducted a retrospective study on 264 patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) who underwent transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) may cause damage to the hepatic artery (HA) and impact the postoperative course of the liver transplantation (LT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the diagnostic value of diffusion weighted imaging (DWI) combined with dynamic contrast-enhanced (DCE) MRI in monitoring the efficacy for hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To find a subgroup that benefits most from transarterial chemoembolization (TACE) in terms of tumor number and size and liver profile in patients with intermediate-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Importantly, upregulation of TMEM98 mRNA in patients with hepatocellular carcinoma who received transarterial chemoembolization (TACE) treatment was significantly higher than in patients without TACE treatment (P = 0.046). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In the present study, we investigated whether baseline serum IGF-1 levels predict time-to-progression (TTP) and overall survival (OS) in hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To retrospectively assess long-term survival benefit and safety of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) patients with portal vein tumour thrombosis (PVTT), and to evaluate factors that significantly affect outcomes of these patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of the combination of sorafenib and transarterial chemoembolization (TACE)in the treatment of primary hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate treatment response of hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) with a new real-time imaging fusion technique of contrast-enhanced ultrasound (CEUS) with multi-slice detection computed tomography (CT) in comparison to conventional post-interventional follow-up. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the clinical characteristics of patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 and A hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "As we previously reported LDH is an important predictive factor in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To analyze the technical success and tumor response of ultraselective transcatheter arterial chemoembolization (TACE) for small hepatocellular carcinoma (HCC) using automated tumor-feeders detection (AFD) software. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The purpose of this retrospective study was to investigate the incidence of contrast-induced nephropathy (CIN) caused by transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare the effectiveness of transarterial chemoembolization (TACE), radiofrequency ablation (RFA), and hepatic resection (HR) in patients with small single-nodule hepatocellular carcinoma by using inverse probability weighting to control selection bias. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The study included 197 consecutive patients (146 men and 51 women; mean age \u00b1 standard deviation, 57.4 years \u00b1 9.7) with single-nodule hepatocellular carcinomas measuring 3 cm or smaller and no vascular invasion who were treated initially with HR (n = 52), RFA (n = 79), or TACE (n = 66) from January 2005 to December 2006 at a single tertiary hospital. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: TACE is an effective treatment that allows achievement of long-term survival rates comparable to those with HR and RFA in patients with small single-nodule hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Accurate assessment of viability of hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) is important for therapy planning. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Currently image-guided trans-arterial chemoembolization (TACE) has a significant role in the therapy of patients with hepatocellular carcinoma and liver metastases. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS AND METHODS: From June to December 2012, 15 patients met the inclusion criteria of unresectable hepatocellular carcinoma (HCC) that was treated with conventional TACE (cTACE) and had intraprocedural CBCT and 1-day post-TACE MDCT. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The long-term survival in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) who received surgical resection (SR) or transarterial chemoembolization (TACE) remains unclear. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The most common non-surgical approaches for the treatment of localized hepatocellular carcinoma remain hepatic artery-delivered particles laden with chemotherapy (TACE), or radioactive microparticles (TARE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: We assessed the clinical implications of the best response compared with the initial response during repeated transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the predictive utility of apparent diffusion coefficient (ADC) changes at diffusion-weighted (DW) magnetic resonance (MR) imaging 1 month after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) compared with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, European Association for the Study of the Liver (EASL) criteria, and modified RECIST (mRECIST). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: We aimed to elucidate the treatment outcomes of transcatheter arterial chemoembolization (TACE) and survival-associated factors in hepatocellular carcinoma (HCC) patients with hepatic vein (HV) and/or inferior vena cava (IVC) invasion. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolisation (TACE) is an effective treatment for unresectable hepatocellular carcinoma (HCC), but can cause severe toxicity. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We aimed to elucidate whether serum VEGFR2 concentration before and after transarterial chemoembolization (TACE) can predict survival in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) is the current standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) and relatively preserved liver function. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: The aim of this study was to compare the outcomes of surgery and transarterial chemoembolization (TACE) for a solitary huge hepatocellular carcinoma (HCC) of Barcelona Clinic Liver Cancer (BCLC) stage A. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Recent studies suggest that a combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) may have theoretical advantages over TACE alone for treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report a case of multiple intrahepatic recurrence of hepatocellular carcinoma( HCC) that was successfully treated with transcatheter arterial chemoembolization( TACE) and sorafenib therapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "After transcatheter arterial chemoembolization( TACE) for hepatocellular carcinoma (HCC), abdominal computed tomography (CT) revealed a gas-containing lesion in the liver. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To investigate the safety and effectiveness of combined (131)I-metuximab and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This prospective, randomised, two-arm clinical trial aims to investigate the feasibility, safety and effectiveness of transarterial chemoembolisation (TACE) combined with the endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus conventional TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This study examines the safety and efficacy of transarterial chemoembolization using doxorubicin-loaded 30-60 \u00b5m QuadraSphere microspheres (DEM-TACE) for the treatment of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus computed tomography (CT)-guided percutaneous radiofrequency ablation (RFA) for small hepatocellular carcinoma (HCC) in special locations. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study aimed to investigate the feasibility of combined transarterial chemoembolization and radiotherapy (TACE+RT) in comparison with sorafenib for advanced hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To assess the value of fusion imaging of real-time ultrasonography (US) with liver computed tomography (CT)/magnetic resonance imaging (MRI) images for planning US of radiofrequency ablation (RFA) in improving conspicuity of the lesions and reducing false-positive detection of local tumour progression (LTP) found after transcatheter arterial chemoembolization (TACE) or RFA of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the clinical value of iodine[131I] metuximab infusion combined with transcatheter arterial chemoembolization (TACE) for treating cases of post-intervention relapse of mid or advanced stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the effect of preoperative transarterial chemoembolization (TACE) on hepatocellular carcinoma located in caudate lobe. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: For hepatocellular carcinoma located in caudate lobe, preoperative TACE does not significantly increase the surgical difficulty and impair the safety. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The role of CBCT has been recognized in transarterial chemo-embolization (TACE) treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) using miriplatin emulsion in unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the incidence of extrahepatic collateral arteries involved in the blood supply to hepatocellular carcinoma (HCC) and to assess the technical success rates and complications of transcatheter arterial chemoembolization (TACE) through the collaterals. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: TACE through extrahepatic collaterals is safe and feasible, and with a high success rate in the treatment of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolization (TACE) is used as palliative treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: To explore long-term predictors of outcome after TACE and resection in a population of patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Nausea and vomiting after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) are common in clinical practice, but few studies have reported the incidence and risk factors of such events. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare the characteristics of magnetic resonance perfusion-weighted imaging (MRPWI) scans before and after transcatheter arterial chemoembolization (TACE) treatment of hepatocellular carcinoma (HCC) and to apply MRPWI in evaluating the therapeutic effect of TACE and prognosis of HCC. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of this study was to compare the effectiveness of combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) with that of RFA alone in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Patients with unresectable hepatocellular carcinoma (HCC) usually receive transarterial chemoembolization (TACE) or systemic therapies with intermediate and advanced-stage disease. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In July 2012, an Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) was re-convened in Shanghai in an attempt to provide a consensus on the practice of TACE, particularly in regard to evaluating TACE 'failure'. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) is a novel locoregional treatment for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Locoregional treatment [including percutaneous ethanol injection (PEI) therapy and transcatheter arterial chemoembolization (TACE)] provides an alternative treatment for early-diagnosed hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of the present study was to compare clinical outcomes in patients with intermediate-stage hepatocellular carcinoma (HCC) who underwent the following treatments: transcatheter arterial chemoembolization (TACE) using an epirubicin-mitomycin-lipiodol (EML) emulsion at initial therapy (TACE group; n=145), and transcatheter chemotherapy infusion (TACI) using an EML emulsion at initial therapy (TACI group; n=81). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The aim of the present study was to evaluate whether serum alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) trends might be correlated with overall survival rates in patients with recurrent hepatocellular carcinoma (HCC) undergoing trans-catheter arterial chemo-embolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Trans-arterial chemoembolization (TACE) is associated with better survival in BCLC-stage B patients with hepatocellular carcinoma (HCC) and Child-Pugh A whereas in Child-Pugh B there is no definite evidence of benefit. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of this study is to compare the overall survival in patients with hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) versus RFA alone. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) moderately prolongs the survival of patients with intermediate-stage hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Transarterial chemoembolization (TACE) is the current standard therapy for patients with Barcelona Clinic Liver Cancer (BCLC) intermediate-stage hepatocellular carcinoma (HCC) [1, 2, 3]. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate pathologic, imaging, and technical predictors of therapy response in patients with hepatocellular carcinoma (HCC) within the Milan criteria undergoing doxorubicin drug-eluting beads transarterial chemoembolization (DEB-TACE) before orthotopic liver transplantation (OLT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Percutaneous transluminal angioplasty using balloon catheters for Budd-Chiari syndrome (BCS) and transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) have become increasingly accepted as alternative therapeutic modalities. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare effectiveness of transarterial ethanol ablation (TEA) and transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma and determine whether TEA leads to better overall survival and tumor response than TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To retrospectively compare the outcome of combined transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, TACE-RFA) with that of surgical resection (SR) in patients with hepatocellular carcinoma (HCC) within the Milan criteria. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND STUDY AIMS: Our aim was to assess the efficacy and tolerability of drug-eluting beads-transarterial chemoembolization (DEB-TACE) in the treatment of hepatocellular carcinoma (HCC), evaluating the response to the treatment after 1, 6, 12, and 24 months with multidetector computed tomography (MDCT) comparing European Association for the study of the Liver (EASL) and modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of adjuvant IFN therapy for viral hepatitis-related hepatocellular carcinoma (HCC) after treatment with surgical resection or transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The purpose of this study is to assess clinical efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) on patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The combination of sorafenib, TACE, and RFA proved both safe and effective in the treatment for unresectable hepatocellular carcinoma patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The role of CBCT has been recognized in transcatheter arterial chemoembolization (TACE) treatment of liver cancer especially with the recent introduction of dual-phase CBCT (DP-CBCT) for unresectable hepatocellular carcinoma (HCC) treatment. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To assess the possible effect of two different types of preoperative transcatheter arterial chemoembolization (TACE) on recurrence-free survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) and to analyze the effects of TACE on tumor histology. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "This study evaluated the clinical implications of cytokine changes after transarterial chemo-embolization (TACE) in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Transarterial chemoembolization (TACE) is recommended as standard care for intermediate hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To explore the therapeutic efficacy of a combined treatment modality using transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) to treat hepatocellular carcinoma (HCC) complicated with main branch intraportal vein tumor thrombosis (PVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Recently, we developed the ART score (assessment for re-treatment with TACE) to guide the decision for a second transarterial chemoembolization (TACE-2) in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: We aimed to evaluate local tumor control after transarterial chemoembolization (TACE) for hepatocellular carcinoma using miriplatin and low-dose epirubicin combination therapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Additional usage of low-dose epirubicin for TACE using miriplatin improved local tumor control of hepatocellular carcinoma with adverse effects comparable to those observed with TACE using miriplatin alone. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "To compare the number of image acquisitions and procedural time required for transarterial chemoembolization (TACE) with and without tumor-feeder detection software in cases of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Radiographical features associated with a favourable response to trans-arterial chemoembolization (TACE) are poorly defined for patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The objective of our study was to investigate the diagnostic performance of C-arm CT and its value to predict response of hepatocellular carcinoma (HCC) to trans-catheter arterial chemoembolization (TACE) compared with gadoxetic acid-enhanced MRI. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: The therapeutic efficacy of transcatheter arterial chemoembolization (TACE) using miriplatin was evaluated in comparison with that using epirubicin in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To examine cumulative survival and Medicaid-paid expenses associated with multiple courses of transarterial chemoembolization (TACE) as primary treatment for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "To identify the efficiency and safety of transcatheter arterial chemoembolization (TACE) combined with percutaneous ethanol (PEI) for patients with hepatocellular carcinoma (HCC) more than 3\u2009cm in diameter in comparison with those of transcatheter arterial chemoembolization monotherapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This study was designed to investigate the safety and efficacy of the circumferential clip-based (StarClose) vascular closure device (VCD) in coagulopathic and cirrhotic patients with hepatocellular carcinoma (HCC) after doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Transarterial chemoembolization (TACE) is the mainstay of management for patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To retrospectively compare the short-term antitumor efficacy and safety of transcatheter arterial chemoembolization (TACE) with a cisplatin-iodized oil suspension (C-IS) and a miriplatin-iodized oil suspension (M-IS) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To compare the effectiveness of radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) with surgical resection in patients with a single hepatocellular carcinoma (HCC) ranging from 2 to 5 cm. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare the overall survival (OS) and progression-free survival (PFS) with associated adverse events (AE) in patients with unresectable hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) + sorafenib vs TACE alone. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Against the background of the current preparation of the national disease management guideline for the diagnosis and treatment of hepatocellular carcinoma (HCC), the German Society for Interventional Radiology (DEGIR) launched a statewide survey in order to evaluate the current status of transarterial chemoembolization (TACE) in Germany. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Despite the widespread use of locoregional therapies [radiofrequency ablation and transarterial chemoembolization (TACE)], there is currently a lack of high-quality evidence supporting their use for hepatocellular carcinoma (HCC) in patients on the liver transplantation (LT) waiting list or requiring down-staging. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: The current study analysed the association between radiologic tumour response and survival times of patients with hepatocellular carcinoma (HCC) who were treated with transcatheter hepatic arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To assess the technical safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with immediate radiofrequency ablation (RFA) for large hepatocellular carcinomas (HCC) (maximum diameter \u2265 5 cm). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare the time to progression (TTP) and overall survival (OS) in patients with advanced-stage hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment combined with transarterial chemoembolization (TACE) versus sorafenib monotherapy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare treatment response after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) in patients with and without a transjugular intrahepatic portosystemic shunt (TIPS). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine whether 5-fluorouracil (5-FU) sensitivity is associated with the mRNA expressions of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and thymidine phosphorylase (TP) in patients with hepatocellular carcinoma (HCC) treated with 5-FU-based transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: In previous randomized trials, transarterial chemoembolization (TACE) has shown an improvement of survival rate in hepatocellular carcinoma (HCC) when combined with radiofrequency ablation (RFA), percutaneous ethanol injection (PEI) or other therapies. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To compare radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) with RFA monotherapy in hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The present study aimed to investigate the correlation between cytokine changes and clinical characteristics in hepatocellular carcinoma (HCC) patients receiving transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The efficacy of sorafenib for hepatocellular carcinoma (HCC) patients refractory to transcatheter arterial chemoembolization (TACE) has not yet been clarified. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This study was designed to compare technical success and local recurrence rates of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with/without monitoring of embolized areas using cone-beam computed tomography (CBCT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: We evaluated the efficacy of contrast-enhanced ultrasonography (US), compared with contrast-enhanced computed tomography (CT), for early assessments after transarterial chemoembolization (TACE) for the treatment of hypervascular hepatocellular carcinoma (HCC) lesions. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We evaluated the efficacy and safety of TSU-68 in combination with transarterial chemoembolisation (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To explore the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: The combined use of TACE and sorafenib is both safe and efficacious in the treatment of advanced hepatocellular carcinoma with tumor thrombosis in portal vein. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the clinical utility and limitations of a computer software program for detecting tumor feeders of hepatocellular carcinoma (HCC) during transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of this study is to evaluate the survival rates of patients with unresectable hepatocellular carcinoma (HCC) following transarterial chemoembolization (TACE) performed in a single teaching hospital. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " This study evaluated the clinical efficacy of autologous cytokine-induced killer (CIK) cell transfusion in combination with transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA), compared to sequential therapy with TACE and RFA, for the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To compare the effect of radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for the treatment of 3 - 5 cm hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Radiofrequency ablation plus TACE is better than radiofrequency ablation alone for the treatment of 3 - 5 cm hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIMS: Advanced hepatocellular carcinoma (HCC) with vascular invasion or extrahepatic metastasis has been considered a contraindication for transarterial chemoembolization (TACE) treatment according to Barcelona Clinic Liver Cancer (BCLC) staging classification. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: This study reports treatment outcomes after helical intensity-modulated radiotherapy (IMRT) in unresectable hepatocellular carcinoma (HCC) patients for whom transarterial chemoembolization (TACE) was considered ineffective or unsuitable. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The purpose of this study was to clarify the frequency of and risk factors for liver abscess formation after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma or metastatic hepatic tumors after undergoing bilioenteric anastomosis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS AND METHODS: From January 1996 to June 2012, 25 patients (21 men, four women; age range, 34-74 years) with hepatocellular carcinoma (n = 12) or metastatic hepatic tumors (n = 13) with an underlying bilioenteric anastomosis underwent 65 TACE procedures. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This work aimed to evaluate the safety and clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with c-arm cone-beam CT guided synchronous radiofrequency ablation (RFA) in treatment of large hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: A prospective cohort study, from 2001 to 2010, compared clinical outcomes following TACE between patients \u2265 75 years old and younger patients (aged between 65 and 75 years and younger than 65 years) with hepatocellular carcinoma (HCC), diagnosed according to the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases criteria. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To explore the prognostic significance of serum vascular endothelial growth factor receptor-2 (VEGFR-2) in patients with hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the efficacy of transarterial chemoembolization (TACE) using a suspension of a fine-powder formulation of cisplatin (DDPH) in lipiodol (LPD) in the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND PURPOSE: Reactivation of hepatitis B virus (HBV) happens after systemic chemotherapy, transarterial chemoembolization (TACE) or hepatic resection for HBV-related hepatocellular carcinoma (HCC) patients. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "The authors report a 63-years-old woman with unresectable large (7.4 x 7.9 cm) hepatocellular carcinoma (HCC) who had been diagnosed pulmonary lipiodol embolism after the first TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: Transcatheter arterial chemoembolization (TACE) is an essential therapy for patients with hepatocellular carcinoma (HCC) in whom administering other treatments such as liver transplantation, resection or local therapy is not feasible. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: To evaluate the effectiveness and safety of sorafenib combined with transarterial chemoembolization (TACE) in patients with advanced primary hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODOLOGY: A retrospective analysis of 65 patients with advanced primary hepatocellular carcinoma who had been administered sorafenib for more than one month and treated by TACE was performed. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSIONS: Sorafenib combined with TACE is a safe and effective treatment of advanced primary hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Although transarterial chemoembolization (TACE) has been used extensively for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), no consensus has been reached and an evidence base for practice is lacking. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) has therapeutic effects in patients with unresectable hepatocellular carcinoma (HCC), but its impact on the cellular immune response during disease progression is largely unknown. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolisation (TACE) is the mainstay of treatment for large or multifocal hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To compare the efficacies of portal vein stenting and transcatheter arterial chemoembolization (TACE) combined therapy performed with or without endovascular implantation of iodine-125 (125I) seeds strand in patients with hepatocellular carcinoma (HCC) and main portal vein tumor thrombus (MPVTT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Radiofrequency ablation therapy (RFA) combined with transarterial chemoembolization (TACE) (combination therapy) is effective for early-stage hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transcatheter arterial chemoembolization (TACE) is an effective treatment for hepatocellular carcinoma (HCC) that can occasionally lead to the shortening of life expectancy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Data on the efficacy and safety of sorafenib in combination with transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) are lacking. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " RATIONALE AND OBJECTIVES: To evaluate the precision and reproducibility of a semiautomatic tumor segmentation software in measuring tumor volume of hepatocellular carcinoma (HCC) before the first transarterial chemo-embolization (TACE) on contrast-enhancement magnetic resonance imaging (CE-MRI) and intraprocedural dual-phase C-arm cone beam computed tomography (DP-CBCT) images. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To assess the technical feasibility and local efficacy of percutaneous radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) for an intermediate-sized (3-5 cm in diameter) hepatocellular carcinoma (HCC) under the dual guidance of biplane fluoroscopy and ultrasonography (US). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "MATERIALS & METHODS: Sixty two Chinese patients (median age 52 years) with unresectable hepatocellular carcinoma had transarterial chemoembolization (TACE) performed with an emulsion of Lipiodol(\u00ae) (Guerbet, Paris, France) and doxorubicin (30-60 mg) followed by embolization with absorbable particles. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: The combination of the TACE and sorafenib proved both safe and effective in the treatment of Chinese patients with unresectable hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AIMS: Transarterial chemoembolization (TACE) is increasingly used as a treatment of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transarterial chemoembolisation (TACE) has not been shown to be superior to bland embolisation (TAE) for treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: In this study, we analyzed the rates and patterns of recurrences in hepatocellular carcinoma (HCC) patients who had achieved complete remission (CR) by transarterial chemoembolization (TACE) or radiofrequency ablation (RFA), and also examined the differences of recurrence patterns between TACE-treated and RFA-treated groups. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine the relationship between hepatitis B virus (HBV) DNA level and the survival of patients with hepatocellular carcinoma treated by means of transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "From January 2005 to March 2007, 183 patients with HBV-related hepatocellular carcinoma who underwent TACE but never received antiviral therapy were consecutively enrolled in our cohort. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: A high pre-TACE serum level of HBV DNA was associated with poor overall survival and rapid progression of hepatocellular carcinoma after TACE, and the cause of mortality was not hepatitis exacerbation but cancer progression. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Two randomized controlled trials identified that transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) shows a significant survival benefit compared with controls, after a long-term controversy. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) is widely performed in 32% of patients with unresectable hepatocellular carcinoma (HCC) at initial diagnosis and in 58% of those with recurrent HCC in Japan. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: The effects of transarterial chemoembolization (TACE) prior to hepatectomy for patients with hepatocellular carcinoma (HCC) are controversial. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: The purpose of this retrospective study was to determine the characteristics of hepatocellular carcinoma (HCC) associated with lower, local recurrence rates after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: To determine if hepatocellular carcinoma refractory to conventional transarterial chemoembolization (TACE) responds to TACE with DC beads. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Recently, new methods, including the concept of viable enhancing tumor such as EASL and mRECIST, have been proposed for substitution of the conventional WHO and RECIST criteria in hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Main bile duct necrosis develops after transcatheter arterial chemoembolization (TACE) through the caudate artery (A1) and medial subsegmental artery (A4) of the hepatic artery in the treatment of hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To explore the effect of lipiodolized transarterial chemoembolization (lip-TACE) in hepatocellular carcinoma (HCC) patients at different risk of recurrence after curative resection. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " INTRODUCTION: Regional therapy with trans-arterial chemoembolization (TACE) is a common treatment for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To clarify the role of surgical resection for multiple hepatocellular carcinomas (HCCs) compared to transarterial chemoembolization (TACE) and liver transplantation (LT). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Recent studies suggest that the combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) may have a synergistic effect for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: The aim of our study was to determine the predictors of recurrences in hepatocellular carcinoma (HCC) patients who had achieved complete remission (CR) by transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This study was undertaken to evaluate the feasibility, safety and efficacy of a new combined single-step therapy in patients with unresectable multinodular unilobar hepatocellular carcinoma (HCC), with at least one lesion >3 cm, with balloon-occluded radiofrequency ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE) of the main lesion and TACE of the other lesions. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To elucidate whether warming may reduce the viscosity of miriplatin-lipiodol suspension (MPT/LPD) and also the injection pressure through microcatheters, for potential use as a chemotherapeutic agent of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: Four hundred forty-three hepatocellular carcinoma (HCC) patients who underwent the first session of transcatheter arterial chemoembolization (TACE) between January 2005 and December 2009 were analyzed retrospectively. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To retrospectively evaluate agreement between modified RECIST (mRECIST) assessed at Computed Tomography (CT) and pathology in a large series of patients with hepatocellular carcinoma (HCC) who were transplanted after transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "In September 2011, an Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) was convened in HK in an attempt to provide a consensus on the practice of TACE. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To assess the long-term efficacy and investigate the prognostic factors of cytokine-induced killer (CIK) combined with the sequential transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) on hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) vs\u2005TACE alone for the treatment of patients with unresectable intermediate or advanced hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To investigate the additional diagnostic value of color mapping of the hepatic arterial enhancement fraction (AEF) for detecting recurrent or residual hepatocellular carcinoma (HCC) in patients treated with transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We aimed to establish an objective point score to guide the decision for retreatment with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: Patients with unresectable hepatocellular carcinoma (HCC) often undergo transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: In the evaluation set, a total of 820 patients who underwent TACE as a first treatment for hepatocellular carcinoma were included. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: This meta-analysis was designed to compare the effectiveness of the combination of transarterial chemoembolization (TACE) and percutaneous radiofrequency ablation (PRFA) with that of TACE and PRFA monotherapy in hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "METHODS: From January 2006 to January 2010, 90 patients with recurrent hepatocellular carcinoma (HCC) were treated with MCT and TACE in our hospital. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Transarterial chemoembolization (TACE) is highly effective and safe therapeutic modality for unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare radiofrequency ablation (RFA) with or without transcatheter arterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Treatments for hepatocellular carcinoma(HCC) including surgical resection, transcatheter arterial chemoembolization (TACE), percutaneous local therapy, and systemic chemotherapy are decided upon according to tumor progression and liver function. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " A 66-year-old man with multiple hepatocellular carcinomas(HCCs) underwent transcatheter arterial chemoembolization(TACE) twice and radiofrequency ablation(RFA) twice at another hospital in June 2009. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To assess the role of apparent diffusion coefficient (ADC) measured with diffusion-weighted imaging (DWI) in predicting and assessing response of hepatocellular carcinoma (HCC) to transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To retrospectively elucidate the preliminary clinical impact of warmed miriplatin-lipiodol suspension (MPT-LPD) when used as a chemotherapeutic agent for transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "drug-eluting beads transarterial chemoembolization (DEB TACE) in patients with unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: To evaluate the clinical benefits of transarterial chemoembolization (TACE) monotherapy or TACE combined with percutaneous microwave coagulation therapy (PMCT) and the long-term survival rate of patients with large primary hepatocellular carcinoma (HCC) treated with these techniques. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIMS: To compare the tumor control and safety of stereotactic body radiation therapy (SBRT) combined with transcatheter arterial chemoembolization (TACE) for small, solitary, and hypervascular hepatocellular carcinoma (HCC) with TACE alone. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the efficiency of a multimodality approach consisting of transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) as bridging therapy for patients with hepatocellular carcinoma (HCC) awaiting orthotopic liver transplantation (OLT) and to evaluate the histopathological response in explant specimens. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The aim of the present study was to evaluate the influence of preoperative transcatheter arterial chemoembolization (TACE) on survival after surgical resection (SR) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To evaluate the initial safety and efficacy of combination therapy using miriplatin plus low-dose epirubicin for transarterial chemoembolisation (TACE) of unresectable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: The aim of our study was to assess the results and cost of a treatment strategy involving transarterial chemoembolisation with drug eluting beads (DEB-TACE) in patients with unresectable non-metastatic hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To investigate whether C-arm dual-phase cone-beam computed tomography (CT) performed during transcatheter arterial chemoembolization (TACE) with doxorubicin-eluting beads can help predict tumor response at 1-month follow-up in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: There is a continuing debate on whether transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation (RFA) is more effective than RFA alone in the treatment of patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transarterial chemoembolization (TACE) represents a first-line noncurative therapy for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To assess the technical feasibility and local efficacy of biplane fluoroscopy plus US-guided percutaneous radiofrequency ablation (RFA) for viable hepatocellular carcinoma (HCC) around retained iodized oil after transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: Transarterial chemoembolization (TACE) is a widely applied standard treatment option for treatment-na\u00efve patients with multifocal hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The purpose of this study was to elucidate the clinicoradiologic characteristics of pseudolesions of the liver in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) as observed on gadoxetate disodium-enhanced MR images. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: Intermediate-stage hepatocellular carcinoma (HCC) is usually treated with locoregional therapy using transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We report a case of post-TACE necrotizing pancreatitis with abscess formation in a patient with hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Transcatheter arterial chemoembolization (TACE) has been used widely to treat patients with unresectable hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We experienced a case of paraplegia that occurred after conducting TACE through the intercostal artery to treat hepatocellular carcinoma that had metastasized to the rib. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: The aim of this retrospective study was to compare the local control effects of transcatheter arterial chemoembolization (TACE) using epirubicin (EPIR) and that using miriplatin (MPT) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: In Asian countries, transarterial chemoembolization (TACE) is widely applied in hepatocellular carcinoma (HCC) patients with extra-hepatic metastasis in the absence of main portal vein thrombosis. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to investigate the symptom and symptom clusters of patients with hepatocellular carcinoma (HCC) before and after transcatheter arterial chemoembolization (TACE), and to discuss the relationship between symptoms, symptom clusters, and symptom interference. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The purpose of this study was to determine the rate and risk factors for the development of irreversible hepatotoxicity after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) and synthetic hepatic dysfunction. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To reveal the mechanism of dense accumulation of lipiodol emulsion (LE) in hepatocellular carcinoma (HCC) during selective balloon-occluded transarterial chemoembolization (B-TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Sera of 50 prospectively and consecutively included hepatocellular carcinoma (HCC) patients, undergoing TACE therapy, were taken before and 24 h after TACE application. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To retrospectively investigate the short-term therapeutic effects and adverse effects associated with the use of miriplatin-lipiodol suspension for transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC), using TACE with cisplatin-lipiodol suspension as the historical control. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: The effect of transcatheter arterial chemoembolization (TACE) therapy on hepatitis B virus (HBV) reactivation in hepatocellular carcinoma (HCC) patients with prior resolved hepatitis B is not fully understood. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate the initial tumour response after one, respectively, two transarterial chemoembolizations (TACE) with drug-eluting (DC) beads in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transcatheter arterial chemoembolization (TACE) has been widely performed for inoperable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " AIM: To determine local response, its predictors and survival and complication rates after DC-Bead\u2122-TACE in patients with hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND & AIMS: Transarterial chemoembolization (TACE) is a widely used treatment for hepatocellular carcinoma. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "AIMS: We hypothesized that the polymorphisms in circadian genes may be associated with prognosis of hepatocellular carcinoma (HCC) patients treated with transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVES: To investigate whether the addition of nitroglycerine to transcatheter arterial (chemo)embolization (TAE/TACE) can increase the delivery and effectiveness of TAE/TACE in patients with hepatocellular carcinoma (HCC) by dual-energy CT. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "\u2022 In hepatocellular carcinoma, nitroglycerine added to TAE/TACE showed greater tumour reduction. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Recent studies suggest that the combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) may have a synergistic effect for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " The main methods of treatment for hepatocellular carcinoma (HCC) in Japan are hepatic resection, radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The objective of this study was to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) as a local salvage treatment after incomplete transarterial chemoembolization (TACE) for inoperable hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To evaluate the time dependent changes of microcirculation in hepatocellular carcinoma (HCC) lesions during degradable starch microsphere (DSM)-TACE using contrast enhanced ultrasound (CEUS). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: To retrospectively compare the therapeutic effects of combined high-intensity focused ultrasound (HIFU) and transarterial chemoembolisation (TACE) with TACE alone for the treatment of non-advanced hepatocellular carcinomas (HCCs) <5 cm. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We report a case of transcatheter arterial chemoembolization (TACE) to treat hepatocellular carcinoma (HCC) that was supplied by the short gastric artery. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND AND AIM: Renal insufficiency (RI) often coexists with hepatocellular carcinoma (HCC) and predicts a poor outcome in patients receiving transarterial chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transcatheter arterial chemoembolization (TACE) is an effective treatment for hepatocellular carcinoma (HCC), but it sometimes makes liver function worse. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The long-term survival outcomes of hepatic resection (HR) compared with transcatheter arterial chemoembolization (TACE) for resectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) are unclear. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To compare the efficacy of transcatheter arterial chemoembolization (TACE) using multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, and 5-furuorouracil: Multi group) with TACE using epirubicin (EP group) for hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To assess the time to disease progression (TTP), long-term survival benefit and safety of patients with unresectable hepatocellular carcinoma (HCC) treated with computed tomography (CT)-guided radiofrequency ablation (RFA) with transarterial chemoembolization chemoembolization (TACE). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We describe a case of a patient with unresectable hepatocellular carcinoma who subsequently developed right-lower-lobar pulmonary infarction approximately three weeks after receiving TACE, owing to an abnormal vascular connection between the superior epigastric artery and the distal right pulmonary artery. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: Transcatheter arterial chemoembolization (TACE) is an effective treatment for hepatocellular carcinoma (HCC) that would occasionally lead to energy malnutrition through therapeutic hypoxic stress. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " We aimed to compare the survival benefit of transarterial chemoembolization (TACE) with conservative treatment for patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT), furthermore, to reveal which PVTT types benefit from TACE treatment. "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: An Asian study showed that gamma glutamyl transpeptidase (GGT) can predict survival after transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). "}, {"drug": "TACE", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Tranarterial chemoembolization (TACE) has been established by a meta-analysis of randomized controlled trials as the standard of care for nonsurgical patients with large or multinodular noninvasive hepatocellular carcinoma (HCC) isolated to the liver and with preserved liver function. "}, {"drug": "dovitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Interestingly, Dovitinib triggered a G2 /M arrest in cancer cell lines from diverse origins including HeLa, nasopharyngeal carcinoma, and hepatocellular carcinoma. "}, {"drug": "dovitinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Dovitinib is currently in clinical trials for the treatment of hepatocellular carcinoma (HCC). "}, {"drug": "Leucovorin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " Background: The Oxaliplatin plus 5-Fluorouracil /Leucovorin (FOLFOX4) regimen have been approved by Chinese Food and Drug Administration (CFDA), and covered by health insurance for patients with advanced hepatocellular carcinoma (HCC) in China. "}, {"drug": "Leucovorin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND: The EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) compared with doxorubicin alone in terms of overall survival (OS), progression-free survival (PFS), and safety in patients with advanced hepatocellular carcinoma (HCC). "}, {"drug": "Leucovorin", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " PURPOSE: To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin. "}, {"drug": "Steroids", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Multivariate analysis indicated that HCV, alcoholic liver disease, autoimmune liver disease, nonalcoholic steatohepatitis, re-transplantation, combined transplantation, hepatocellular carcinoma, immunosuppression regime of cellcept, cyclosporine, sirolimus, steroids and tacrolimus were independent predictors for the development of solid malignancies after liver transplantation. "}, {"drug": "Steroids", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " BACKGROUND/AIMS: We aimed to evaluate the efficacy and safety of an immunosuppressive regimen without steroids after liver transplantation (LT) for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). "}, {"drug": "Steroids", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "CONCLUSION: Hepatocellular carcinoma occurring in association with anabolic androgenic steroid abuse should sensitize physicians and especially professional bodybuilders for the harmful use of high doses of steroids. "}, {"drug": "Steroids", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We did not find any association between NODAT and age at transplantation, gender, pretransplant body mass index, presence of hepatocellular carcinoma, type of initial immunosuppression (cyclosporine, tacrolimus or corticosteroids) or acute rejection treated with steroids. "}, {"drug": "Steroids", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Using human hepatocellular carcinoma cells cultured in the presence of progesterone and 17\u03b2-estradiol, we demonstrated that the level of TAFI protein is decreased by those sex steroids. "}, {"drug": "Apatinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": " OBJECTIVE: This study was designed to compare the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma (HCC). "}, {"drug": "Apatinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "We report one case with advanced hepatocellular carcinoma (HCC), who received apatinib combined with transhepatic arterial chemotherapy and embolization (TACE), and chemotherapy respectively. "}, {"drug": "Apatinib", "disease": "Hepatocellular carcinoma", "polarity": 1, "orig_sen": "Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2, has demonstrated encouraging anticancer activity across a broad range of malignancies, including gastric cancer, non-small-cell lung cancer, breast cancer, and hepatocellular carcinoma. "}]